DE2155658B2 - Verfahren zum nachweis und zur bestimmung von einem hapten oder dessen antikoerper - Google Patents
Verfahren zum nachweis und zur bestimmung von einem hapten oder dessen antikoerperInfo
- Publication number
- DE2155658B2 DE2155658B2 DE19712155658 DE2155658A DE2155658B2 DE 2155658 B2 DE2155658 B2 DE 2155658B2 DE 19712155658 DE19712155658 DE 19712155658 DE 2155658 A DE2155658 A DE 2155658A DE 2155658 B2 DE2155658 B2 DE 2155658B2
- Authority
- DE
- Germany
- Prior art keywords
- hapten
- determination
- enzyme
- solution
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Description
25
Zum Nachweis und zur Bestimmung niedermolekularer Substanzen, die in geringen Konzentrationen
vorliegen, wie Steroidhormonen in Körperflüssigkeiten, wurden Verfahren entwickelt, bei denen Proteine
verwendet werden, die fähig sind, die nachzuweisende 3» Substanz spezifisch zu binden. Diese Verfahren beruhen
auf der Konkurrenz zwischen der nachzuweisenden Substanz in der Probe und einer bekannten Menge
der gleichen Substanz, die radioaktiv markiert ist, mit einer begrenzten Menge des spezifischen bindenden
Proteins. Durch die unbekannte Menge der bindungsfähigen Substanz wird bestimmt, welcher Anteil der
radioaktiv markierten Substanz an das spezifische bindende Protein gebunden wird.
Es ist auch möglich, mit Hilfe dieser Verfahren, eine unbekannte Menge eines spezifischen bindenden Proteins
durch Umsetzung einer Probe, die eine unbekannte Menge des spezifischen bindenden Proteins
enthält, mit einer bestimmten Menge einer bindungsfähigen radioaktiv markierten Substanz zu bestim- +5
men.
In der Literatur ist es üblich, diese Bestimmungsverfahren, je nach Art des verwendeten spezifischen
bindenden Proteins 7u unterscheiden, obwohl das grundlegende Prinzip all dieser Bestimmungen das
gleiche ist. So wird z. B. von »konkurrierenden Protein-Bindungsversuchen« gesprochen, wenn Rezeptor-
oder Transportproteine verwendet werden, die im Körper vorkommen und von »radioimmunologischen
Bestimmungen«, wenn Antisubstanzen verwendet werden.
Für beide Arten von Bestimmungen sind radioaktiv markierte Substanzen erforderlich. Das Arbcilen mit
diesen Substanzen erfordert das Vorhandensein präziser
Meßvorrichlungcn, gut ausgerüstete Laboratoneu
und ein qualifiziertes Personal. Diese hohen Anforderungen machen eine allgemeine Anwendung dieser
Bcslimmungsverfahren besonders in kleineren Laboratorien unmöglich.
Aus der USA.-Patentschrift 35 05 019 ist ein \ erfahren
/ur Bestimmung von Vitamin 13 12 in einer wäßrigen Probe bekannt, bei dem ein wasserunlösliches
Polymer, an das Intrinsicfaktor gebunden ist.
mit der zu untersuchenden Probe und radioaktiv markiertem B 12 zusammengebracht wird. In BuU. Soc.
Chem. Biol., 50, 1968, Nr. 5/6, S. 1169 bis 1178 ist
angegeben, daß es möglich ist, ein Antigen mit einem Enzym zu markieren und dann mit dem entsprechenden
Antikörper auszufällen. In Science, VoI. 168, 1970, S. 1347 und 1348 ist ein immunologisches Verfahren
zur Bestimmung von Morphin bekannt, bei dem Morphin mit einem Protein gekuppelt und das Konjugat
mit einem radioaktiv markierten Antikörper ausgefällt und die Radioaktivität des Niederschlages
gemessen wird.
Es ist Aufgabe der Erfindung, ein Verfahren zum Nachweis und zur Bestimmung von einem Hapten
oder dessen Antikörper zu entwickeln, das einfach und bequem durchgeführt werden kann, kein Arbeiten mit
radioaktiven Substanzen erfordert und in kurzer Zeit zu zuverlässigen reproduzierbaren Ergebnissen führt.
Diese Aufgabe wird gelöst durch ein Verfahren zum Nachweis und zur Bestimmung von einem Hapten
oder dessen Antikörper unter Ausnutzung der für derartige Substanzen bekannten Bindungsaktivität, das
dadurch gekennzeichnet ist, daß die Bestimmung mit einer bestimmten Menge eines Kopolungsprortuktes
aus derr Hapten und einem Enzym und einem in unlösliche Form gebrachten Bestandteil der Reaktion
Hapten-Antikörper durchgeführt wird und die Enzymaktivität in der flüssigen oder festen Phase bestimmt
wird.
Haptene sind nach der Definition von K. Landsteiner
proteinfreie Substanzen mit einem Molekulargewicht bis zu ungefähr 1500, die mit spezifischen
Antikörpern reagieren, jedoch nicht selbst zur Bildung von Antikörpern führen können. Um jedoch trotzdem
Antikörper zu Haptenen bilden zu können, müssen die Haptene, bevor sie dem Testtier injiziert werden,
an Polypeptide gekuppelt werden. Daraus resultieren besondere Schwierigkeiten beim Arbeiten mit Haptenen.
üa es bekannt ist, daß durch die Kupplung einer immunogenen Komponente, z. B. eines Antikörpers
an ein unlösliches Polymer die Reaktionsfähigkeit einer solchen Komponente gegenüber dem entsprechenden
Antigen vermindert wird, war zu befürchten, daß ein Antikörper der gegen das Kupplungsprodukt
eines Haptens mit einem Protein (z. B. Albumin) gebildet worden ist und der anschließend durch Binden
an ein unlösliches Polymer unlöslich gemacht worden ist, mit dem reinen Hapten nicht mehr reagieren würde.
Umso mehr mußte der Fachmann davon ausgehen, daß ein solcher unlöslich gemachter Antikörper mit
einem Hapten, das auch noch an ein Enzym gekuppelt ist, nicht mehr reagieren würde. Da ein Hapten eine
niedermolekulare Substanz und ein Enzym ein voluminöser Proteinkomplex ist, mußte angenommen
werden, daß sowohl eine zu starke sterische Hinderung als auch besondere Schwierigkeiten beim Nachweis
des Haptens eintreten würden. Das ist überraschenderweise nicht der Fall, sondern es hat sich gezeigt, daß
durch Vet Wendung eines derartigen Hapten-Enzym-Komplexes
cm sehr empfindliches genau reproduzierbares und einfaches Teslvcrfahrcn zur Bestimmung
von einem Hapten oder dessen Antikörper möglich wird.
Bei der Bestimmung eines Haptens konkurriert dieses Hapien und sein Kopplungsprodukt mit einem
Hnzvm um eine bestimmte Menge des unlöslichen spezifischen Antikörpers. .Ic mehr Hapten die Probe
enthalt, um so geringe)· ist die Chance, für das
iflUDlun-sprodukt aus dem löslichen Enzym und dem Bestimmung von Antikörpern gegen Penicillin oder
u nten sich mit dem unlöslichen spezifischen Anti- zur Bestimmung des Intnnsik-Faktors.
™ /u verbinden und um so meh? des Koppl^gs Im Folgenden wird die Erfindung durch allgemeine
Produktes bleibt in der flüssigen Phase zuiück, in der und spezielle Beispiele naher erläutert,
^aktivität auf einfache Weise gemessen wer- 5 ^^^^^
ιοί Bestimmung eines spezifischen Antikörpers durchgeführt werden, ^ge Haptene^nnen schon
■t ΛΡη Bleichen Reagentien treten der zu bestimmende Gruppen besitzen, die mit reaktionatanigen^γ vv
Siehe An körper und der unlösliche Antikörper in an der Oberfläche des Enzyms vernetzt werden können
Skurrtz um eine bestimmte Menge des Kopp.ungs- „ während andere «^^gPg^^S
rnrfuktes aus dem Hapten und dem Enzym. Wenn sehe Reaktion erhalten mu.^
GeSt an Antikörper in der Probe höher ist, wird hch, daß die -prünghcher,
oder mehr15
den d. h. mit dem Enzym-Kopplungsprodukt und sitzt, kann dl- !^ΡΡ1""«= ^, ind durcheeführt
dm Hapten in unlöslicher Form. Die flüssige Phase » sie ^^^ ^ ^ Substanzen,
VT
fst, um so mehr Enzymaktivität bes.tzt d,e fluss.ge ^^'^J^i^^S^.erden angewandt zur Her-
"SJ Hilfe einer Bestimmungskurve für ein bestimm- ,teUung von .^ ^mSsSü""E^
tes System, bei dem der zunehmende Gehalt an dem 3o sie ko."^^^"s mit einem En,>m ange-
zu bestimmenden Hapten oder Ant.korper gegen die '«"BJP'^" d d Vür P das „findungsgemaBe Ver-
Befundene Enzymaklivitat, vorzugsweise in der flus.- vvt ndl s\e™e"·
g Phase, aufgetragen ,st, kann die Menge des m fahren wie ^ das eine Kompo„ente für
der Probe enthaltenen Haptcns oder Antikörpers fur Die ^h- d« tn >
^^ Fn7ym ^^
Sen gefundenen Wert für die Enzymakuv.tat abge- 35 ^oppjuntsprodu^ ^ P^ spezjfischen Akt;.
-Äigste Reagens für dieses Best.mmung, ^^-^^e^vS^nd Sffi^
verfahren ist das Kopplungsprodukt aus dem Hapten Empf.ndhckhe, Dje Bcstimmung ei„es
und einem Enzym, im folgenden auch Enzym-Kopp- der^Best.tnnlunt >
d,u kata|yslCrt. bc. der
lun,gsprodukt genannt, das einerse.ts mit dem spez.fi- 4o Enzyms, das emc ^ vcrschwinde t
sehen Antikörper über das Hapten reagieren kann und gefa bte ^joc colorimetrische Bestimmungen konandererseits
Enzymaktiv.tät bes.tzt Dieses Reagens einfach üe^ aulomatisiert werden,
wird nach einem für ähnliche Produkte beschriebenen nen auj e^ t ^ ^ mög,ichi E mc zu
Verfahren hergestellt. Das zweite Reagens, die unlo - E^unfe^ Umw.andIungen katalysieren, be, denen
Phase neben einer flüssigen Phase. ma"?1 die Herstellune der Kopplungsprodukte sind
Die Enzymaktivität einer Frakt.on des Reakuons- 5» Pu^d.^ Her« Peroxidase, ^Glukuronidase,
gemisches kann bestimmt werden, indem diese Frak- enzyme wie ^D.Galactosidase, Urease GIu-Sn
mit einem Substrat und anderen Substanzen zur J-D-C hgosulase ^ xidase geeignet, bevor-Durchführung
einer Enzymreakuon inkub.er v.rd^ kos ο dase ^ Oxidoreddktasen
Besonders geeignet ist dabei eine R^akt.on bt der zug ^ h spezifische Antikörper oder das uneine
gefärbte Verbindung geb.ldet oder entfernt wird e uijU; _ _. ^ erfindungsgernaßen Bederen
Absorption auch leicht quantitativ gemessen Jf^^^w^det werden, können auf bekannte
werden kann. Vorzugsweise wird als Enzym eineOx.do- stimrnunt erwc^ ^ Vernet7ung mit chlor-amcsenreduktase
verwendet. Surc-atnvlcster. durch kovalcntc Bindung nut unlos-Haptenc,
die nach dem neuen Vcrfah.cn na.h^ ame ·>
, Acarosc. Vemct/ung mi Dcx.an
wicscS werden können sind / H. S.croidc. \ ι an ,n ' : οφ p,c, oder durch physikalische Kopplung
B1.,. Folinsiiure. Th>roxin und Tnjodo hvu . η .- ; du ^1 ^.^ KunslslüflCi hergestellt
le-isinc laclors Histamin. Serotonin und andei, hui- ^n um
gene Amine. Digoxin. Digit^in, l'ros,agland,ne \drc- ^uWn. ^^ R micn vcrwCndei -culcn
für Hantcne kann angeuaiuii sNcrden. /. h. /m
streifen, der mit dem Kopplungsprodukt imprägniert ist, verwendet werden.
Die unlösliche Komponente kann in Form von Teilchen verschiedener Form, wie Körner, Kugeln und
Stäbchen oder in Form eines Streifens des einen oder anderen Trägermaterials gebracht werden.
Zur Durchführung des erfindungsgemäßen Verfahrens kann eine Testpackung verwendet werden, die
hauptsächlich besteht aus:
a) einer bestimmten Menge des Kopplungsproduktes aus einem Hapten und einem Enzym;
b) einer entsprechenden Menge einer der Komponenten des Reaktionssystems in unlöslicher Form;
c) einem Substrat zur Bestimmung der Aktivität des verwendeten Enzyms.
Wenn erforderlich, kann die Testpackung auch die notwendigen Hilfsmittel zur Herstellung einer Verdünnungsreihe
der zu untersuchenden Probe für eine quantitative Bestimmung, wie Reagenzgläser, Pipetlen
und Kolben mit Verdünnungsmittel, enthalten.
Die Erfindung wird durch die folgenden speziellen Beispiele noch näher erläutert:
Bestimmung von Testosteron
A) Herstellung von Testosteron-3-HRP
A) Herstellung von Testosteron-3-HRP
100 mg Testcsteron-3-(O-carboxymethyl)-oxim und
0,143 ml Tri-n-butylamin wurden in 5ml Dioxan gelöst. Die Lösung wuide auf 2 C abgekühlt und dann
wurden 0,03 ml lsobutylchlorcarbonat zugegeben. Nach 30 min wurde die Lösung zu 100 mg HRP
(Meerrettichperoxidase) in einem Gemisch von 9 ml Wasser und 6 ml Dioxan zugegeben und mit 0.1 η
NaOH auf einem pH-Wert von 9 eingestellt. Diese Lösung wurde 4 h bei 2 C gerührt und über Nacht
dialysiert. Der Niederschlag, der nach Einstellung des Dialysats auf einen pH-Wert von 4.6 erhalten worden
war, wurde nachdem er über Nacht stehengelassen worden war, zentrifugiert, in 10 ml Wasser su>pendicrt
und mit Hilfe von Natronlauge gelöst. Das Material wurde dreimal mit 15 ml Aceton bei einem pH-Wert
von 4,5 ausgefällt, in 15 ml Wasser, das mit Natriumhydroxid-Lösung auf einen pH-Wert von 7.8 einge- +5
stellt war, gelöst, dialysiert und schließlich lyophilisiert.
B) Herstellung von Testosteron-3-BSA
Dieses Kopplungsprodukt wurde auf die gleiche Weise wie das Testosteron-3-HRP hergestellt, wobei
jedoch als Ausgangsmaterial 50 mg Testosteron-3-(O-carboxymethyl)-oxim
und 150 mg BSA (Rinderserumalbumin) verwendet wurden.
C) Herstellung von Antikörpern gegen Testosteron-3-BSA
5 Kaninchen wurden intramuskulär zunehmende Dosen von Testosteron-3-BSA in vollständigem
Freund'schen Adjuvans (0,5, 1 und 2 mg) in Intervallen von 3 Wochen injiziert. Zwei Wochen nach der letzten
Injektion wurden den Tieren intravenös 2 mg Antigen in physiologischer Kochsalzlösung injiziert. Eine
Woche danach wurde den Tieren Blut abgenommen. Die gegen BSA gebildeten Antikörper wurden entfernt,
indem das Serum anteilweise mit BSA-m-aminobenzyloxymethylcellulose.
die nach dem Verfahren von Gurvich (siehe D) hergestellt worden war, behandelt wurde.
D) Herstellung von Aniitestosteroneellulose
Diese Substanz wurde entsprechend dem von Gurvich in Biokhimiya 26,934 (1961) beschriebenen Vcrfahren
hergestellt.
1. Herstellung von »Aminoccllulose«:
50 g Whatman Cellulose, die mehrfach gewaschen und dekantiert worden war, wurden in 100 ml
ίο einer 0,7"„igen Natriumacetatlösung suspendiert,
die 2 g N(m-Nitrobcnzoxy)-inethylpyridin enthielt. Das Gemisch wurde bei 60 bis 80 C getrocknet
und 40 min auf 125 C erhitzt. Das entstehende Produkt wurde gründlich mit destilliertem
Wasser gewaschen, bei 80 C getrocknet, mit Benzol gewaschen und erneut getrocknet. 50 g des
getrockneten Produktes wurden durch Suspension in 300 ml einer 15",',igen Na2S.,O4-Lösung reduziert
und 31) min bei 50 bis 60 C gerührt. Das
ao Produkt wurde filtriert und nacheinander mit
destilliertem Wasser, 30%iger Essigsäure und wieder mit destilliertem Wasser gewaschen.
2. Behandlung: mit ammoniakalischer Kupferlösung:
40 ml 10",,!.scr Schwefelsäure, 20 ml 50"„iger
Salpetersäure und 140 ml destilliertes Wasser wurden unter Rühren auf 90 C erhitzt. Anschließend
wurden 5.9 g CuO in kleinen Anteilen zugegeben. D e Lösung wurde 2 h zum Sieden erhitzt
und mit destilliertem Wasser auf 500 ml aufgefüllt. 80 ml dieser Lösung wurden in ein Eisbad
gegeben urd unter Rühren zu 160 ml kalter 4 η NaOH zugegeben. Nach 30minütigem Rühren
wurde der Niederschlag zweimal mit destilliertem Wasser gewaschen und in 80 ml 25"„igem Ammoniak
gelös:. Zu dieser Lösung wurde nach und nach 1 g »Aminocellulose« zugegeben. Das Gemisch
wurd: IV2 h gerührt und anschließend wurden 4C ml siedendes Wasser zugegeben und
die Lösung: schnell auf 0 C abgekühlt. Die Lösung wurde mit 10'!„igcr Schwefelsäure neutralisiert,
worauf die Aminoccllulose ausflockte. Sie wurde mit kaltem destillierten Wasser gewaschen.
3. Herstellung von v-Globulin:
Zu Kaninchen Antitcstosteronserum wurden 180 mg Na2SO1 pro ml Serum zugegeben. Das
Gemisch wurde 1 h bei Raumtemperatur gerührt und der entstehende Niederschlag zentrifugiert,
zweimal mit einer 18%igen Na2SO4-Lösung gewaschen
und in so viel 0,05 m Natriumborat mil einem pH-Wert von 8,6 aufgenommen, daß di«
Proteinkonzentration ungefähr 10 mg/ml betrug
4. Bindung des y-Globulins an Aminocellulose:
350 mg »Aminocellulose« wurden in 50 ml destil liertem Wasser suspendiert. Die Suspension wurd
auf 0 C abgekühlt. 10 ml 36°oige Salzsäure wur
den zugegeben und anschließend 10 ml 10°oig
NaNO2-Lösung zugetropft. Die Suspension wurd
zentrifugiert, mit kaltem destillierten Wasser un anschließend mit 0,05 m Natriumborat mit einer
pH-Wert von 8,6 gewaschen. Die Cellulose wurd in 43 ml 0,05 m Natriumborat mit einem pH-Wei
von 8,6 suspendiert. Zu dieser Suspension wurde 7 ml der wie oben hergestellten y-Globulinlösun
zugegeben. Das Gemisch wurde 26 h bei 4 C gi rührt, zentrifugiert und mit 0,02 m Phosphatpufff
35
40
mit einem pH-Wert von 6.0 gewaschen. Von dem Antisemit! jedes der 5 immunisierten Kaninchen
wurde eine Celluloscsuspcnsion hergestellt (A bis E).
) Bestimmung von Testosteron mit Hilfe von Testosteron-3-HRP
und Antitestoslcroneellulose
Das folgende System wurde aufgebaut:
) Immunreaktion
) Immunreaktion
0.5 ml einer Probe, enthaltend Testosteron, 0,2 ml Testosleron-3-HRP (100 mg/ml) und 0.3 ml einer
Antilestosteroncellulosc-Suspension wurden 2 h bei Raumtemperatur rotiert und dann 5 min mit
1000 g zentrifugiert.
Die Immunreaktion fand in 0,02 m Phosphatpuffer bei einem pH-Wert von 6,0, enthaltend 2"„
Schafserum, statt.
11) Enzymrcaktion
0.5 ml der überstehenden Flüssigkeit wurden bei Raumtemperatur mit 1,5 ml Substrat 30 min
inkubiert. Die Extinktion wurde bei 460 nm gemessen.
Das Enzymsubstrat enthielt 10 ul, 30"Jgcs
Wasserstoffperoxid und 20 mg 5-A.minosalicylsäure in 150 ml 0,02 m Phosphatpuffer mit einem
pH-Wert von 6.2.
Die Fig. 1 zeigt Meßwerte, bei denen Testosleron-3-HRP
an die Antitestostcroncellulose-Zubcreitungcn
gebunden worden ist. In diesem Falle wurde nur Puffer als Probe in dem Tesisystem
zugegeben. Wenn Cellulose an Stelle von Antitestoslcroneellulose z.ugegeben wird, bleiben mehr
als 95",, der Enzymaktivität in der überstehenden Flüssigkeit enthalten. Die Zubereitungen B, D
und E zeigten, daß fast kein Tcstosteron-3-HRP
gebunden worden war. jedoch bei den Zubereitungen A und C.
Fig. 2 zeigt die Ergebnisse der Inkubation einer
Testosteron Verdünnungsreihe mit Testosteron-3-HRP bei vier verschiedenen Konzentrationen von
Antistestostcronccllulose C.
mg/ml (1), 2 mg/ml (II), 4 mg/ml (111) und 16 mg ml
(IV). Es ist offensichtlich, daß mit diesem System eine
Menge von ungefähr 10 ng Testosteron gezeigt werden kann.
Beispiel 2
Bestimmung von Östradiol
Bestimmung von Östradiol
östradiol-17-succinyl-HR.P wurde hergestellt
durch die in Beispiel 1 A) beschriebene gemischte Anhydrid-Methode, wobei 50 mg Östradiol-17-hemisuccinat
und 50 mg HRP als Ausgangsmaterialien verwendet wurden.
D) Antiöstradioleellulosc wurde auf die in Beispiel I D) für Antitestosteroncellulose beschriebene Weise
hergestellt. Von jedem der immunisierten Kaninchen wurde eine Cellulosezubereitung hergestellt,
die mit 16 bis einschließlich 20 numeriert wurden.
E) Die Untersuchung wurde analog derjenigen für Testosteron in Beispiel 1 E) durchgeführt.
Die Fig. 3 und 4 zeigen einige Ergebnisse. Die Fig. 3 zeigt, daß drei \erwendbare Antisera durch die
Immunisierung erhalten wurden, on denen 17 den höchsten Titel besitzt. Die Fig. 4 zeigt das Testsyslem,
bei dem Antiöstradiolccllulose 17 in einer Konzentration
von 8 mg/ml verwendet wurde. Das System unterscheidet
nicht zwischen Östron und 17 p'-Östradiol, 17 «-Östradiol, besonders Östriol, zeigen eine geringere
Kreuzreaktion. Testosteron und Progesteron beeinflussen das System nur in sehr hohen Konzentrationen.
Bestimmung von Antikörpern gegen Penicillin Pcnicilloyl-Katalase
30 mg Bcnzylpenicillinsäurc wurden in 5 ml 96 " J gern Äthanol gelöst und zu 200 mg Katalase in 45 ml 0.1 m
Phosphatpuffer mit einem pH-Wert von 7,5 zugetropft. Die Reaktion wurde 2 h fortgesetzt, wobei der
pH-Wert mit 0.5 η NaOH zwischen 7.2 und S.2 gehalten
wurde. Das Reaktionsgemisch wurde gegen 6-31
0.02 m Phosphatpuffer mit einem pH-Wert von 7,0 dialysiert.
Auf die gleiche Weise wurden 250 mg Benzylpenicillinsäurc
an 5 g m-Aminobenzyloxymcth\lccllulose. die nach dem Verfahren von Gurvich (Biokhimiya
26, 934 [1961]) hergestellt worden war. gekoppelt. Das Kopplungsprodukt wurde jedoch nicht
dialysiert. sondern auf einem Glasfilter gewaschen.
Eine Überempfindlichkeit von Menschen gegenüber Penicillin konnte auf folgende Weise gezeigt werden:
0.2 ml einer Probe von niclu-hämolysieriem Serum
wurden mit 0,5 ml einer Lösung von Penieilloyl-Katalasc (!800) vermischt. Nach 30 min wurden
10 mg Pcnicilloyl-m-aminohcnzyloxymeihylcellulose
zugegeben. Das Gemisch wurde 30 min rotiert und anschließend die Enzymaktivität in der überstehenden
Flüssigkeit bestimmt, indem 0.02 ml dieser Flüssigkeit zu 2,S ml 0,05 m Phosphatpuffer mit einem pH-Wert
von 6,8 zugegeben wurden, der 1.2 μΐ 30",,JgCS H2O2
enthielt und anschließend die Abnahme der Extinktion bei 240 nm gemessen wurde. Im Serum von Patienten,
die gegenüber Penicillin überempfindlich waren, wurde eine geringere Enzymaktivität in der Flüssigkeit gefunden
als bei Kaninchenserum. Die Werte für Menschen, die nicht überempfindlich waren, wichen nichi
wesentlich von denjenigen mit Kaninchenserum ab.
35
40
45
Östradiol-H-succinyl-BSA wurde nach der in
Beispiel 1 A) beschriebenen gemischten Anhydrid-Methode hergestellt, wobei 100 mg Östradiol-17-hcmisuccinat
und 150 mg BSA als Ausgangsmaterialien verwendet wurden.
C) 7\n Herstellung der Antikörper jictcn Östradiol-17-succinyl-B^A
wurden 5 Kaninchen nach dem in Beispiel 1 C) beschriebenen Schema immunisiert
Die Sera wurden mit BSA-m-Aminobcnzylo\\
mei In !cellulose absorbiert.
Bestimmung von Folinsäure A) Herstellung von Folatglukoseoxidase
200 mg Glukoseoxidase (140 lL'/mg) wurden 11
10 mg PBS (mit Phosphat gepufferte Salzlösung eine phosphathaltige physiologische Kochsah
lösung) mit einem pH-Wert von 7,0 gelöst. 30 m 1-Cyclohexyl-3-(2-morpholinoäthyl)-carbodiimi
(MCDl) wurden zugegeben und anschließen 24 mg Folinsäure. Die Reaktion dauerte 2 h un
anschließend wurde eine soigfältige Dialyse gege
PBS mit einem pH-Wert von 7,0 durchgefühlt.
609 532/4C
B) Herstellung von Folat-MBSA (methyliertes Rinderserumalbumin)
Folat-MBSA wurde hergestellt nach dem von Ricker und Slollar beschriebenen
Verfahren (Biochemistry 6, 2001 [1967]). 25 mg MCDI wurden zu 50 mg BSA in 50 ml
Wasser zugegeben und anschließend 20 mg l-olinsäure.
2 h später hatte sich ein gelber Niederschlag gebildet. Schließlich wurde das ganze
Reaktionsgemisch eine beträchtliche Zeil gegen physiologische Kochsalzlösung dialysiert.
C) Herstellung von Antiserum gegen Folat-MBSA
Am Tage 0. 21 und 42 wurden jeweils 4 Kaninchen intramuskulär 2 mg Folat-MBSA in vollständigem
Frcund'schen Adjuvans und am Tage 35 intravenös 2 mg Folat-MBSA in physiologischer
Kochsalzlösung injiziert. Am Tage 49 wurde den Tieren Blut abgenommen.
D) Antifolatcellulose wurde entsprechend dem in Beispiel I D) beschriebenen Verfahren hergestellt.
E) Bestimmung von Folinsäure
100 μΙ der zu untersuchenden Probe und 700 μΐ
einer Antifolatccllulose-Suspcnsion wurden 3 h rotiert. 200 μΙ Folatglukoseoxidase (1:1500) wurden
zugegeben. Das (Jemisch wurde nochmals 3 h rotiert und zentrifugiert und anschließend die
Enzymaktivität in der überstehenden Flüssigkeit bestimmt. Diese Bestimmung wurde durchgeführt
durch Vermischen von 0,5 ml der überstehenden Flüssigkeit mit einer Lösung von 50 mg Glukose,
10 μg HRP und I mg 5-Aminosalicylsäure in
2,5 ml 0.05 η Phosphatpuffer mit einem pH-Wert von 6,0 und Messung der Extinktion nach 30 min
bei 460 um.
Fig. 5 zeigt den Prozentsatz des gebundenen Enzyms
gegen die Konzentration der Antifolatcellulose.
Fig. 6 zeigt die Empfindlichkeit des Testsystems in einer Ariiifoiatceliuiose-Koiuentraiion von 2 mg/ml
und die Wirkung von Glycin, Asparagin, Alanin und Glutaminsäure.
Beispiel 5
Bcstimmuna von Diaoxin
Bcstimmuna von Diaoxin
Herstellung von Digoxin-HRP
Zu 22 mg Digoxin, in 1 ml abs. Äthanol suspendiert, wurde unter Rühren 1 ml 0,1 m
Natriummetap-vjodat zugetropft. Nach 25 min wurden 0,3 ml 0,1 m Äthylenglykol zugegeben.
5 min später wurde dieses Gemisch unter Rühren zu einer Lösung von 32 mg Meerrettichperoxidase
(HRP) in 1 ml destilliertem Wasser zugetropft, das mit 5"„iger K2CO3-Lösung auf einen pH-Wert
von 9,5 eingestellt war. Während der Reaktion wurde der pH-Wert durch Zugabe 5o;,iger
K2CO3-LoSUnC auf 9 bis 9,5 gehalten. Als der pH-Wert
stabil war, wurden 15 mg NaBH4 in 1 ml destilliertem Wasser zugegeben. Nach 3 h wurde
der pH-Wert mit 1 m Ameisensäure auf 6,5 eingestellt. 1 h später wurde 1 m NH4OH zugegeben,
bis ein pH-Wert von 8,5 erreicht war. Das Gemisch vvurde über Nacht gegen kaltes fließendes
Wasser dialysiert. Schließlich wurde der pH-Wert mit 0,1 η Salzsäure auf 4.5 eingestellt. Das Gemisch
wurde I h bei Raumtemperatur und 4 h bei 4 C stehengelassen, um einen Niederschlag zu
erhalten, der I h bei 1000 g zentrifugiert wurde. Der Niederschlag wurde in 5 ml 0,1 m NaHCO-,
gelöst, gründlich dialysiert und gefriergetrocknet.
B) Herstellung von Digoxin-BSA
Diüxin-Rindcrserumalhumin (BSA) wurde auf die gleiche Weise, wie sie oben für Digoxin-HRP
angegeben ist, hergestellt, wobei jedoch von 436 mg Digoxin und 560 mg BSA ausgegangen
wurde und die Mengen der anderen Reagenzen in gieichem Verhältnis erhöht wurden wie das
Dioxin.
C) Herstellung von Antikörpern gegen Dioxin
5 Kaninchen wurden 400, 800 bzw. 1600 ug Dioxin-BSA im Absland von 14 Tagen injiziert.
Das Immunogen wurde mit vollständigem Freund"-schen Adjuvans vermischt und intramuskulär verabreicht.
14 Tage nach der letzten Injektion wurde
den Tieren intravenös SOO μg Digoxin-BSA in physiologischer Kochsalzlösung injiziert. 10 Tage
später wurde den Tieren das Blut entnommen. Das Serum wurde mit BSA-m-Aminbenzyloxymethvlcellulosc
adsorbiert.
D) Herstellung von Antidigoxincellulose
Antidigoxincellulose wurde nach dem Gurvich-Verfahrcn,
wie unter 1 D) beschrieben, hergestellt.
E) Bestimmung von Digoxin
Eine Verdünnungsreihe wurde mit Digoxin in 0,1 m Phosphatpuffer mit einem pH-Wert von 7.5
hergestellt, enthaltend 0,9"„ NaCl. 0.5 "o Twcen-20
und 1,0°,, BSA. Die Verdünnungsreihe ging von 0.1 bis 100 ng,ml. 1 ml einer Üigoxin-Lösung
wurde mit 0,1 ml Digoxin-HRP in einer geeigneten Verdünnung vermischt und anschließend wurden
2 mg Antidigoxincellulose, die in 0.4 ml Puffer suspendiert war, zugegeben. Das Gemisch wurde
6 h hei Raumtemperatur rotiert und anschließend zentrifugiert und die Enzymaktivität in der überstehenden
Flüssigkeit bestimmt.
Zugabe von 0.8 ng Digoxin führte zu einer meßbaren Zunahme der Enzymaktivität in der
überstehenden Flüssigkeit. Digoxin allein zeigte eine geringe Kreuzreaktion in dem System während
Cholesterin, Cortisol. Östradiol. Testosteron und Progesteron keine Kreuzreaktion in deir
System zeigten.
Beispiel 6
Bestimmung von Cortisol
Bestimmung von Cortisol
A) Herstellung von Cortisol-21-galactose-oxidase
50 mg Cortisol-21-hemisuccinat und 100 mi
Galactoseoxidase wurden nach dem in Beispiel A) beschriebenen gemischten Anhydridverfahrei
hergestellt.
B) Herstellung von unlöslichem Transcoi tin
100 mg Transcortin, das durch Chromatogra phie mit DEAE, Cellulose b/w. Hydroxylapat
gercinigi worden war. wurden folgendermaße mit Hilfe des CNBr-Verfahrens an 3 g Sepharos
4 B gekoppelt: 3 g Scpharosc 4 B-Suspensio wurden aktiviert durch Vermischen mit 4 ml eine
2,5"„igen (Gewicht,Volumen) CNBr-Lösung i
destilliertem Wasser und anschließend wurde dt pH-Wert mit 1 η NaOH auf 10 bis 11 cingestel
45
und 6 min auf diesem Wert gehalten. Die Sepharose
wurde mit Eiswasser und 0,1 m NaHCO., gewaschen. Dann wurden 100 mg Transcoitin in
20 ml 0,1 m NaHCO3 zugegeben und die Suspension
24 h bei 4' C geschüttelt. Dann wurde nacheinander mit 0,5 m NaHCO3, 0,05 m Citratpuffer
mit einem pH-Wert von 1,1 und 0,05 m Phosphatpuffer mit einem pH-Wert von 6 gewaschen und
die Sepharose in dem letzten Puffer gelassen, zu dem 0,1 "■„ Merthiolat zugegeben worden war.
C) Bestimmung von Cortisol
0,5 ml einer cortisolhaltigen Probe (Standard.
Plasma oder Urin) wurden zweimal mit Melhylenchlorid extrahiert (2 ■ 3 ml). Die vereinigten Auszüge
wurde zur Troekne eingedampft. Der Rückstand wurde in 0,5 ml physiologischer Kochsalzlösung
aufgenommen und mit 0,2 ml Cortisol-21-galactosc-oxida.se
in einer geeigneten Konzentration und 0,3 ml Transcortin-Scpharose-Suspension
(5 mg nil) vermischt. Das Gemisch wurde 15 min bei 4 C rotiert und zentrifugiert. Anschließend
wurde die Enzymak'tivität in der überslehcnden Flüssigkeit durch Zugabe von 0,5 ml dieser Flüssigkeit
zu 1,5 ml eines Substrats bestimmt. Das Substrat bestand aus 100 mg D-Galaciosc, 20 mg
5-Aminosalicylsäure und IO μ« Pcroxidasc in
450 ml 0,02 m Phosphatpuffer mit einem pH-Wert von 6.0. 30 min später wurde die Lxtinklioi
bei 460 um gemessen.
5 ng;inI Cortisol in der Probe führten zu eine
meßbaren Zunahme der Enzymakliv ität in de überstehenden Flüssigkeit. Corticostcrin und Pro
gcstcron beeinflussen das System nur. wenn gii"
ßere Mengen zugegeben wurde. Testosteron um
Aldostcron besaßen kaum einen Einfluß.
Bestimmung von Tnmseoriin
Die zur Bestimmung \on Cortisol, wie in Beispiel (
beschrieben, verwendeten Reagenlien winden ebeiiM
zur Bestimmung von Transcorlin verwendet.
Von einer Verdünnungsreihe von Transcoitin von ( bis 1280 ng/ml wurden 0,5 ml 15 min bei 4 C mi
0.2 ml Cortisol-21-galnctosc-oxidase in einer einsprechenden
Verdünnung mkubiert. Zu dieser Verdiiiv nungsreihe wurden 0.3 ml Transcortin-Scpharosi
(15 mg ml) zugegeben und das Gemisch 15 min be 4 C roiicrl. Die Aktivität der überstehenden Flüssigkeit
wurde, wie in Beispiel 6 beschrieben, gemessen.
Eine Probe, enthaltend 40 ng nil Transcoitin. zeigte eine meßbare Zunahme der Enzymaktiv ität in dci überstehenden Flüssigkeit, wahrend sich bei Gegenwart von 320 ng'ml die gesamte Enzymaktivität in dci überstellenden Flüssigkeit fand.
Eine Probe, enthaltend 40 ng nil Transcoitin. zeigte eine meßbare Zunahme der Enzymaktiv ität in dci überstehenden Flüssigkeit, wahrend sich bei Gegenwart von 320 ng'ml die gesamte Enzymaktivität in dci überstellenden Flüssigkeit fand.
Hierzu 3 Blatt Zeichnungen
i ·.
Claims (3)
1. Verfahren zum Nachweis und zur Bestimmung von einem Hapten oder dessen Antikörper unter
Ausnutzung der für derartige Substanzen bekannten Bindungsaktivität, dadurch gekennzeichnet,
daß die Bestimmung mit einer bestimmten Menge eines Kopplungsproduktes aus dem Hapten und einem Enzym und einem in unlösliche
Form gebrachten Bestandteil der Reaktion Hapten-Antikörper durchgeführt wird und die
Enzym-Aktivität in der flüssigen oder festen Phase bestimmt wird.
2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß ein Vitamin oder Hormon als Hapten
verwendet wird.
3. Verfahren nach Anspruch ] oder 2, dadurch gekennzeichnet, daß eineOxidoreduktase als Enzym
verwendet wird. ao
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL707016396A NL154598B (nl) | 1970-11-10 | 1970-11-10 | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
Publications (3)
Publication Number | Publication Date |
---|---|
DE2155658A1 DE2155658A1 (de) | 1972-05-18 |
DE2155658B2 true DE2155658B2 (de) | 1976-08-05 |
DE2155658C3 DE2155658C3 (de) | 1978-09-14 |
Family
ID=19811504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2155658A Expired DE2155658C3 (de) | 1970-11-10 | 1971-11-09 | Verfahren zum Nachweis und zur Bestimmung von einem Hapten oder dessen Antikörper |
Country Status (16)
Country | Link |
---|---|
US (1) | US3850752A (de) |
AU (1) | AU468060B2 (de) |
BE (1) | BE775187A (de) |
BR (1) | BR7107459D0 (de) |
CA (1) | CA967464A (de) |
CH (1) | CH617774A5 (de) |
DE (1) | DE2155658C3 (de) |
DK (1) | DK140268B (de) |
ES (1) | ES396741A1 (de) |
FI (1) | FI54033C (de) |
FR (1) | FR2113733A5 (de) |
GB (1) | GB1348935A (de) |
IT (1) | IT986829B (de) |
NL (1) | NL154598B (de) |
SE (1) | SE451162B (de) |
ZA (1) | ZA717192B (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2323467A1 (de) * | 1972-05-11 | 1973-11-29 | Akzo Nv | Verfahren zum nachweis und zur bestimmung von haptenen |
DE2743445A1 (de) * | 1976-09-29 | 1978-03-30 | Mochida Pharm Co Ltd | Immunchemisches haptenmessverfahren |
DE2811537A1 (de) * | 1977-03-16 | 1978-09-21 | Miles Yeda Ltd | Empfindlicher quantitativer assay |
EP0174652A2 (de) * | 1984-09-13 | 1986-03-19 | Roche Diagnostics GmbH | Immunchemisches Messverfahren für Haptene und Proteine |
Families Citing this family (1624)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630328B2 (en) | 1909-07-15 | 2003-10-07 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms |
USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
US3905871A (en) * | 1971-05-14 | 1975-09-16 | Syva Co | Lactam conjugates to enzymes |
US4203802A (en) * | 1971-05-14 | 1980-05-20 | Syva Company | Inhibitable enzyme amplification assay |
US4282325A (en) * | 1971-05-14 | 1981-08-04 | Syva Company | Enzyme bound corticosteroids |
US4046636A (en) * | 1974-06-20 | 1977-09-06 | Syva Company | Diazepam enzyme conjugates |
US4191613A (en) * | 1971-05-14 | 1980-03-04 | Syva Company | Malate dehydrogenase conjugates for enzyme immunoassays |
US4039385A (en) * | 1972-05-08 | 1977-08-02 | Syva Company | Cardiac glycoside enzyme conjugates |
US3790447A (en) * | 1972-07-05 | 1974-02-05 | Abbott Lab | Streptococci diagnostic method |
US3966556A (en) * | 1972-11-06 | 1976-06-29 | Syva Company | Compounds for enzyme amplification assay methadone analogs |
US3975237A (en) * | 1972-11-06 | 1976-08-17 | Syva Company | Compounds for enzyme amplification assay - - ecgonine analogs |
US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
NL7501215A (nl) * | 1975-02-01 | 1976-08-03 | Akzo Nv | Methode voor het aantonen en bepalen van een antigeen of antilichaam. |
US4043872A (en) * | 1975-02-20 | 1977-08-23 | Syva Company | Polyiodothyronine immunoassay |
USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
US4096138A (en) * | 1975-12-08 | 1978-06-20 | Scherr George H | Immunological test procedure |
US4166767A (en) * | 1976-03-25 | 1979-09-04 | Dainippon Pharmaceutical Co., Ltd. | Insolubilized antibody |
GB1572220A (en) * | 1976-10-07 | 1980-07-30 | Mochida Pharm Co Ltd | Immunochemical process of measuring physiologically active substances |
US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4134792A (en) * | 1976-12-06 | 1979-01-16 | Miles Laboratories, Inc. | Specific binding assay with an enzyme modulator as a labeling substance |
IT1153999B (it) * | 1977-03-15 | 1987-01-21 | Snam Progetti | Composizione atta alla determinazione della triiodotironina e metodo diagnostico impiegante la stessa |
US4156081A (en) * | 1977-04-15 | 1979-05-22 | Syva Company | Theophylline antigens and antibodies |
IT1114861B (it) * | 1977-05-12 | 1986-01-27 | Sclavo Inst Sieroterapeut | Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo |
US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
FR2422956A1 (fr) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
DE2825650C3 (de) * | 1978-06-12 | 1981-02-05 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur Bestimmung des Thyroxin-bindungsindex im Serum |
US4269938A (en) * | 1979-03-08 | 1981-05-26 | Eastman Kodak Company | Assay of peroxidatively active materials |
US4376825A (en) * | 1979-05-07 | 1983-03-15 | Syva Company | Enzyme amplification compounds for assays for androgens |
JPS55152459A (en) * | 1979-05-18 | 1980-11-27 | Yamasa Shoyu Co Ltd | Method and reagent for measuring quantity of cyclic nucleotide |
US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
US4391904A (en) * | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4347312A (en) * | 1980-03-20 | 1982-08-31 | Research Triangle Institute | Detection of antibiotics in milk |
JPS5714748A (en) * | 1980-07-01 | 1982-01-26 | Dainippon Pharmaceut Co Ltd | Kit for quantitative determination of valproic acid and its method for quantitative determination |
US4323647A (en) * | 1980-10-15 | 1982-04-06 | University Of Miami | Steric hindrance enzyme immunoassay |
US4604365A (en) * | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
EP0079962B1 (de) * | 1981-06-02 | 1985-08-28 | Electro-Nucleonics, Inc. | Test durch immunoniederschlag |
US5703206A (en) * | 1981-09-08 | 1997-12-30 | Univ Rockefeller | Macrophage inflammatory protein 2 (MIP-2) |
US4419453A (en) * | 1981-09-28 | 1983-12-06 | The Dow Chemical Company | Immunological agglutination assays with dyed or colored latex and kits |
US4506009A (en) * | 1982-03-30 | 1985-03-19 | University Of California | Heterogeneous immunoassay method |
US4535057A (en) * | 1982-07-26 | 1985-08-13 | Amf Incorporated | Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system |
US4530900A (en) * | 1982-09-13 | 1985-07-23 | Seragen Diagnostics Inc. | Soluble insoluble polymers in enzymeimmunoassay |
ZA841924B (en) * | 1983-07-25 | 1984-10-31 | Becton Dickinson Co | Chromogenic tracers for use in an assay |
EP0154631A4 (de) * | 1983-07-27 | 1985-11-25 | American Hospital Supply Corp | Verfahren zur selektiven redurzierung von nitrilen. |
FR2550799B1 (fr) * | 1983-08-17 | 1986-02-21 | Commissariat Energie Atomique | Compose marque par une enzyme, son procede de preparation et son utilisation en enzymoimmunologie |
US4713347A (en) * | 1985-01-14 | 1987-12-15 | Sensor Diagnostics, Inc. | Measurement of ligand/anti-ligand interactions using bulk conductance |
US4786594A (en) * | 1986-05-14 | 1988-11-22 | Syntex (U.S.A.) Inc. | Enzyme immunoassay |
JPH04500970A (ja) * | 1988-09-02 | 1992-02-20 | ザ ロックフェラー ユニヴァーシティ | マクロファージ由来炎症メディエーター (mip―2) |
DE3856224T2 (de) | 1988-09-29 | 1998-12-03 | Chiron Corp., Emeryville, Calif. | Nachweis eines Polynukleotids durch Ersätzung einer Kette an einer Fangsonde |
CA2031109C (en) * | 1990-07-27 | 1992-01-28 | Susan J. Danielson | Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products |
CA2029006C (en) * | 1990-07-27 | 2001-07-17 | Michael R. Detty | Dicarboxylic acid oxidation products |
US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
US5268298A (en) * | 1991-04-26 | 1993-12-07 | Life Technologies, Inc. | System for delivering oxygen to a cell culture medium |
ATE184703T1 (de) * | 1991-07-19 | 1999-10-15 | Cytimmune Sciences Inc | Verfahren und testsatz zur messung von endogenen zytokinen |
US5965379A (en) * | 1991-07-19 | 1999-10-12 | Cytimmune Sciences Inc. | Method for measuring endogenous cytokines |
US5464749A (en) | 1991-07-22 | 1995-11-07 | Bayer Corporation | Immunoassay of free substances in biological fluids |
US5939524A (en) * | 1991-12-09 | 1999-08-17 | The Scripps Research Institute | Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US5354692A (en) * | 1992-09-08 | 1994-10-11 | Pacific Biotech, Inc. | Analyte detection device including a hydrophobic barrier for improved fluid flow |
US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
US7060283B1 (en) | 1992-09-15 | 2006-06-13 | Ortho Diagnostic Systems, Inc. | Immunoreactive peptides from Epstein-Barr virus |
US7326535B2 (en) | 1993-09-15 | 2008-02-05 | Ortho Diagnostic Systems Inc. | Immunoreactive peptides from Epstein-Barr virus |
US5637467A (en) * | 1992-10-13 | 1997-06-10 | Behringwerke Ag | Heterogeneous assay using a pendulous drop |
US6953573B1 (en) * | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
US6495343B1 (en) | 1993-06-18 | 2002-12-17 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US6638905B2 (en) * | 1993-06-18 | 2003-10-28 | The Salk Institute For Biological Studies | Cloning and recombinant production of CFR receptor(s) |
US20040259113A1 (en) * | 1993-07-22 | 2004-12-23 | Mayo Foundation For Medical Education And Research, Hybritech Incorporated | Method for detection of metastatic prostate cancer |
US6103237A (en) * | 1993-07-22 | 2000-08-15 | Hybritech Incorporated | Stable variant hK2 polypeptide |
US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
US5684144A (en) * | 1993-07-28 | 1997-11-04 | University Of North Texas | Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof |
US5681699A (en) * | 1994-02-11 | 1997-10-28 | Cedars-Sinai Medical Center | Methods of diagnosing ulcerative colitis and Crohn's disease |
US6884590B1 (en) | 1994-02-11 | 2005-04-26 | Cedars-Sinai Medical Center | Methods of screening for ulcerative colitis and crohn's disease |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
EP0804593A1 (de) * | 1994-05-10 | 1997-11-05 | Mayo Foundation For Medical Education And Research | Rekombinantes hk2 polypeptid |
AU2635295A (en) * | 1994-06-13 | 1996-01-05 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
US5589344A (en) * | 1994-06-15 | 1996-12-31 | Johnson & Johnson Clinical Diagnostics, Inc. | Test kit and method for competitive specific binding assay |
AU686004B2 (en) | 1994-08-12 | 1998-01-29 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
ATE209660T1 (de) | 1994-08-12 | 2001-12-15 | Myriad Genetics Inc | 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US8236493B2 (en) | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US6974666B1 (en) * | 1994-10-21 | 2005-12-13 | Appymetric, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
US7005509B1 (en) | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
US6506553B1 (en) | 1995-03-30 | 2003-01-14 | Ortho Diagnostics Systems, Inc. | Method for diagnosis of Epstein-Barr virus associated disease |
US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
US5858661A (en) * | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
GB0112226D0 (en) * | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
EP2258726A1 (de) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | Menschliche Antikörper mit hoher Affinität gegen c-erbB-2 |
US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
CA2239733C (en) | 1995-12-18 | 2001-04-03 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
US7282327B2 (en) * | 1996-01-23 | 2007-10-16 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US7468243B2 (en) | 2001-03-12 | 2008-12-23 | Affymetrix, Inc. | 2-aminopyrimidin-4-one nucleic acid labeling compounds |
US20010018514A1 (en) * | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
US20040210045A1 (en) * | 1996-01-23 | 2004-10-21 | Mcgall Glenn | Nucleic acid labeling compounds |
US6864059B2 (en) * | 1996-01-23 | 2005-03-08 | Affymetrix, Inc. | Biotin containing C-glycoside nucleic acid labeling compounds |
US7291463B2 (en) | 1996-01-23 | 2007-11-06 | Affymetrix, Inc. | Nucleic acid labeling compounds |
EP0880598A4 (de) * | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Verfahren zur analyse von nukleinsäure |
US6965020B2 (en) | 1996-01-23 | 2005-11-15 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US7423143B2 (en) * | 1996-01-23 | 2008-09-09 | Affymetrix. Inc. | Nucleic acid labeling compounds |
WO1997029212A1 (en) | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
US6924094B1 (en) * | 1996-02-08 | 2005-08-02 | Affymetrix, Inc. | Chip-based species identification and phenotypic characterization of microorganisms |
EP1728875A3 (de) | 1996-02-08 | 2007-05-09 | Affymetrix, Inc. | Speziesbestimmung und phenotypische Charakterisierung von Mikroorganismen auf der Basis eines Chips |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
WO1997034629A1 (en) * | 1996-03-22 | 1997-09-25 | University Of Georgia Research Foundation, Inc. | Immunogenic compositions comprising porphyromonas gingivalis peptides and methods |
US6942862B2 (en) * | 1996-04-01 | 2005-09-13 | University Of Washington | Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
ATE403001T1 (de) | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
IL127938A (en) | 1996-07-08 | 2002-09-12 | Burstein Lab Inc | A device with a main signal fixed for diagnostic applications and a test method |
US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
US20050214827A1 (en) * | 1996-07-08 | 2005-09-29 | Burstein Technologies, Inc. | Assay device and method |
US6331275B1 (en) | 1996-07-08 | 2001-12-18 | Burstein Technologies, Inc. | Spatially addressable, cleavable reflective signal elements, assay device and method |
US6342349B1 (en) | 1996-07-08 | 2002-01-29 | Burstein Technologies, Inc. | Optical disk-based assay devices and methods |
EP0920505B1 (de) | 1996-08-16 | 2008-06-04 | Schering Corporation | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
JP4299886B2 (ja) * | 1996-09-24 | 2009-07-22 | タノックス インコーポレイテッド | アポトーシス関連ペプチドをコードする遺伝子ファミリー、それによってコードされるペプチド、およびそれらの使用方法 |
US20070299005A1 (en) * | 1996-09-24 | 2007-12-27 | Tanox, Inc. | Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
GB2321642B8 (en) | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6808880B2 (en) * | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
US6479263B1 (en) | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
CA2272850C (en) | 1996-11-15 | 2009-02-24 | Board Of Regents, The University Of Texas System | Genetic test for equine severe combined immunodeficiency disease |
EP1995318A1 (de) | 1996-12-13 | 2008-11-26 | Schering Corporation | Säugerzelloberflächenantigene und damit zusammenhängende Reagenzien |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
ES2331595T3 (es) | 1997-02-07 | 2010-01-08 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Factor neurotrofico dependiente de actividad iii (adnf iii). |
US6268165B1 (en) | 1997-03-19 | 2001-07-31 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian cancer |
ATE403672T1 (de) | 1997-04-01 | 2008-08-15 | Theracos Inc | Oral aktive fraktion der momordica charantia, ihre aktiven peptide und ihre verwendung bei der behandlung des diabetes |
US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US7413864B2 (en) * | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
DE69841514D1 (de) | 1997-05-07 | 2010-04-01 | Schering Corp | Menschliche Toll-Like-Rezeptorproteine, zugehörige Reagenzien und Verfahren |
US7115722B1 (en) | 1997-05-22 | 2006-10-03 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
US6528271B1 (en) | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
WO1998059073A1 (en) | 1997-06-20 | 1998-12-30 | Mayo Foundation For Medical Education And Research | Method for detection of breast cancer |
US20020122807A1 (en) * | 1998-07-07 | 2002-09-05 | Dan Michael D. | Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
IL133494A0 (en) | 1997-07-09 | 2001-04-30 | Schering Corp | Isolated dendritic cell membrane protein genes |
EP0927266A1 (de) | 1997-07-11 | 1999-07-07 | The University Of North Texas Health Science Center At Fort Worth | Das escherichia coli csrb gen, davon kodierter rns, und verfahren zu deren anwendung |
US20030157642A1 (en) | 1997-07-15 | 2003-08-21 | Caldwell Robert M. | Increasing production of proteins in gram-positive microorganisms |
US6762039B2 (en) * | 1997-07-15 | 2004-07-13 | Genencor International, Inc. | Bacillus subtillis with an inactivated cysteine protease-1 |
US6506579B1 (en) | 1997-07-15 | 2003-01-14 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms using SecG |
US6723550B1 (en) * | 1997-07-15 | 2004-04-20 | Genencor International, Inc. | Proteases from gram-positive organisms |
US6521421B1 (en) * | 1997-07-16 | 2003-02-18 | Genencor International, Inc. | Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6180411B1 (en) | 1997-08-01 | 2001-01-30 | The Regents Of The University Of California | Light-triggered indicators that memorize analyte concentrations |
PT1003861E (pt) | 1997-08-01 | 2007-01-31 | Schering Corp | Proteínas de membrana de células de mamíferos;reagentes relacionados |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
US6521440B1 (en) * | 1997-09-15 | 2003-02-18 | Genencor International, Inc. | Proteases from gram-positive organisms |
US6300117B1 (en) * | 1997-09-15 | 2001-10-09 | Genencor International, Inc. | Proteases from gram-positive organisms |
US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
AU748467B2 (en) | 1997-10-17 | 2002-06-06 | University Of South Florida | Method to diagnose and monitor cellular immune deficiencies |
GB9724627D0 (en) | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Gram positive microorganism formate pathway |
US6316241B1 (en) * | 1997-11-20 | 2001-11-13 | Genencor International, Inc. | Alpha/beta hydrolase-fold enzymes |
GB9724629D0 (en) * | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Alpha/beta hydrolase-fold enzymes |
US6599731B1 (en) * | 1997-12-30 | 2003-07-29 | Genencor International, Inc. | Proteases from gram positive organisms |
US6465186B1 (en) * | 1997-12-30 | 2002-10-15 | Genecor International, Inc. | Proteases from gram positive organisms |
GB9727470D0 (en) * | 1997-12-30 | 1998-02-25 | Genencor Int Bv | Proteases from gram positive organisms |
US6528255B1 (en) * | 1997-12-30 | 2003-03-04 | Genencor International, Inc. | Proteases from gram positive organisms |
US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
US6780609B1 (en) | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
US6596501B2 (en) | 1998-02-23 | 2003-07-22 | Fred Hutchinson Cancer Research Center | Method of diagnosing autoimmune disease |
US6060260A (en) * | 1998-02-27 | 2000-05-09 | Dade Behring Inc. | Methods for reducing adsorption in an assay |
BR9908422A (pt) | 1998-03-04 | 2000-10-31 | Genencor Int | Pululanase modificada, ácido nucleico, vetor de expressão, microorganismo hospedeiro, processo para a produção de uma pululanase modificada em uma célula hospedeira, composição enzimática, processo para sacarificação de amido, e, b. licheniformis |
AU768018C (en) | 1998-03-20 | 2004-09-30 | Curators Of The University Of Missouri, The | Early pregnancy diagnosis using PAGS (pregnancy- associated glycoproteins) |
US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
ATE328278T1 (de) * | 1998-03-30 | 2006-06-15 | Orasure Technologies Inc | Sammelapparat für einschrittigen test von mundflüssigkeiten |
US8062908B2 (en) * | 1999-03-29 | 2011-11-22 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
CA2323058C (en) * | 1998-03-31 | 2011-03-29 | Genzyme Corporation | Methods for the diagnosis and treatment of lung cancer by detection of proto-oncogene overexpression |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
US7108968B2 (en) * | 1998-04-03 | 2006-09-19 | Affymetrix, Inc. | Mycobacterial rpoB sequences |
US6872537B1 (en) | 1998-04-14 | 2005-03-29 | Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
US6699969B1 (en) | 1998-04-14 | 2004-03-02 | The Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
EP1071943A4 (de) | 1998-04-14 | 2005-08-10 | Univ California | Test zum nachweis von mikrotubulus depolymerisierungshemmern |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
AU4994899A (en) | 1998-07-13 | 2000-02-01 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
JP2002521666A (ja) * | 1998-07-21 | 2002-07-16 | バースタイン テクノロジーズ,インコーポレイティド | 光ディスクをベースとするアッセイ装置および方法 |
DE69904941T3 (de) | 1998-07-21 | 2008-01-31 | Danisco A/S | Lebensmittel |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
SE9803099D0 (sv) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
WO2000017356A2 (en) * | 1998-09-18 | 2000-03-30 | The Rockefeller University | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
JP2002526079A (ja) | 1998-09-21 | 2002-08-20 | シェーリング コーポレイション | ヒトインターロイキン−b50、治療的使用 |
EP0997476A3 (de) | 1998-09-25 | 2000-07-19 | Schering-Plough | Antikörper gegen ein Antigen auf Langerhans Zellen in Säugetieren und deren Verwendungen |
CA2344653A1 (en) | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
EP2341144A1 (de) | 1999-01-11 | 2011-07-06 | Schering Corporation | Interleukin-17-verbundene Säugetier-Cytokine. |
RU2249039C2 (ru) | 1999-02-04 | 2005-03-27 | Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. | Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты) |
US6156515A (en) * | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
EP1159299B1 (de) | 1999-03-11 | 2009-01-14 | Schering Corporation | Cytokine aus säugetieren, verwandte reagenzien und verfahren |
KR101005124B1 (ko) | 1999-05-13 | 2011-01-04 | 쉐링 코포레이션 | Ox2 수용체 동족체 |
EP2385124B1 (de) | 1999-05-14 | 2013-09-11 | Arbor Vita Corporation | Peptide oder Peptidanaloga zur Modulation der Bindung zwischen einem PDZ-Protein und einem PL-Protein |
US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
EP1950299A1 (de) | 1999-06-01 | 2008-07-30 | Schering Corporation | Säuger-Rezeptorproteine, zugehörige Reagenzien und Verfahren |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
GB9914210D0 (en) | 1999-06-17 | 1999-08-18 | Danisco | Promoter |
CA2377541A1 (en) * | 1999-06-25 | 2001-01-04 | Eduardo N. Mitrani | Method of inducing angiogenesis by micro-organs |
US6531130B1 (en) * | 1999-07-06 | 2003-03-11 | The Board Of Trustees Of The Leland Stanford University | Treatment of demyelinating autoimmune disease with ordered peptides |
CN1365391A (zh) | 1999-07-30 | 2002-08-21 | 先灵公司 | 哺乳动物细胞因子以及相关试剂 |
US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
EP1905832A3 (de) | 1999-09-09 | 2009-09-09 | Schering Corporation | Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen |
ATE426016T1 (de) | 1999-09-24 | 2009-04-15 | Cybios Llc | Pluripotent embryonale stammzellen-ahnliche zellen, zusammensetzungen und ihre vervendungen |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
US20030190644A1 (en) | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
US7030228B1 (en) * | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
AU784258B2 (en) * | 1999-11-19 | 2006-03-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aspegillus niger beta-glucosidase gene, protein and uses thereof |
EP2275447A1 (de) | 1999-11-24 | 2011-01-19 | Schering Corporation | Verfahren zur Inhibierung von Krebs Metastasen |
EP1247095B1 (de) | 1999-12-06 | 2008-10-15 | Board Of Trustees Of The University Of Illinois | Hochaffine t-zellrezeptorproteine und verfahren |
US6544792B1 (en) | 1999-12-21 | 2003-04-08 | Genencor International, Inc. | Production of secreted polypeptides |
US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
US7385106B2 (en) * | 2000-01-24 | 2008-06-10 | Ramot At Tel Aviv University Ltd. | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
DE10003734A1 (de) * | 2000-01-28 | 2001-08-02 | Bosch Gmbh Robert | Detektionsverfahren und -vorrichtung |
CA2400948A1 (en) * | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US7875442B2 (en) * | 2000-03-24 | 2011-01-25 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
US7829313B2 (en) * | 2000-03-24 | 2010-11-09 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
US8288128B2 (en) * | 2004-11-18 | 2012-10-16 | Eppendorf Array Technologies S.A. | Real-time quantification of multiple targets on a micro-array |
EP1294748B1 (de) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2001074841A1 (en) | 2000-03-31 | 2001-10-11 | The Scripps Research Institute | Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
US20030108927A1 (en) * | 2000-04-03 | 2003-06-12 | Kathryn Leishman | Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases |
SI1274450T1 (sl) | 2000-04-18 | 2009-04-30 | Schering Corp | Medicinske uporabe agonistov in antagonistov IL-174 |
IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
NZ522146A (en) | 2000-05-10 | 2004-10-29 | Schering Corp | Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5 |
EP1283849A2 (de) | 2000-05-25 | 2003-02-19 | Schering Corporation | Menschlische-rezeptor proteine; verwandte reagenzien und methoden |
WO2005000087A2 (en) * | 2003-06-03 | 2005-01-06 | Chiron Corporation | Gene products differentially expressed in cancerous colon cells and their methods of use ii |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
ATE493147T1 (de) | 2000-08-08 | 2011-01-15 | Technion Res & Dev Foundation | Pharmazeutische zusammensetzungen und methoden nützlich zur behandlung von krebs oder leberfibrose |
EP1810978B1 (de) | 2000-08-08 | 2013-02-13 | St. Jude Children's Research Hospital | Für Polypeptide aus Gruppe-B-Streptokokkus kodierende Nukleinsäuren und therapeutische Zusammensetzung sowie Impfstoffe daraus |
GB0020498D0 (en) | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
EP1683874A3 (de) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Verfahren zur Isolierung von Genen, die für Proteine mit spezifischer Funktion kodieren, und zur Auslese von pharmazeutisch aktiven Wirkstoffen |
JP2004509617A (ja) | 2000-09-08 | 2004-04-02 | シェーリング コーポレイション | 哺乳動物遺伝子;関連試薬および方法 |
EP2028187A1 (de) | 2000-09-08 | 2009-02-25 | Board Of Regents, The University Of Texas System | Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide |
US6673623B1 (en) | 2000-09-12 | 2004-01-06 | Novocure, Inc. | Methods and compositions that control lipid production |
US7316924B2 (en) * | 2000-09-18 | 2008-01-08 | Genencor International, Inc. | Twin-arginine translocation in Bacillus |
US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
WO2002026191A2 (en) * | 2000-09-28 | 2002-04-04 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
US7632522B2 (en) | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US20050136431A1 (en) * | 2000-11-03 | 2005-06-23 | Oakley Robert H. | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
US7163800B2 (en) * | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
US7018812B2 (en) * | 2000-11-03 | 2006-03-28 | Duke University | Modified G-protein coupled receptors |
US6890734B2 (en) | 2000-11-10 | 2005-05-10 | Schering Corporation | Nucleic acids encoding a cytokine receptor complex |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
ES2338529T3 (es) | 2000-11-17 | 2010-05-10 | Vascular Biogenics Ltd. | Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion. |
WO2002041827A2 (en) | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US20040248093A1 (en) * | 2000-11-27 | 2004-12-09 | Coombs James Howard | Magneto-optical bio-discs and systems including related methods |
US20020172980A1 (en) * | 2000-11-27 | 2002-11-21 | Phan Brigitte Chau | Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems |
US20030003464A1 (en) * | 2000-11-27 | 2003-01-02 | Phan Brigitte C. | Dual bead assays including optical biodiscs and methods relating thereto |
JP2004514445A (ja) * | 2000-11-29 | 2004-05-20 | リンクス バイオテック ジーエムビーエイチ | 新規な網膜特異的ヒトタンパク質C7orf9、C12orf7、MPP4およびF379 |
AU2085502A (en) | 2000-11-30 | 2002-06-11 | Molecular Skincare Ltd | Diagnosis and treatment of disease |
WO2002043651A2 (en) * | 2000-11-30 | 2002-06-06 | Yeda Research And Development Co. Ltd. | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
WO2002046400A2 (en) * | 2000-12-08 | 2002-06-13 | The Board Of Trustees Of The University Of Illinois | Mutated class ii major histocompatibility proteins |
US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
GB0101762D0 (en) * | 2001-01-23 | 2001-03-07 | Medical Res Council | Method |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
WO2002060376A2 (en) * | 2001-01-31 | 2002-08-08 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
CA2439687A1 (en) | 2001-03-01 | 2002-09-12 | Hollis-Eden Pharmaceuticals, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
US20030104410A1 (en) * | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
US20030220475A1 (en) * | 2001-04-03 | 2003-11-27 | Fields Howard A. | Neutralizing immunogenic hev polypepetides |
AU2002254524A1 (en) * | 2001-04-06 | 2002-10-21 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Use of semenogelin in the diagnosis, prognosis and treatment of cancer |
US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
JP4309137B2 (ja) | 2001-05-18 | 2009-08-05 | ダニスコ エイ/エス | 酵素を使用した練り粉の調製方法 |
EP1395275B1 (de) | 2001-05-22 | 2008-11-12 | Merck & Co., Inc. | Beta-secretase-substrat und seine verwendung |
AU2002312329A1 (en) * | 2001-06-05 | 2002-12-16 | The Regents Of The University Of California | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule |
US20090324612A1 (en) * | 2001-06-05 | 2009-12-31 | Kaufman Daniel L | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
US20070190534A1 (en) * | 2001-06-11 | 2007-08-16 | Genesis Genomics Inc. | Mitochondrial sites and genes associated with prostate cancer |
WO2003008534A2 (en) * | 2001-07-19 | 2003-01-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
AU2002312543A1 (en) * | 2001-08-01 | 2003-02-17 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
US20030082596A1 (en) * | 2001-08-08 | 2003-05-01 | Michael Mittmann | Methods of genetic analysis of probes: test3 |
US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
CA2458640A1 (en) | 2001-08-16 | 2003-03-06 | Bar-Ilan University | Diagnosis, prevention and treatment of cancer |
US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
US20060068405A1 (en) * | 2004-01-27 | 2006-03-30 | Alex Diber | Methods and systems for annotating biomolecular sequences |
US7718387B2 (en) | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
US7393696B2 (en) | 2001-09-28 | 2008-07-01 | Aspenbio Pharma, Inc. | Bovine pregnancy test |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
JP4381140B2 (ja) | 2001-10-12 | 2009-12-09 | シェーリング コーポレイション | 免疫応答を調節するための二重特異性抗体の使用 |
EP2277887A3 (de) | 2001-10-19 | 2011-02-16 | Vascular Biogenics Ltd. | Polynukleotidkonstrukte, pharmazeutische Zusammensetzungen und Verfahren zur gezielten Abwärtsregulation der Angiogenese und Therapie gegen Krebs |
US7175983B2 (en) * | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
WO2003043524A2 (en) | 2001-11-20 | 2003-05-30 | The Curators Of The University Of Missouri | Compositions and methods for accurate early pregnancy diagnosis |
US6952704B2 (en) * | 2001-11-26 | 2005-10-04 | Microsoft Corporation | Extending a directory schema independent of schema modification |
US8178128B2 (en) * | 2001-12-05 | 2012-05-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles containing polymeric nucleic acid homologs |
WO2003054155A2 (en) * | 2001-12-19 | 2003-07-03 | Bristol-Myers Squibb Company | Pichia pastoris formate dehydrogenase and uses therefor |
US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
US7341844B2 (en) * | 2002-01-16 | 2008-03-11 | Regents Of The University Of Minnesota | Methods for diagnosing autism |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
NZ534399A (en) | 2002-01-25 | 2008-08-29 | G2 Therapies Ltd | Monoclonal antibodies against extracellular loops of C5aR |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20070021345A1 (en) | 2003-06-30 | 2007-01-25 | Ehud Gazit | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
EP2311869B2 (de) | 2002-02-01 | 2020-06-17 | Merck Sharp & Dohme Corp. | Verwendung von mit Zytokinen verwandten Reagentien von Säugetieren |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
WO2003072799A2 (en) | 2002-02-22 | 2003-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Brother of the regulator of imprinted sites (boris) |
US7053188B2 (en) | 2002-02-22 | 2006-05-30 | Purdue Research Foundation | Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase |
CA2479679A1 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
US20030182669A1 (en) * | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
IL164191A0 (en) * | 2002-03-26 | 2005-12-18 | Nanocyte Inc | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc. |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
US7534580B2 (en) * | 2002-05-01 | 2009-05-19 | Ambrilia Biopharma Inc. | PSP94 diagnostic reagents and assays |
US7432342B2 (en) | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
JP4646625B2 (ja) | 2002-05-30 | 2011-03-09 | メモリアル スローン−ケタリング キャンサー センター | Ras媒介性腫瘍形成の治療のためのRas不活性化キナーゼサプレッサ |
CA2492631C (en) * | 2002-05-31 | 2013-03-12 | Genetic Technologies Limited | Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood |
US7290215B2 (en) * | 2002-06-03 | 2007-10-30 | Microsoft Corporation | Dynamic wizard interface system and method |
US7504215B2 (en) | 2002-07-12 | 2009-03-17 | Affymetrix, Inc. | Nucleic acid labeling methods |
AU2003242967A1 (en) * | 2002-07-12 | 2004-02-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and device for inducing biological processes by micro-organs |
NZ584715A (en) | 2002-07-15 | 2011-12-22 | Univ Texas | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
JP4570565B2 (ja) | 2002-07-15 | 2010-10-27 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | ペリプラズム発現によるコンビナトリアルタンパク質ライブラリーのスクリーニング |
US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
CA2494348C (en) | 2002-08-01 | 2014-04-08 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
CA2495121A1 (en) * | 2002-08-10 | 2004-02-19 | Yale University | Nogo receptor antagonists |
CA2496867A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
EP1537415B1 (de) | 2002-09-09 | 2008-12-17 | Arbor Vita Corporation | Verfahren zur diagnose von gebärmutterhalskrebs |
EP1546331B2 (de) | 2002-09-26 | 2016-01-13 | K.U.Leuven Research & Development | Integrase-assoziiertes protein |
US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
KR20050059294A (ko) | 2002-10-24 | 2005-06-17 | 스테릭스 리미티드 | 11-베타-하이드록시 스테로이드 데하이드로게나제 형태 1및 형태 2의 억제제 |
US20040146949A1 (en) * | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
EP2295980A1 (de) | 2002-10-30 | 2011-03-16 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Moleküle und diese verwendende Verfahren zur Messung von nicht-transferringebundenem Eisen |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
WO2004047778A1 (en) | 2002-11-26 | 2004-06-10 | Uc Tech | Materials and methods for preventing and treating microbe-mediated epithelial disorders |
US7947499B2 (en) * | 2002-11-29 | 2011-05-24 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
US8323897B2 (en) | 2002-12-04 | 2012-12-04 | Applied Biosystems, Llc | Multiplex amplification of polynucleotides |
US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
US7422734B2 (en) | 2002-12-12 | 2008-09-09 | R.B.T. (Rakuto Bio Technologies) Ltd. | Methods of producing lignin peroxidase and its use in skin and hair lightening |
JP4613069B2 (ja) | 2002-12-16 | 2011-01-12 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 支持細胞非含有、異種非含有のヒト胚性幹細胞の調製方法およびこれらを使用して調製された幹細胞培養物 |
AU2002953431A0 (en) * | 2002-12-19 | 2003-01-09 | Murdoch University | BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof |
CA2512499A1 (en) | 2003-01-02 | 2004-07-22 | Rappaport Family Institute For Research In The Medical Sciences | Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients |
US20040229245A1 (en) * | 2003-01-06 | 2004-11-18 | Anton Bittner | Methods and algorithms for performing quality control during gene expression profiling on DNA microarray technology |
EP2058275A1 (de) | 2003-01-07 | 2009-05-13 | Ramot at Tel-Aviv University Ltd. | Peptidnanostrukturen mit einem verkapselten Fremdstoff und Verfahren zu ihrer Herstellung |
ATE487796T1 (de) | 2003-01-17 | 2010-11-15 | Danisco | Verfahren zur in-situ-herstellung eines emulgators in einem nahrungsmittel |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
DE602004030000D1 (de) * | 2003-01-17 | 2010-12-23 | Danisco | Verfahren zur in-situ-herstellung eines emulgators in einem nahrungsmittel |
US20050196766A1 (en) | 2003-12-24 | 2005-09-08 | Soe Jorn B. | Proteins |
CA2514179A1 (en) * | 2003-01-24 | 2004-08-12 | Duke University | Modified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera |
EP1599730A2 (de) * | 2003-03-03 | 2005-11-30 | Kouyama, Yoshihisa | Methoden und vorrichtung zur verwendung in der detektion und quantifizierung von verschiedenen zelltypen und verwendung einer optischen bio-disk zur durchführung derselben. |
EP2319857A3 (de) | 2003-03-04 | 2012-06-27 | Yeda Research And Development Co., Ltd. | Pon-Polypeptide, diese codierende Polynukleotide und Zusammensetzungen und verfahren unter Verwendung davon |
US8394582B2 (en) * | 2003-03-05 | 2013-03-12 | Genetic Technologies, Inc | Identification of fetal DNA and fetal cell markers in maternal plasma or serum |
WO2004078917A2 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
KR20060015468A (ko) | 2003-03-07 | 2006-02-17 | 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 | IgA1 침착 질환 치료 |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
ES2433440T3 (es) | 2003-04-04 | 2013-12-11 | Yeda Research And Development Co. Ltd. | Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas |
JP4865540B2 (ja) | 2003-04-08 | 2012-02-01 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 化学誘引物質に対する増大された感受性を有する幹細胞およびそれを産生および使用する方法 |
FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
WO2004092402A1 (en) * | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Dual reporter/dye reduction methodology for evaluating antiviral activity and cytotoxicity of hepatitis c virus inhibitors |
CA2522649A1 (en) * | 2003-04-16 | 2004-11-04 | Biogen Idec Ma Inc. | Treatment of conditions involving amyloid plaques |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
AU2005234725B2 (en) | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
CA2526440C (en) | 2003-05-22 | 2017-10-24 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby |
US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
WO2004111183A2 (en) * | 2003-06-19 | 2004-12-23 | Evogene Ltd. | Plant trichome-specific promoter and leucoplast signal sequence |
JP2007511738A (ja) | 2003-08-08 | 2007-05-10 | ジーンニュース インコーポレーテッド | 変形性関節症のバイオマーカー及びその使用 |
US20050064479A1 (en) * | 2003-08-12 | 2005-03-24 | Affymetrix, Inc. | Compounds and methods for post incorporation labeling of nucleic acids |
CN101076585A (zh) * | 2003-08-14 | 2007-11-21 | 生物平衡公司 | 细菌株系、包括该细菌株系的组合物和其益生菌用途 |
CA2535901A1 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Ups as modifiers of the beta catenin pathway and methods of use |
EP1664796B1 (de) | 2003-09-15 | 2010-12-15 | Oklahoma Medical Research Foundation | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
US20050064435A1 (en) * | 2003-09-24 | 2005-03-24 | Xing Su | Programmable molecular barcodes |
US7625707B2 (en) | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
JP4943848B2 (ja) | 2003-10-07 | 2012-05-30 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Nikに対する抗体、その調製および使用 |
US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
RU2006113588A (ru) * | 2003-10-23 | 2006-08-10 | Пфайзер Продактс Инк. (Us) | Вакцина для периодонтального заболевания |
AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
EP1689786B1 (de) | 2003-11-30 | 2014-05-14 | Yeda Research And Development Co., Ltd. | Verfahren und mittel zur immunmodulierung und verfahren zur identifizierung von immunmodulatoren |
EP2135619A1 (de) | 2003-12-10 | 2009-12-23 | Millennium Pharmaceuticals, Inc. | Humanisierte Anti-CCR2-Antikörper und Anwendungsverfahren |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
DK1722834T3 (da) | 2003-12-22 | 2012-10-22 | Regentis Biomaterials Ltd | Matrix, som omfatter naturligt forekommende tværbundet proteinskelet |
AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
EP1704236B1 (de) | 2003-12-24 | 2017-11-29 | DuPont Nutrition Biosciences ApS | Proteine |
US7718408B2 (en) * | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
GB0716126D0 (en) * | 2007-08-17 | 2007-09-26 | Danisco | Process |
US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
EP1730173A4 (de) * | 2004-02-18 | 2008-10-08 | Merck & Co Inc | Nukleinsäuremoleküle, codierend für neue, durch niedrige spannungen aktivierte, als alpha 1h bezeichnete calciumkanalproteine aus der maus, codierte proteine und verfahren zu deren anwendung |
GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
EP2208797A3 (de) | 2004-03-01 | 2010-11-24 | Applied Biosystems, LLC | Verfahren, Zusammensetzungen und Kits für Polynukleotidamplifikation |
WO2005084699A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
GB0405637D0 (en) | 2004-03-12 | 2004-04-21 | Danisco | Protein |
NZ549787A (en) | 2004-03-12 | 2010-05-28 | Vasgene Therapeutics Inc | Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth |
WO2006073430A2 (en) * | 2004-04-20 | 2006-07-13 | The University Of Chicago | Therapeutic delivery system comprising a high molecular weight peg-like compound |
EP1766095B1 (de) | 2004-05-18 | 2013-10-23 | The Board of Trustees of the Leland Stanford Junior University | Nachweis der proteintranslokation durch beta-galactosidase-reporterfragment-komplementierung |
EP1753871B1 (de) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | An psca-proteine bindende antikörper und verwandte moleküle |
CA2877145C (en) | 2004-06-14 | 2020-03-24 | Evogene Ltd. | Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
US8034553B2 (en) | 2004-06-24 | 2011-10-11 | Kimberly-Clark Worldwide, Inc. | Biomarkers for wound healing |
ITBO20040412A1 (it) * | 2004-07-01 | 2004-10-01 | Eurodent Spa | Lampada dentale particolarmente per ambulatori medico-dentistici |
US8680062B2 (en) | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
DK1776455T3 (da) | 2004-07-16 | 2015-06-22 | Dupont Nutrition Biosci Aps | Lipolytisk enzym, anvendelser deraf i fødevareindustrien |
WO2006014798A2 (en) * | 2004-07-27 | 2006-02-09 | Mount Sinai School Of Medicine | Methods and compositions for using sax2 |
CA2579790A1 (en) * | 2004-07-30 | 2006-02-09 | Mount Sinai School Of Medicine Of New York University | Npc1l1 and npc1l1 inhibitors and methods of use thereof |
US20060073168A1 (en) * | 2004-08-11 | 2006-04-06 | Stephens David S | Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions |
SI2386640T1 (sl) | 2004-08-26 | 2015-06-30 | Engeneic Molecular Delivery Pty Ltd | Dostava funkcionalnih nukleinskih kislin celicam sesalcev preko bakterijsko izvirajočih, intaktnih minicelic |
FI20050753A (fi) | 2004-09-03 | 2006-03-04 | Licentia Oy | Uudet peptidit |
CA2581086C (en) | 2004-09-14 | 2023-11-07 | The Regents Of The University Of Colorado, A Body Corporate | Method for treatment with bucindolol based on genetic targeting |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
JP5307397B2 (ja) | 2004-09-18 | 2013-10-02 | ユニバーシティ オブ メリーランド,ボルチモア | NCCa−ATPチャネルを標的とする治療剤およびその使用方法 |
ATE487484T1 (de) | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür |
CA2580796C (en) * | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
ATE479762T1 (de) | 2004-09-29 | 2010-09-15 | Collplant Ltd | Kollagenproduzierende pflanzen sowie verfahren zu deren erzeugung und verwendung |
ES2524601T3 (es) * | 2004-09-29 | 2014-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | RNasa T2 humana recombinante y usos de la misma |
GB0422052D0 (en) | 2004-10-04 | 2004-11-03 | Dansico As | Enzymes |
US7390489B2 (en) * | 2004-10-08 | 2008-06-24 | Komed Co., Ltd. | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody |
US7781402B2 (en) * | 2004-10-12 | 2010-08-24 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
US20090104170A1 (en) * | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
GB0424940D0 (en) | 2004-11-11 | 2004-12-15 | Danisco | Transcription factors |
EP1812594B1 (de) | 2004-11-18 | 2013-01-09 | Eppendorf Array Technologies | Echtzeitquantifizierung mehrerer ziele auf einem mikro-array |
PT1828249E (pt) | 2004-12-03 | 2011-02-25 | Schering Corp | Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r |
US7504769B2 (en) * | 2004-12-16 | 2009-03-17 | E. I. Du Pont De Nemours + Company | Aromatic chalcogen compounds and their use |
US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
WO2006075334A2 (en) | 2005-01-16 | 2006-07-20 | Zlango Ltd. | Iconic communication |
WO2006075335A2 (en) * | 2005-01-16 | 2006-07-20 | Zlango Ltd. | Communications network system and methods for using same |
ES2562406T3 (es) | 2005-01-31 | 2016-03-04 | Realbio Technologies Ltd. | Dispositivo capilar de flujo lateral de reacción multietapa |
JP5265923B2 (ja) | 2005-02-07 | 2013-08-14 | ジーンニュース インコーポレーテッド | 軽度の変形性関節症のバイオマーカーおよびその使用 |
ES2366654T3 (es) | 2005-02-17 | 2011-10-24 | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. | Biofosfonatos para tratar la endometriosis. |
GB0503546D0 (en) * | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
US8216801B2 (en) | 2005-02-25 | 2012-07-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), The Volcani Center | Methods for treating inflammatory disorders |
US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
KR20080003390A (ko) | 2005-03-31 | 2008-01-07 | 어젠시스 인코포레이티드 | 161p2f10b 단백질과 결합하는 항체 및 관련 분자 |
EP1872136B9 (de) | 2005-04-04 | 2023-02-08 | Biogen MA Inc. | Verfahren und stoffe zur bewertung einer immunantwort auf ein therapeutisches protein |
US20090068207A1 (en) * | 2005-04-15 | 2009-03-12 | Vascular Biogenics Ltd. | Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease |
DE602006017534D1 (de) | 2005-04-18 | 2010-11-25 | Mitomics Inc | Mitochondriale mutationen und umlagerungen als diagnostisches werkzeug zum nachweis von sonneneinstrahlung, prostatakrebs und anderen krebserkrankungen |
US20130022979A1 (en) | 2005-04-18 | 2013-01-24 | Genesis Genomics Inc. | 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
BRPI0611534A2 (pt) | 2005-05-12 | 2010-09-21 | Novartis Ag | genes e proteìnas da brachyspira hyodysenteriae e uso das mesmas para diagnose e terapia |
EP2279726A3 (de) | 2005-05-26 | 2012-06-20 | Biorest Ltd. | Zusammensetzungen und diese verwende Verfahren zur Abgabe von Mitteln in ein Zielorgan geschützt durch eine Blutbarriere |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
ES2524996T3 (es) | 2005-06-16 | 2014-12-16 | Ramot At Tel Aviv University Ltd. | Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC |
EP3042963A1 (de) | 2005-06-20 | 2016-07-13 | Advanced Cell Diagnostics, Inc. | Verfahren zum nachweis von nukleinsäuren in einzelnen zellen und zur identifikation seltener zellen aus grossen heterogenen zellpopulationen |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
AU2006267841B2 (en) | 2005-07-07 | 2011-12-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating H19, and methods of using same |
JP5086254B2 (ja) | 2005-07-07 | 2012-11-28 | フルクルム エスピー リミテッド | Sp1ポリペプチド、変性sp1ポリペプチドおよびそれらの使用 |
EP2484768A3 (de) | 2005-07-18 | 2012-11-21 | Protalix Ltd. | Mukosale oder enterale Verabreichung biologisch aktiver Makromoleküle |
CA2616766A1 (en) | 2005-07-26 | 2007-02-01 | University Of Medicine And Dentistry Of New Jersey | Antibody profiles characteristic of tuberculosis state |
EP1945257A4 (de) * | 2005-08-08 | 2009-05-06 | Onconon Llc | Antikörperzusammensetzungen, verfahren zur behandlung von neoplastischer erkrankung und verfahren zur regulierung der fertilität |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US8916147B2 (en) | 2005-08-24 | 2014-12-23 | Yeda Research and Devolpment Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
EP3354723B1 (de) | 2005-08-29 | 2023-12-13 | Technion Research & Development Foundation Ltd. | Medien zur züchtung von stammzellen |
PL1931710T3 (pl) | 2005-08-31 | 2017-06-30 | Merck Sharp & Dohme Corp. | Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej |
US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
WO2007034487A1 (en) | 2005-09-22 | 2007-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
WO2007041340A2 (en) * | 2005-09-30 | 2007-04-12 | The Trustees Of Columbia University In The City Of New York | Microfluidic cells with parallel arrays of individual dna molecules |
US20070202515A1 (en) * | 2005-10-12 | 2007-08-30 | Pathologica, Llc. | Promac signature application |
US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
ATE518007T1 (de) | 2005-10-21 | 2011-08-15 | Genenews Inc | Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen |
CA2626592C (en) | 2005-10-24 | 2018-07-17 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and fertilizer use efficiency of a plant |
US7842823B2 (en) * | 2005-10-27 | 2010-11-30 | The Regents Of The University Of California | Fluorogenic probes for reactive oxygen species |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EA014900B1 (ru) | 2005-11-07 | 2011-02-28 | Зе Скрипс Ресеч Инститьют | Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором |
US8124351B2 (en) | 2005-11-18 | 2012-02-28 | Board Of Regents, The University Of Texas System | Quantification of fusion proteins and their activity from chromosomal translocation |
EP2390312A1 (de) | 2005-11-29 | 2011-11-30 | Gamida Cell Ltd. | Verfahren zur Verbesserung von Stammzellen-homing und -implantationwirbelschichten |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP1960547A2 (de) | 2005-12-08 | 2008-08-27 | Novartis AG | Auswirkungen von fgfr3-inhibitoren auf die gentranskription |
US20070134814A1 (en) * | 2005-12-09 | 2007-06-14 | Kajander E O | Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease |
EP2674440B1 (de) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Polyvalente bioaktive anordnungen auf immunglobulinbasis |
EP2172210A1 (de) | 2005-12-23 | 2010-04-07 | Partnership&Corp. Technology Transfer | Synthetische Peptide zur Verwendung als Inhibitoren der Neurotransmiter-Sekretion |
US7465544B2 (en) * | 2006-01-11 | 2008-12-16 | Wisconsin Alumni Research Foundation | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use |
EP1977312A2 (de) | 2006-01-16 | 2008-10-08 | Zlango Ltd. | Bildzeichenkommunikation |
EP1982450A2 (de) * | 2006-01-16 | 2008-10-22 | Zlango Ltd. | Kommunikationsnetzsystem und verfahren zu seiner verwendung |
WO2007089601A2 (en) | 2006-01-27 | 2007-08-09 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
EP1991577A2 (de) | 2006-01-31 | 2008-11-19 | Parkinson, John F. | Modulation der mdl-1-aktivität zur behandlung entzündlicher krankheiten |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
BRPI0706967A2 (pt) | 2006-02-06 | 2011-04-12 | Rappaport Family Inst For Res | método e kit para diagnosticar dmt1 |
JP5706602B2 (ja) | 2006-02-08 | 2015-04-22 | ジェンザイム・コーポレーション | ニーマンピック病a型に対する遺伝子治療 |
EP1996940B1 (de) | 2006-02-09 | 2011-12-21 | University of South Florida | Nachweis von krebs anhand von erhöhten bcl-2-konzentrationen |
LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
KR20080104343A (ko) | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
CA2641954C (en) | 2006-03-06 | 2016-04-26 | Zetiq Technologies Ltd. | Methods and compositions for identifying a cell phenotype |
WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
EP3091071B1 (de) | 2006-03-23 | 2019-07-03 | Pluristem Ltd. | Verfahren zur zellexpansion sowie verwendungen von damit produzierten zellen und konditionierten medien für die therapie |
US20090226909A1 (en) | 2006-03-28 | 2009-09-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for Determining Predisposition to Warfarin Resistance |
US20070232556A1 (en) * | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
EP2010567A2 (de) * | 2006-04-07 | 2009-01-07 | The Government of the United States of America as Represented by The Department of Health and Human Services | Antikörperzusammensetzungen und verfahren zur behandlung von neoplasien |
US8202977B2 (en) | 2006-04-21 | 2012-06-19 | Minister for Primary Industries For And On Behalf Of The State Of New South Wales | Pestivirus species |
FR2900341B1 (fr) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer |
BRPI0712084A2 (pt) * | 2006-05-09 | 2012-01-03 | Musc Found For Res Dev | detecÇço de insuficiÊncia cardÍaca diastàlica por identificaÇço do perfil plasmÁtico de protease e de inibidor de protease |
WO2007136778A2 (en) * | 2006-05-19 | 2007-11-29 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
AU2007269714A1 (en) | 2006-07-03 | 2008-01-10 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
RU2009104460A (ru) * | 2006-07-11 | 2010-08-20 | Маск Фаундейшн Фор Рисерч Дивелопмент (Us) | Прогнозирование сердечной недостаточности после инфаркта миокарда по профилю протеаз и ингибиторов протеаз |
US20080026394A1 (en) * | 2006-07-11 | 2008-01-31 | Antara Biosciences Inc. | Methods of detecting one or more cancer markers |
AU2007275873B2 (en) | 2006-07-14 | 2012-06-14 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
EP2046109A4 (de) | 2006-07-20 | 2010-01-06 | Yeda Res & Dev | Fotosynthetisch aktive organismen und zusammensetzungen und verfahren zu ihrer herstellung |
WO2008021954A2 (en) * | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
JP2008043332A (ja) | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
CN104059149B (zh) * | 2006-08-22 | 2017-04-12 | 诺沃诺蒂斯克股份有限公司 | 具有改进性能的抗‑C5aR抗体 |
WO2008023840A2 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
EP2064319B1 (de) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Verfahren zur erzeugung von glia- und neuronalen zellen und verwendung davon für die behandlung medizinischer leiden des zns |
JP2008111824A (ja) * | 2006-09-01 | 2008-05-15 | Nox Technologies Inc | 腫瘍特異的tNOXアイソフォーム及び方法 |
US7951776B2 (en) | 2006-09-01 | 2011-05-31 | American Type Culture Collection | Methods for treatment of type 1 diabetes |
US7985542B2 (en) * | 2006-09-07 | 2011-07-26 | Institut Pasteur | Genomic morse code |
EP2469282A1 (de) | 2006-09-08 | 2012-06-27 | University of Oxford | Klinische Diagnose von Leberfibrose mithilfe einer neuartigen Tafel von menschlichen Serumprotein-Biomarkern |
US8050516B2 (en) * | 2006-09-13 | 2011-11-01 | Fluidigm Corporation | Methods and systems for determining a baseline during image processing |
US8055034B2 (en) * | 2006-09-13 | 2011-11-08 | Fluidigm Corporation | Methods and systems for image processing of microfluidic devices |
US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
US20100129656A1 (en) | 2006-10-05 | 2010-05-27 | Technion Research & Develpment Foundation Ltd | Microtubes and methods of producing same |
WO2008043566A2 (en) | 2006-10-11 | 2008-04-17 | Janssen Pharmaceutica N.V. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
EP1912067A1 (de) * | 2006-10-12 | 2008-04-16 | Eppendorf Array Technologies S.A. | Verfahren zur Quantifizierung eines Analyten in einer biologischen Probe durch Microarray-Chips |
EP2076591A2 (de) | 2006-10-20 | 2009-07-08 | Danisco US, INC., Genencor Division | Polyol-oxidasen |
CA2667012A1 (en) * | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
US7776605B2 (en) | 2006-10-26 | 2010-08-17 | Abbott Laboratories | Assay for cardiac troponin autoantibodies |
US20080305512A1 (en) * | 2006-10-26 | 2008-12-11 | Mattingly Phillip G | Assay for cardiac troponin autoantibodies |
EP2402752A3 (de) | 2006-10-27 | 2012-06-06 | Janssen Pharmaceutica, N.V. | Verfahren für pharmakologische Profilierungsverbindungen |
CA2668235A1 (en) | 2006-11-02 | 2008-06-05 | Yale University | Assessment of oocyte competence |
US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
US8473216B2 (en) * | 2006-11-30 | 2013-06-25 | Fluidigm Corporation | Method and program for performing baseline correction of amplification curves in a PCR experiment |
CA2671264C (en) | 2006-11-30 | 2015-11-24 | Research Development Foundation | Improved immunoglobulin libraries |
JP5059119B2 (ja) | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗tslp抗体 |
MX349479B (es) | 2006-12-20 | 2017-07-31 | Evogene Ltd | Polinucleotidos y polipeptidos involucrados en el desarrollo de fibra vegetal y metodos de uso. |
WO2008085895A2 (en) * | 2007-01-04 | 2008-07-17 | Musc Foundation For Research Development | Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling |
AU2008204338B2 (en) * | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
EP2111224B1 (de) | 2007-01-12 | 2016-07-13 | University of Maryland, Baltimore | Targeting des ncca-atp-kanals für organschutz nach einer ischämischen episode |
ATE548454T1 (de) * | 2007-01-16 | 2012-03-15 | Yissum Res Dev Co | Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis |
EP2405007B1 (de) | 2007-01-25 | 2013-12-04 | DuPont Nutrition Biosciences ApS | Herstellung einer Lipid-Acyltransferase aus transformierten Bacillus licheniformis-Zellen |
WO2008092094A2 (en) * | 2007-01-26 | 2008-07-31 | University Of South Florida | Method and materials for detection, diagnosis and management of ovarian cancer |
JP5175864B2 (ja) | 2007-01-26 | 2013-04-03 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッド | 疾患の検出及び特徴付けのために自己抗体を検出する方法 |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
EP2117616A2 (de) | 2007-01-31 | 2009-11-18 | Technion Research & Development Foundation Ltd. | Elektrisch gesponnene gerüste und verfahren zu ihrer erzeugung und verwendung |
AU2008211549B2 (en) | 2007-02-01 | 2012-12-06 | Abraham Katzir | Albumin fibers and fabrics and methods of generating and using same |
PE20130588A1 (es) | 2007-02-02 | 2013-05-21 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
US8143046B2 (en) * | 2007-02-07 | 2012-03-27 | Danisco Us Inc., Genencor Division | Variant Buttiauxella sp. phytases having altered properties |
US20080220498A1 (en) * | 2007-03-06 | 2008-09-11 | Cervin Marguerite A | Variant Buttiauxella sp. phytases having altered properties |
KR100855299B1 (ko) * | 2007-02-16 | 2008-08-29 | 건국대학교 산학협력단 | 인간 il-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 il-32측정법 |
JP2008203195A (ja) * | 2007-02-22 | 2008-09-04 | Japan Science & Technology Agency | Bshの免疫測定用キットおよびbshの測定方法 |
WO2008103473A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
CN101675076B (zh) | 2007-02-28 | 2013-09-18 | 默沙东公司 | 工程化的抗il-23r抗体 |
US20100105071A1 (en) * | 2007-02-28 | 2010-04-29 | Children's Medical Center Corporation | Methods for predicting the onset of menarche |
EP2839839B1 (de) | 2007-02-28 | 2018-01-17 | Yeda Research And Development Company Limited | Nuklear-Targeting-Sequenzen |
US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
US20100216654A1 (en) | 2007-03-12 | 2010-08-26 | Miraculins, Inc. | Biomarkers of prostate cancer and uses thereof |
US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
AU2008234530B2 (en) | 2007-03-29 | 2013-03-28 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
DK2865755T3 (en) | 2007-03-30 | 2017-05-15 | Engeneic Molecular Delivery Pty Ltd | BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA |
CN101702920B (zh) | 2007-04-02 | 2013-03-13 | 特拉维夫大学拉莫特有限公司 | 癌细胞的检测方法及其在诊断和监测疾病治疗中的应用 |
JP5684563B2 (ja) | 2007-04-06 | 2015-03-11 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | カルバペネマーゼ遺伝子の同定のための組成物および方法 |
BRPI0809796B1 (pt) | 2007-04-09 | 2021-09-08 | Evogene Ltd | Métodos para aumentar o teor de óleo, taxa de crescimento, biomassa, vigor e/ou rendimento de uma planta, e para produzir óleo |
CA2683804A1 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
US8715665B2 (en) | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
US8003314B2 (en) | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
ES2516827T3 (es) * | 2007-04-23 | 2014-10-31 | Deliversir Ltd | Un sistema para entregar agentes terapéuticos a células vivas y núcleos de células |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
ES2564312T3 (es) | 2007-05-01 | 2016-03-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Métodos y kits para detectar células fetales en la sangre materna |
EP2152730A4 (de) * | 2007-05-02 | 2011-08-03 | Univ Emory | Erweiterung der glycoproteininkorporation in virusähnlichen partikeln |
CN101820910B (zh) | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
SI2150608T1 (en) | 2007-05-07 | 2018-04-30 | Protalix Ltd. | An extensive disposable bioreactor |
WO2008150496A2 (en) * | 2007-05-31 | 2008-12-11 | Genelux Corporation | Assay for sensitivity to chemotherapeutic agents |
US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
WO2009000089A1 (en) * | 2007-06-28 | 2008-12-31 | University Of Saskatchewan | Immunomodulatory compositions and methods for treating disease with modified host defense peptides |
WO2009009662A1 (en) * | 2007-07-10 | 2009-01-15 | University Of South Florida | Method of predicting non-response to first line chemotherapy |
EP2500428A3 (de) | 2007-07-11 | 2012-12-26 | Yeda Research and Development Co. Ltd. | Nucleinsäurekonstruktsysteme zur Diagnose oder Behandlung eines Zellzustands |
CA2692761C (en) * | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
AU2008277257B2 (en) | 2007-07-15 | 2014-03-06 | Hillman, Yitzchak Mr | Disease treatment via antimicrobial peptides or their inhibitors |
AU2008278654B2 (en) | 2007-07-24 | 2014-06-05 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
AU2008284015B2 (en) | 2007-08-03 | 2014-05-15 | Musc Foundation For Research Development | Human monoclonal antibodies and methods for producing the same |
US8992938B2 (en) | 2007-08-03 | 2015-03-31 | Matthew Bellgard | Genes and proteins of Brachyspira hyodysenteriae and uses thereof |
US8420315B2 (en) | 2007-08-06 | 2013-04-16 | Orion Genomics Llc | Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene |
RU2488592C2 (ru) | 2007-08-08 | 2013-07-27 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Пептиды направленного действия на vegfr-1/nrp-1 |
WO2009023676A1 (en) * | 2007-08-12 | 2009-02-19 | Integrated Dna Technologies, Inc. | Microarray system with improved sequence specificity |
US20090136916A1 (en) * | 2007-08-13 | 2009-05-28 | Trustees Of Tufts College | Methods and microarrays for detecting enteric viruses |
CA2695969A1 (en) | 2007-08-15 | 2009-02-19 | Yeda Research & Development Co. Ltd. | Regulators of mmp-9 and uses therof |
US8741315B2 (en) | 2007-09-12 | 2014-06-03 | Yeda Research And Development Co. Ltd. | Methods of treating tumors in immune-privileged sites |
WO2009072001A2 (en) * | 2007-09-12 | 2009-06-11 | Aurelium Biopharma Inc. | Slc9a3r1 directed diagnostics for neoplastic disease |
PL2200622T5 (pl) | 2007-09-19 | 2016-08-31 | Pluristem Ltd | Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii |
WO2009048530A2 (en) | 2007-10-05 | 2009-04-16 | Panomics, Inc. | Highly multiplexed particle-based assays |
WO2009050691A2 (en) | 2007-10-19 | 2009-04-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
JP2011504374A (ja) | 2007-11-26 | 2011-02-10 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | 繊維状ポリペプチドおよび多糖を含む組成物 |
MX357387B (es) | 2007-12-27 | 2018-07-06 | Evogene Ltd | Polipeptidos, polinucleotidos aislados utiles para modificar la eficacia en el uso de agua, eficacia en el uso del fertilizante, la tolerancia al estres biotico/abiotico, el rendimiento y biomasa en plantas. |
ES2535419T3 (es) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
US9605035B2 (en) | 2008-01-10 | 2017-03-28 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
US9175078B2 (en) | 2008-01-25 | 2015-11-03 | Amgen Inc. | Ferroportin antibodies and methods of use |
US20090233295A1 (en) * | 2008-01-29 | 2009-09-17 | Elias Georges | Trim59 directed diagnostics for neoplastic disease |
WO2009095925A2 (en) * | 2008-01-31 | 2009-08-06 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
EP3272353A1 (de) | 2008-02-07 | 2018-01-24 | Cornell University | Verfahren zur vorbeugung oder behandlung von insulinresistenz |
CN101970494B (zh) | 2008-02-20 | 2015-01-21 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US9297094B2 (en) | 2008-02-21 | 2016-03-29 | Technion Research & Development Foundation Ltd. | Use of electrospun microtubes for drug delivery |
EP2363407A1 (de) | 2008-02-28 | 2011-09-07 | Murdoch University | Neuartige Brachyspira-Sequenzen, immunogene Zusammensetzungen, Herstellungsverfahren dafür und Verwendung davon |
US20090311695A1 (en) * | 2008-03-12 | 2009-12-17 | Talat Nasim | Method |
BRPI0909388A2 (pt) | 2008-03-27 | 2016-07-19 | Spirogene Pty Ltd | sequências de brachyspira, composições imunogênicas, métodos para a preparação e uso das mesmas |
AU2009227935B2 (en) | 2008-03-28 | 2015-07-09 | Mdna Life Sciences Inc. | Aberrant mitochondrial DNA, associated fusion transcripts and hybridization probes therefor |
EP2107125A1 (de) | 2008-03-31 | 2009-10-07 | Eppendorf Array Technologies SA (EAT) | Echtzeit-PCR von Targets auf einem Mikroarray |
US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
WO2009125395A1 (en) * | 2008-04-09 | 2009-10-15 | Technion Research & Development Foundation Ltd. | Anti influenza antibodies and uses thereof |
EP2274153B1 (de) * | 2008-04-10 | 2012-07-04 | Objet Ltd. | System und verfahren für dreidimensionalen modelldruck |
WO2009129319A2 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Silencing of csn5 gene expression using interfering rna |
HUE034483T2 (en) | 2008-04-15 | 2018-02-28 | Protiva Biotherapeutics Inc | New lipid preparations for introducing a nucleic acid |
PL2288376T3 (pl) | 2008-04-18 | 2016-07-29 | Collplant Ltd | Sposoby generowania i wykorzystywania prokolagenu |
GB0807161D0 (en) * | 2008-04-18 | 2008-05-21 | Danisco | Process |
US8791324B2 (en) | 2008-04-21 | 2014-07-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
CN102066899A (zh) * | 2008-04-23 | 2011-05-18 | 卢米耐克斯公司 | 建立针对生物来源之起始材料中多种分析物的标准品的方法 |
EP2281062B1 (de) * | 2008-04-24 | 2017-11-29 | The Trustees of Columbia University in the City of New York | Geometrische muster und lipiddoppelschichten zur dna-molekülorganisation |
EP2281034B1 (de) | 2008-04-30 | 2015-10-21 | DuPont Nutrition Biosciences ApS | Verfahren zur Verwendung von Pseudoglucanobacter saccharoketogenes Alcohol Dehydrogenase |
JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
EP2291390B1 (de) * | 2008-05-22 | 2014-11-05 | Centre National de la Recherche Scientifique (CNRS) | Neue optisch reine verbindungen für verbesserte therapeutische wirksamkeit |
CA2724545C (en) | 2008-05-22 | 2018-12-11 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
AU2009252722A1 (en) | 2008-05-27 | 2009-12-03 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
EP2285951B1 (de) | 2008-05-28 | 2018-07-04 | Ramot at Tel-Aviv University Ltd. | Mesenchymale stammzellen zur behandlung von erkrankungen des zentralnervensystems |
WO2009152102A2 (en) * | 2008-06-10 | 2009-12-17 | The Regents Of The University Of California | Pro-fluorescent probes |
US9952211B2 (en) | 2008-06-29 | 2018-04-24 | Realbio Technologies Ltd. | Liquid-transfer device particularly useful as a capturing device in a biological assay process |
AU2009279458B2 (en) | 2008-08-08 | 2015-07-02 | Code Biotherapeutics, Inc. | Long-acting DNA dendrimers and methods thereof |
JP5756014B2 (ja) | 2008-08-08 | 2015-07-29 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | がんの診断および治療のためのvhz |
AU2009283785B2 (en) | 2008-08-18 | 2016-01-28 | Evogene Ltd. | Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants |
EP2334783B1 (de) | 2008-09-02 | 2016-06-22 | Pluristem Ltd. | Adhärente zellen aus plazentagewebe und verwendung davon in der therapie |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
WO2010031006A1 (en) | 2008-09-12 | 2010-03-18 | Cryopraxis Criobiologia Ltda. | Ischemic tissue cell therapy |
ES2690348T3 (es) | 2008-09-24 | 2018-11-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Péptidos y composiciones para la prevención de la adhesión celular y métodos de uso de los mismos |
WO2010036323A1 (en) | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
WO2010035261A2 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
US9207242B2 (en) | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
AR074071A1 (es) | 2008-10-30 | 2010-12-22 | Evogene Ltd | Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico de las plantas y eficacia en el uso de nitrogeno |
WO2010054328A2 (en) | 2008-11-07 | 2010-05-14 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
WO2010055525A1 (en) | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
EP2370092A1 (de) | 2008-12-03 | 2011-10-05 | Research Development Foundation | Modulierung von olfml-3-vermittelter angiogenese |
WO2010064247A1 (en) | 2008-12-03 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
CN104940928B (zh) | 2008-12-05 | 2018-03-30 | 阿布拉西斯生物科学有限责任公司 | 结合SPARC的scFv |
US8734759B2 (en) | 2008-12-05 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
EP2373997A1 (de) | 2008-12-09 | 2011-10-12 | Dako Denmark A/S | Verfahren zur bewertung einer vorbehandlung |
WO2010068757A1 (en) | 2008-12-12 | 2010-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
CA3052515A1 (en) | 2008-12-29 | 2010-07-08 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same |
SG10201401054YA (en) | 2008-12-29 | 2014-07-30 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
EP2808402A3 (de) | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur Vorhersage des Ansprechens auf Interferonbehandlung |
WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
WO2010093450A2 (en) | 2009-02-11 | 2010-08-19 | Ludwing Institute For Cancer Research Ltd. | Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis |
WO2010093465A1 (en) | 2009-02-11 | 2010-08-19 | Caris Mpi, Inc. | Molecular profiling of tumors |
AU2010213727A1 (en) | 2009-02-11 | 2011-09-29 | Orion Genomics Llc | Combinations of polymorphisms for determining allele-specific expression of IGF2 |
WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
WO2010097794A1 (en) | 2009-02-26 | 2010-09-02 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of reprogramming renal cells |
HUE041819T2 (hu) | 2009-03-02 | 2019-05-28 | Evogene Ltd | Izolált polinukleotidek és polipeptidek, és azok alkalmazási eljárásai növényhozam és/vagy mezõgazdasági jellemzõk fokozására |
ES2564265T3 (es) | 2009-03-09 | 2016-03-21 | Ramot At Tel-Aviv University Ltd. | Composiciones para prevención y tratamiento de enfermedades neurodegenerativas |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
US20100240065A1 (en) * | 2009-03-18 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Prolyl Hydroxylase Compositions and Methods of Use Thereof |
US8481698B2 (en) * | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
BRPI1014121A2 (pt) | 2009-03-27 | 2016-11-08 | Gojo Ind Inc | composições e métodos para investigação e uso de compostos que antagonizam as interações esporo-superfície |
JP5734947B2 (ja) | 2009-03-27 | 2015-06-17 | ミトミクス インコーポレイテッドGenesis Genomics Inc. | 異常型ミトコンドリアdna、関連融合転写物および翻訳産物、並びにそのハイブリダイゼーションプローブ |
WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
JP2012522762A (ja) | 2009-04-01 | 2012-09-27 | ザ メディカル リサーチ, インフラストラクチャー, アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター | ケラチノサイトの増殖および分化を調節する方法 |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
AU2010239131A1 (en) | 2009-04-21 | 2011-11-17 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
GB0908770D0 (en) | 2009-04-24 | 2009-07-01 | Danisco | Method |
CA2760385C (en) | 2009-04-30 | 2021-04-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti ceacam1 antibodies and methods of using same |
WO2010124689A1 (en) | 2009-05-01 | 2010-11-04 | Dako Denmark A/S | New antibody cocktail |
EP2799876B1 (de) * | 2009-05-14 | 2021-11-03 | ShOx Science Limited | Klinische Diagnose von Leberfibrose mithilfe einer neuartigen Tafel mit Biomarkern mit einer geringen Menge menschlichem Plasmaprotein |
EP2433136B1 (de) | 2009-05-19 | 2015-08-26 | Zetiq Technologies Ltd. | Kits und verfahren zum differentiellen anfärben von zervixkarzinomzellen und/oder geweben |
CN102428177B (zh) | 2009-05-19 | 2015-01-14 | 杜邦营养生物科学有限公司 | 提高面包耐码垛性的方法及其产品 |
EP2432499A2 (de) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen |
WO2010137017A2 (en) | 2009-05-27 | 2010-12-02 | Yeda Research And Development Co. Ltd. | Proteasome inhibitors and uses thereof |
WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
US20120070449A1 (en) | 2009-05-28 | 2012-03-22 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
KR20120122869A (ko) | 2009-06-02 | 2012-11-07 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 신경변성 질환을 갖는 대상에서 항체에 의해 인식되는 소분자의 확인법 |
CA3095630A1 (en) | 2009-06-10 | 2010-12-16 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
CN102483406A (zh) | 2009-06-24 | 2012-05-30 | 健康公司-拉姆巴姆 | 用于分离胎盘来源微粒的方法和试剂盒以及它们用于诊断胎儿疾病的应用 |
KR20120103431A (ko) | 2009-06-25 | 2012-09-19 | 대니스코 에이/에스 | 단백질 |
CN102725410B (zh) | 2009-06-29 | 2016-03-16 | 西澳大学 | 来自檀香属的萜烯合酶 |
WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
SG10201505075TA (en) | 2009-07-17 | 2015-07-30 | Bioatla Llc | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
ES2753986T3 (es) | 2009-07-21 | 2020-04-15 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Un método de diagnóstico de cáncer |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
EP2467470A2 (de) | 2009-08-17 | 2012-06-27 | Technion Research & Development Foundation Ltd. | Pericytvorläuferzellen sowie verfahren zu ihrer herstellung und verwendung |
AU2010284036B2 (en) | 2009-08-21 | 2014-12-18 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
CN102481311A (zh) | 2009-08-21 | 2012-05-30 | 比欧洛吉科斯公司 | 经由植物转录的分子预防和治疗有益昆虫的疾病 |
CN106619515A (zh) | 2009-08-27 | 2017-05-10 | 工业研究与发展基金会有限公司 | 脂质体组合物及其用途 |
SG178991A1 (en) | 2009-09-03 | 2012-04-27 | Schering Corp | Anti-gitr antibodies |
WO2011030336A1 (en) | 2009-09-08 | 2011-03-17 | Ramot At Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
EP2475381A2 (de) | 2009-09-08 | 2012-07-18 | Yeda Research and Development Co. Ltd. | Verfahren zur mobilisierung eines hämatopoetischen vorläufers |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
JP2013505022A (ja) | 2009-09-16 | 2013-02-14 | バクサート インコーポレーティッド | H1n1感染を予防するための免疫戦略の方法 |
EP2478093A2 (de) | 2009-09-17 | 2012-07-25 | Yeda Research and Development Co. Ltd. | Isolierte pon1-polypeptide, polynucleotide zu deren codierung und verwendung davon bei der behandlung oder vorbeugung von schäden im zusammenhang mit organophosphataussetzung |
CA2773935C (en) | 2009-09-17 | 2018-06-19 | Ramot At Tel Aviv University Ltd. | Peptides for the treatment of oxidative stress related disorders |
US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US9222086B2 (en) | 2009-09-23 | 2015-12-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
US20130023433A1 (en) | 2009-09-28 | 2013-01-24 | Yuling Luo | Methods of detecting nucleic acid sequences with high specificity |
US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
WO2011040973A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
AU2010301105A1 (en) | 2009-10-02 | 2012-04-19 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
CA2776756A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
EP2488646B1 (de) | 2009-10-14 | 2017-12-06 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Zusammensetzungen zur steuerung vpn varroa-milben bei bienen |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
JP2013508013A (ja) | 2009-10-16 | 2013-03-07 | ザ ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 細胞療法戦略を用いた慢性神経組織損傷の治療方法 |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
CA2779223A1 (en) | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
EP2498806B1 (de) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Zusammensetzungen mit pedf und ihre verwendung zur behandlung und prävention von eierstockbedingten syndromen |
ES2779048T3 (es) | 2009-11-12 | 2020-08-13 | Technion Res & Dev Foundation | Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en un estado indiferenciado |
WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
US8592151B2 (en) * | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
GB0920089D0 (en) | 2009-11-17 | 2009-12-30 | Danisco | Method |
WO2011064773A1 (en) | 2009-11-24 | 2011-06-03 | Collplant Ltd. | Method of generating collagen fibers |
US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
IL288647B2 (en) | 2009-11-30 | 2023-12-01 | Pluri Biotech Ltd | Adherent cells of placental origin and their use for the treatment of heart failure |
US8835120B2 (en) | 2009-12-02 | 2014-09-16 | Abbott Laboratories | Assay for cardiac troponin-T (cTnT) |
US8652788B2 (en) * | 2009-12-02 | 2014-02-18 | Abbott Laboratories | Assay for diagnosis of cardiac myocyte damage |
US8183002B2 (en) | 2009-12-03 | 2012-05-22 | Abbott Laboratories | Autoantibody enhanced immunoassays and kits |
US20110136141A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Peptide reagents and method for inhibiting autoantibody antigen binding |
WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
WO2011072091A1 (en) | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
GB0922377D0 (en) | 2009-12-22 | 2010-02-03 | Arab Gulf University The | Mutant LDL receptor |
CA3172119A1 (en) | 2009-12-28 | 2011-07-07 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
ES2627910T3 (es) | 2009-12-29 | 2017-08-01 | Gamida-Cell Ltd. | Métodos para potenciar la proliferación y la actividad de células destructoras naturales |
JP6196040B2 (ja) | 2010-01-05 | 2017-09-13 | バスキュラー バイオジェニックス リミテッド | 特異的な抗血管形成アデノウイルス剤の使用法 |
US9005579B2 (en) | 2010-01-05 | 2015-04-14 | Contrafect Corporation | Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria |
LT3339865T (lt) | 2010-01-11 | 2022-12-12 | Biogen Ma Inc. | Tyrimas, skirtas antikūnams prieš jc virusą nustatyti |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
US20130052165A1 (en) | 2010-01-12 | 2013-02-28 | Livnat Bangio | Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby |
EA201270701A1 (ru) | 2010-01-27 | 2013-01-30 | Йеда Рисеч Энд Девелопмент Ко. Лтд. | Ингибирующие металлопротеины антитела |
US20130171621A1 (en) | 2010-01-29 | 2013-07-04 | Advanced Cell Diagnostics Inc. | Methods of in situ detection of nucleic acids |
US8574832B2 (en) | 2010-02-03 | 2013-11-05 | Massachusetts Institute Of Technology | Methods for preparing sequencing libraries |
MX2012009088A (es) | 2010-02-04 | 2012-12-05 | Gilead Biologics Inc | Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos. |
MX2012008884A (es) | 2010-02-08 | 2012-08-31 | Agensys Inc | Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b. |
US9410131B2 (en) | 2010-02-11 | 2016-08-09 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
EP2538961B1 (de) | 2010-02-24 | 2016-10-12 | Ben Gurion University Of The Negev Research And Development Authority | Hemmung von nekrose |
WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
EP3231872B1 (de) | 2010-03-08 | 2020-05-06 | Monsanto Technology LLC | Polynukleotidmoleküle zur genregulierung in pflanzen |
WO2011111034A1 (en) | 2010-03-08 | 2011-09-15 | Yeda Research And Development Co. Ltd. | Recombinant protein production in heterologous systems |
CN102918159A (zh) | 2010-03-11 | 2013-02-06 | 雅各布·埃德尔 | 产生氢的方法 |
WO2011114251A1 (en) | 2010-03-18 | 2011-09-22 | Danisco A/S | Foodstuff |
WO2011125015A2 (en) | 2010-04-05 | 2011-10-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
GB2491795A (en) | 2010-04-06 | 2012-12-12 | Massachusetts Inst Technology | Gene-expression profiling with reduced numbers of transcript measurements |
US9125931B2 (en) | 2010-04-06 | 2015-09-08 | Massachusetts Institute Of Technology | Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers |
EP2557913B1 (de) | 2010-04-12 | 2016-08-03 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase einer roten mikroalge und verwendungen davon |
WO2011128897A1 (en) | 2010-04-12 | 2011-10-20 | Technion Research & Development Foundation Ltd. | Populations of pancreatic progenitor cells and methods of isolating and using same |
WO2011129382A1 (en) | 2010-04-16 | 2011-10-20 | Abbott Japan Co. Ltd. | Methods and reagents for diagnosing rheumatoid arthritis |
IN2012MN02247A (de) | 2010-04-18 | 2015-06-12 | Yeda Res & Dev | |
BR122021002337B1 (pt) | 2010-04-28 | 2022-03-22 | Evogene Ltd | Método de aumento de produção, biomassa, taxa de crescimento, vigor, teor de óleo, produção de fibra qualidade de fibra, tolerância ao estresse abiótico e/ou eficiência de uso de nitrogênio de uma planta, e construto de ácido nucleico isolado |
WO2011138778A2 (en) | 2010-05-04 | 2011-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
WO2011138785A2 (en) | 2010-05-05 | 2011-11-10 | Rappaport Family Institute For Research In The Medical Sciences | Use of ccl1 in therapy |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
JP2013525814A (ja) | 2010-05-07 | 2013-06-20 | アッヴィ・インコーポレイテッド | 標的化チロシンキナーゼインヒビターでの治療に対する感受性の予測方法 |
US20120190563A1 (en) | 2010-05-07 | 2012-07-26 | Abbott Laboratories | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor |
WO2011141914A1 (en) | 2010-05-13 | 2011-11-17 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Isolated populations of adult renal cells and methods of isolating and using same |
US20110287458A1 (en) | 2010-05-18 | 2011-11-24 | The Texas A&M University System | Method and composition for the diagnosis and monitoring of inflammatory diseases |
JP2013534515A (ja) | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体 |
CN103037891A (zh) | 2010-06-03 | 2013-04-10 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗糖尿病的方法和能够治疗糖尿病的组合物 |
KR20130123357A (ko) | 2010-06-07 | 2013-11-12 | 오스나트 에슈어-파비안 | 저산소증과 관련된 질환의 진단방법 및 키트 |
WO2011158243A2 (en) | 2010-06-16 | 2011-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of diagnosing and treating cancer |
WO2011158242A2 (en) | 2010-06-16 | 2011-12-22 | Futuragene Israel Ltd. | Pest -resistant plants containing a combination of a spider toxin and a chitinase |
US20130316338A1 (en) | 2010-06-29 | 2013-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | CCR6 As A Biomarker of Alzheimer's Disease |
GB201011513D0 (en) | 2010-07-08 | 2010-08-25 | Danisco | Method |
EP2593468B1 (de) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolierte polynukleotide und verfahren sowie pflanzen damit zur regulierung der pflanzensäure |
EP2407242A1 (de) | 2010-07-13 | 2012-01-18 | Dublin City University | Direkte Klonanalyse und Auswahltechnologie |
JP2013538555A (ja) | 2010-07-15 | 2013-10-17 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 |
WO2012007919A2 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Nucleic acid construct for increasing abiotic stress tolerance in plants |
WO2012007950A2 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
EP2593230A2 (de) | 2010-07-16 | 2013-05-22 | Vanderbilt University | Ressourcenarmer prozessor mit oberflächenspannungsventilen zur extraktion, konzentration und erkennung von molekularen spezies |
US10106576B2 (en) | 2010-07-16 | 2018-10-23 | Bioatla, Llc | Methods of protein evolution |
EP2595637B1 (de) | 2010-07-22 | 2017-11-01 | Cellect Biotherapeutics Ltd. | Immunregulatorische zellen mit verstärkter gezielter zelltodwirkung |
KR101866844B1 (ko) | 2010-07-23 | 2018-06-14 | 루미넥스 코포레이션 | 면역분석에서 시약의 반응성을 조절하기 위한 공동 결합 |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
WO2012014208A2 (en) | 2010-07-27 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Methods and systems for assessing clonality of cell cultures |
WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
WO2012017439A2 (en) | 2010-08-04 | 2012-02-09 | Ramot At Tel-Aviv University Ltd. | Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
US9394523B2 (en) | 2010-08-22 | 2016-07-19 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
BR122019017037B1 (pt) | 2010-08-30 | 2022-05-31 | Evogene Ltd | Método de aumento de eficiência do uso de nitrogênio, rendimento, biomassa, taxa de crescimento, vigor e/ou tolerância ao estresse à deficiência de nitrogênio de uma planta |
WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
EP2613799A1 (de) | 2010-09-07 | 2013-07-17 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Readthrough-acetylcholinesterase (ache-r) zur behandlung bzw. prävention von morbus parkinson |
SG10201800628QA (en) | 2010-09-07 | 2018-02-27 | Technion Res & Dev Foundation | Novel Methods And Culture Media For Culturing Pluripotent Stem Cells |
SG188471A1 (en) | 2010-09-08 | 2013-04-30 | Yeda Res & Dev | An immunosuppressive drug combination for a stable and long term engraftment |
PL2613801T3 (pl) | 2010-09-08 | 2016-12-30 | Zastosowanie komórek T pamięci centralnych przeciwko obcym antygenom do leczenia białaczki/chłoniaka | |
CN103210082A (zh) | 2010-09-15 | 2013-07-17 | 雷蒙特亚特特拉维夫大学有限公司 | 扩增胰岛β细胞和使其再分化的方法 |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
WO2012040168A2 (en) | 2010-09-20 | 2012-03-29 | Advanced Cell Diagnostics, Inc. | Biomarkers for differentiating melanoma from benign nevus in the skin |
ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
WO2012045750A2 (en) | 2010-10-04 | 2012-04-12 | Centre National De La Recherche Scientifique (Cnrs) | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
EP2441520A1 (de) | 2010-10-12 | 2012-04-18 | Eppendorf AG | Echtzeitverstärkungs- und Mikroarray-basierte Erkennung von Nukleinsäuretargets in einem Fluss-Chip-Assay |
WO2012052872A2 (en) | 2010-10-17 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
CN107365847A (zh) | 2010-10-21 | 2017-11-21 | 领先细胞医疗诊断有限公司 | 用于原位检测核酸的超灵敏方法 |
WO2012056452A2 (en) | 2010-10-27 | 2012-05-03 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
WO2012056455A1 (en) | 2010-10-28 | 2012-05-03 | Yeda Research And Development Co. Ltd. | Methods of generating antibodies to metalloenzymes |
US20130227724A1 (en) | 2010-11-03 | 2013-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Transgenic plants with improved saccharification yields and methods of generating same |
WO2012059925A2 (en) | 2010-11-04 | 2012-05-10 | Ben-Gurion University Of The Negev Research And Development Authority | Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof |
EP2640737B1 (de) | 2010-11-15 | 2018-08-29 | Ramot at Tel-Aviv University Ltd. | Dipeptidanaloga zur behandlung von störungen im zusammenhang mit amyloid-fibrillenbildung |
EP2640404B1 (de) | 2010-11-17 | 2017-02-22 | Ben Gurion University of The Negev Research and Development Authority | T-zelltherapie für neurodegenerative erkrankungen |
WO2012073238A1 (en) | 2010-12-02 | 2012-06-07 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
EP2463382A1 (de) | 2010-12-07 | 2012-06-13 | Enterologics, Inc. | Verfahren zur Identifizierung von E.-coli-M-17 |
US9404087B2 (en) | 2010-12-15 | 2016-08-02 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
MX354193B (es) | 2010-12-22 | 2018-02-16 | Evogene Ltd | Polinucleótidos y polipéptidos aislados, y métodos para utilizarlos para aumentar la tolerancia al estrés abiótico, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o eficacia en el uso de nitrógeno de las plantas. |
AR084358A1 (es) | 2010-12-27 | 2013-05-08 | Lilly Co Eli | Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc)) |
BR112013016535A2 (pt) | 2010-12-28 | 2016-09-20 | Bio Fd&C Co Ltd | extratos vegetais para o tratamento e prevenção de infecções |
CN105924519B (zh) | 2010-12-31 | 2019-08-23 | 生物蛋白有限公司 | 全面单克隆抗体产生 |
WO2012099896A2 (en) | 2011-01-17 | 2012-07-26 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
EP2665814B1 (de) | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nukleinsäurekonstrukt zur expression von alpha-galaktosidase bei pflanzen und pflanzenzellen |
US20120214152A1 (en) | 2011-01-28 | 2012-08-23 | Xiao-Jun Ma | Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions |
US20130316358A1 (en) | 2011-01-31 | 2013-11-28 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
US8658128B2 (en) | 2011-02-03 | 2014-02-25 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
JP6228014B2 (ja) | 2011-02-07 | 2017-11-08 | リサーチ ディベロップメント ファウンデーション | 操作された免疫グロブリンFcポリペプチド |
WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
EP2678042B1 (de) | 2011-02-23 | 2018-05-09 | The Board of Trustees of the University of Illionis | Amphiphile dendron-spulen, mizellen damit und anwendungen davon |
BR112013022331B1 (pt) | 2011-03-02 | 2021-01-26 | Futuragene Israel Ltd. | vetor de expressão de ácido nucleico, e, método para gerar uma planta que compreende resistência intensificada a um patógeno bacteriano |
US9365828B2 (en) | 2011-03-03 | 2016-06-14 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
US9574003B2 (en) | 2011-03-06 | 2017-02-21 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
CA2829300A1 (en) | 2011-03-08 | 2012-09-13 | King Abdullah University Of Science And Technology | Molecular biomarker set for early detection of ovarian cancer |
WO2012120518A1 (en) | 2011-03-08 | 2012-09-13 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (pku) |
US20140170068A1 (en) | 2011-03-11 | 2014-06-19 | Board Of Regents Of The University Of Nebraska | Biomarker for coronary artery disease |
CN103533934B (zh) | 2011-03-17 | 2016-03-30 | 特尔汗什莫尔医学基础设施研究和服务公司 | 用于治疗自身免疫性疾病的喹诺酮类似物 |
US9624291B2 (en) | 2011-03-17 | 2017-04-18 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
EP2689008B1 (de) | 2011-03-22 | 2017-09-27 | Pluristem Ltd. | Verfahren zur behandlung von strahlungs- oder chemischen verletzungen |
EP2689033B1 (de) | 2011-03-22 | 2017-02-01 | Cornell University | Unterscheidung gutartiger und bösartiger unbestimmter schilddrüsenläsionen |
MX2013010910A (es) | 2011-03-24 | 2014-03-27 | Neurim Pharma 1991 | Peptidos neuroprotectores. |
EP2691538A1 (de) | 2011-03-28 | 2014-02-05 | Novartis AG | Marker im zusammenhang mit cyclinabhängigen kinasehemmern |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
PT2694106T (pt) | 2011-04-01 | 2018-03-05 | Immunogen Inc | Métodos para aumentar eficácia de terapia de cancro de folr1 |
WO2012138941A1 (en) | 2011-04-05 | 2012-10-11 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
CN103518133B (zh) | 2011-04-06 | 2016-08-17 | 雷蒙特亚特特拉维夫大学有限公司 | 监测和分析代谢活性分布的方法及其诊断和治疗用途 |
AR085845A1 (es) | 2011-04-08 | 2013-10-30 | Danisco Us Inc | Composiciones |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
CN108342350A (zh) | 2011-04-15 | 2018-07-31 | 普拉里斯坦有限公司 | 收获细胞的方法和系统 |
CN107189997A (zh) | 2011-04-21 | 2017-09-22 | 洛克菲勒大学 | 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素 |
AU2012251353B2 (en) | 2011-05-03 | 2016-10-27 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
WO2012150600A2 (en) | 2011-05-04 | 2012-11-08 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
JP2014515476A (ja) | 2011-05-20 | 2014-06-30 | アボットジャパン株式会社 | 非特異的結合を減少させるためのイムノアッセイ方法及び試薬 |
EP2709728B1 (de) | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau-protease-anwendungsverfahren |
US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
JP6243838B2 (ja) | 2011-05-31 | 2017-12-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Pmlの危険性を査定する方法 |
CA3075772C (en) | 2011-05-31 | 2022-07-19 | Hutchison Biofilm Medical Solutions Limited | Dispersion and detachment of cell aggregates |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
RU2616881C2 (ru) | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
ES2670596T3 (es) | 2011-06-14 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Terapia de combinación para prevenir la formación del DCIS y la progresión hasta cáncer de mama |
US20140130199A1 (en) | 2011-06-23 | 2014-05-08 | Kaiima Bio Agritech Ltd. | Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same |
WO2013010170A1 (en) | 2011-07-14 | 2013-01-17 | Lovell Mark A | Process for detection of alzheimer's disease from a serum sample |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
CA2842321C (en) | 2011-07-18 | 2022-05-03 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
RU2014106125A (ru) | 2011-07-20 | 2015-08-27 | Каиима Био Агритех Лтд. | Растения кукурузы с частично или полностью умноженным геномом и их применения |
EP2550982A1 (de) | 2011-07-27 | 2013-01-30 | Technion Research & Development Foundation Ltd. | Vorrichtungen für chirurgische Anwendungen |
US9150858B2 (en) | 2011-08-04 | 2015-10-06 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
DK2739310T3 (en) | 2011-08-05 | 2018-07-16 | Res Found Dev | Improved methods and compositions for modulating OLFML3-mediated angiogenesis |
US9499793B2 (en) | 2011-08-09 | 2016-11-22 | Yeda Research And Development Co. Ltd. | Downregulation of miR-7 for promotion of beta cell differentiation and insulin production |
WO2013024481A1 (en) | 2011-08-14 | 2013-02-21 | Kaiima Bio Agritech Ltd. | Durum wheat plants having a partially or fully multiplied genome and uses thereof |
WO2013025834A2 (en) | 2011-08-15 | 2013-02-21 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
WO2013025479A1 (en) | 2011-08-16 | 2013-02-21 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
WO2013035070A1 (en) | 2011-09-07 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Olfactory signature and odorant mixture having the same |
US20140248293A1 (en) | 2011-09-08 | 2014-09-04 | Yeda Research And Development Co., Ltd | Novel risk biomarkers for lung cancer |
US20140212398A1 (en) | 2011-09-08 | 2014-07-31 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
CA2848685A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
CN104160028A (zh) | 2011-09-13 | 2014-11-19 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
MX350771B (es) | 2011-09-13 | 2017-09-15 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
UA116093C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
US9249467B2 (en) | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
US9279118B2 (en) | 2011-10-05 | 2016-03-08 | The Rockefeller University | Dimeric bacteriophage lysins |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
BR112014009536A2 (pt) | 2011-10-21 | 2017-04-18 | Augurex Life Sciences Corp | antígenos derivados de 14-3-3 xitrulinada e usos dos mesmos no diagnóstico de artrite reumatoide |
EP2771464B1 (de) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Verfahren zur behandlung von karzinomen |
WO2013064163A1 (en) | 2011-11-01 | 2013-05-10 | Academisch Medisch Centrum | Methylation markers for colorectal cancer |
US9422560B2 (en) | 2011-11-03 | 2016-08-23 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
EP2776565A1 (de) | 2011-11-08 | 2014-09-17 | Quark Pharmaceuticals, Inc. | Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems |
WO2013076729A1 (en) | 2011-11-23 | 2013-05-30 | Danziger Dan Flower Farm | Otomeria plants |
WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
MX2014006756A (es) | 2011-12-08 | 2015-03-09 | Yeda Res & Dev | Celulas pulmonares fetales mamiferas y uso terapeutico de las mismas. |
CA2859167C (en) | 2011-12-12 | 2021-03-16 | Step Ahead Innovations, Inc. | Submerged chemical indicator and holder |
WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
US20130164193A1 (en) | 2011-12-22 | 2013-06-27 | Life Technologies Corporation | Sequential lateral flow capillary device for analyte determination |
WO2013093919A2 (en) | 2011-12-22 | 2013-06-27 | Yeda Research And Development Co. Ltd. | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
AU2012359984A1 (en) | 2011-12-28 | 2014-07-10 | Kaiima Bio Agritech Ltd. | Cultivated sorghum plant having a partially or fully multiplied genome and uses of same |
CA2862270A1 (en) | 2011-12-29 | 2013-07-04 | Baylor Research Institute | Biomarkers of kawasaki disease |
CA2858336A1 (en) | 2012-01-01 | 2013-07-04 | Qbi Enterprises Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
EP3418397B1 (de) | 2012-01-24 | 2020-10-07 | CD Diagnostics, Inc. | System zum nachweis einer infektion in der synovialflüssigkeit |
WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
WO2013118120A2 (en) | 2012-02-06 | 2013-08-15 | Rosetta Green Ltd. | Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant |
US20150064273A1 (en) | 2012-02-13 | 2015-03-05 | Gamida-Cell Ltd. | Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same |
MX362446B (es) | 2012-02-14 | 2019-01-18 | Opko Biologics Ltd | Factores de coagulacion de accion prolongada y metodos de produccion de los mismos. |
KR20140130495A (ko) | 2012-02-19 | 2014-11-10 | 프로탈릭스 리미티드 | 고셰병 치료용 경구형 단위 투약 형태 및 이의 용도 |
WO2013124816A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
EP3401393B1 (de) | 2012-02-22 | 2020-02-19 | Exostem Biotec Ltd | Mikrornas zur erzeugung von astrocyten |
JP6275655B2 (ja) | 2012-02-24 | 2018-02-07 | プロティバ バイオセラピューティクス インコーポレイテッド | トリアルキルカチオン性脂質およびその使用方法 |
CN107266425B (zh) | 2012-02-29 | 2020-03-03 | 坎莫森特里克斯公司 | 作为ccr9拮抗剂的吡唑-1-基苯磺酰胺 |
EP2833714A1 (de) | 2012-03-01 | 2015-02-11 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Männliche sterile knoblauchpflanzen, hybride nachkommen davon sowie verfahren zur herstellung und verwendung davon |
JP2015516371A (ja) | 2012-03-07 | 2015-06-11 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | キエシンスルフヒドリルオキシダーゼ(qsox1)を阻害するための組成物および該組成物の使用 |
ES2731757T3 (es) | 2012-03-20 | 2019-11-18 | Biogen Ma Inc | Anticuerpos neutralizantes de JCV |
EP2828280B1 (de) | 2012-03-22 | 2018-05-02 | Ramot at Tel-Aviv University Ltd. | Multimere plif-peptide und verwendungen davon |
WO2013149219A2 (en) | 2012-03-30 | 2013-10-03 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
US20140178869A1 (en) | 2012-04-05 | 2014-06-26 | Advanced Cell Diagnostics, Inc. | Detection of immunoglobulin light chain restriction by rna in situ hybridization |
WO2013156989A1 (en) | 2012-04-18 | 2013-10-24 | Ramot At Tel-Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
EP2838552A4 (de) | 2012-04-19 | 2016-05-18 | Opko Biolog Ltd | Langwirkende oxyntomodulinvarianten und verfahren zur herstellung davon |
US20130280696A1 (en) | 2012-04-23 | 2013-10-24 | Elliott Millenson | Devices and methods for detecting analyte in bodily fluid |
EP2841084B1 (de) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs |
EP2841101B1 (de) | 2012-04-26 | 2019-08-07 | University Of Chicago | Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung |
EP2846819B1 (de) | 2012-05-09 | 2017-05-03 | Yeda Research and Development Co. Ltd. | Varianten der tace pro-domäne als tnf-a-hemmer und deren medizinische verwendung |
CA3202536A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla, Llc | Multi-specific monoclonal antibodies |
US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
EP3508497A1 (de) | 2012-05-24 | 2019-07-10 | Mountgate Group Limited | Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion |
CN104619843B (zh) | 2012-05-24 | 2020-03-06 | A.B.种子有限公司 | 用于使基因表达沉默的组合物和方法 |
BR112014029883B1 (pt) | 2012-05-31 | 2023-10-24 | Sorrento Therapeutics Inc. | Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1 |
WO2013181530A1 (en) | 2012-06-01 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
EP2855507B1 (de) | 2012-06-03 | 2018-01-03 | Ben-Gurion University of The Negev Research and Development Authority | Funktionalisierte titanbindende peptide und damit beschichtete implantate |
MX362432B (es) | 2012-06-04 | 2019-01-17 | Opko Biologics Ltd | Variantes de oxm pegilada. |
JP6429771B2 (ja) | 2012-06-21 | 2018-11-28 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | c−Metに結合する抗原結合タンパク質 |
CA2877814A1 (en) | 2012-06-22 | 2013-12-27 | Dingqiu HUANG | Antigen binding proteins that bind ccr2 |
CN104603291B (zh) | 2012-06-22 | 2018-04-06 | Htg分子诊断有限公司 | 黑素细胞病变中的分子恶性肿瘤 |
WO2014006621A1 (en) | 2012-07-03 | 2014-01-09 | Nanospun Technologies Ltd. | Methods and devices for adsorption and biodegradation of petroleum |
US20150322528A1 (en) | 2012-07-09 | 2015-11-12 | Novartis Ag | Biomarkers associated with cdk inhibitors |
US9725698B2 (en) | 2012-07-11 | 2017-08-08 | Imstem Biotechnology, Inc. | Trophoblast-derived mesenchymal stem cells (T-MSCs) produced from human embryonic stem cells, methods and uses thereof |
US20150173883A1 (en) | 2012-07-18 | 2015-06-25 | President And Fellows Of Harvard College | Modification of surfaces for simultaneous repellency and targeted binding of desired moieties |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
AU2013295652B2 (en) | 2012-07-27 | 2018-02-08 | The Board Of Trustees Of The University Of Illinois | Engineering T-cell receptors |
ES2730377T3 (es) | 2012-07-29 | 2019-11-11 | Yeda Res & Dev | Uso de la ruta reductora de la glicina para generar microorganismos formatótrofos y autótrofos |
ES2742285T3 (es) | 2012-07-31 | 2020-02-13 | Novartis Ag | Marcadores asociados con la sensibilidad a inhibidores del doble minuto humano 2 (MDM2) |
EP2879678B1 (de) | 2012-07-31 | 2023-03-01 | Yeda Research and Development Co. Ltd. | Enoxacin zur behandlung von amyotropher lateralsklerose |
US10046010B2 (en) | 2012-08-06 | 2018-08-14 | Brainstorm Cell Therapeutics Ltd. | Methods of generating mesenchymal stem cells which secrete neurotrophic factors |
EP3494996A1 (de) | 2012-08-23 | 2019-06-12 | Agensys, Inc. | An 158p1d7-proteine bindende antikörperwirkstoffkonjugate |
US20140068814A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
WO2014041544A1 (en) | 2012-09-12 | 2014-03-20 | Ramot At Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
ES2776029T3 (es) | 2012-10-08 | 2020-07-28 | St Jude Childrens Res Hospital | Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina |
WO2014057490A1 (en) | 2012-10-09 | 2014-04-17 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
EP4356927A3 (de) | 2012-10-12 | 2024-10-02 | Arizona Board of Regents on behalf of Arizona State University | Auf antikörpern basierende reagenzien zur spezifischen erkennung toxischer oligomerer formen von tau |
AR093058A1 (es) | 2012-10-18 | 2015-05-13 | Monsanto Technology Llc | Metodos y composiciones para el control de pestes en plantas |
US20150354006A1 (en) | 2012-10-19 | 2015-12-10 | Novartis Ag | Markers for acute lymphoblastic leukemia |
WO2014063097A1 (en) | 2012-10-19 | 2014-04-24 | Danisco Us Inc. | Stabilization of biomimetic membranes |
US9395369B2 (en) | 2012-10-19 | 2016-07-19 | Regents Of The University Of Minnesota | Guinea pig cytomegalovirus (CIDMTR strain) |
AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
CA2888345C (en) | 2012-10-24 | 2020-04-21 | Research Development Foundation | Jam-c antibodies and methods for treatment of cancer |
US20150266970A1 (en) | 2012-10-24 | 2015-09-24 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
US9926564B2 (en) | 2012-10-29 | 2018-03-27 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
SG10202010383YA (en) | 2012-11-20 | 2020-11-27 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
WO2015079413A2 (en) | 2013-11-28 | 2015-06-04 | Yeda Research And Development Co. Ltd. | Synaptojanin-2 inhibitors and uses thereof |
CA2877847A1 (en) | 2012-11-29 | 2014-06-05 | Yeda Research And Development Co. Ltd. | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
AU2013371825B2 (en) | 2013-01-01 | 2019-10-24 | A.B. Seeds Ltd. | Methods of introducing dsRNA to plant seeds for modulating gene expression |
US10047399B2 (en) | 2013-01-07 | 2018-08-14 | The Cleveland Clinic Foundation | ABCA1 downregulation in prostate cancer |
WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
EP2946207B1 (de) | 2013-01-17 | 2018-05-16 | Novellusdx Ltd. | Verfahren und systeme zur identifizierung patientenspezifischer treibermutationen |
WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
US9411930B2 (en) | 2013-02-01 | 2016-08-09 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
GB2519255B (en) | 2013-02-01 | 2016-01-06 | Univ California | Methods for genome assembly and haplotype phasing |
EP3323884A1 (de) | 2013-02-01 | 2018-05-23 | The United States Of America as Represented by the Secretary, Department of Health an Human Service | Verfahren zur erzeugung von zellen im retinalen pigmentepithel aus induzierten pluripotenten stammzellen |
EP2950808B1 (de) | 2013-02-04 | 2019-08-21 | Ramot at Tel-Aviv University Ltd. | Erzeugung von zytotoxischen tumorspezifischen zelllinien und verwendungen davon |
WO2014130846A1 (en) | 2013-02-22 | 2014-08-28 | Seungpyo Hong | Transdermal drug delivery using amphiphilic dendron-coil micelles |
BR112015021707A2 (pt) | 2013-03-06 | 2017-12-05 | Hadasit Med Res Service | uso de células de planta que expresam um inibidor de polipeptídeo tnfalfa em terapia. |
WO2014136114A1 (en) | 2013-03-06 | 2014-09-12 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
TWI582239B (zh) | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
AU2014248958A1 (en) | 2013-03-13 | 2015-10-01 | Monsanto Technology Llc | Methods and compositions for weed control |
UY35379A (es) | 2013-03-13 | 2014-09-30 | Monsanto Technology Llc | ?métodos y composiciones para el control de malezas?. |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
JP2016514130A (ja) | 2013-03-14 | 2016-05-19 | ノバルティス アーゲー | Notch3に対する抗体 |
WO2014159242A1 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
WO2014144170A1 (en) | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | In-vitro method for monoclonal antibody production using non-human act1 -deficient mice |
US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
EP3404116B1 (de) | 2013-03-15 | 2022-10-19 | The University of Chicago | Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität |
ES2945160T3 (es) | 2013-03-15 | 2023-06-28 | Gladiator Biosciences Inc | Dominios Gla como agentes terapéuticos |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
CA2907680A1 (en) | 2013-03-21 | 2014-09-25 | Collplant Ltd. | Compositions comprising collagen and prp for tissue regeneration |
JP6294459B2 (ja) | 2013-03-24 | 2018-03-14 | バイオカイン・セラピューティクス・リミテッドBiokine Therapeutics Ltd. | 骨髄性白血病の処置方法 |
AU2014241162A1 (en) | 2013-03-27 | 2015-10-22 | Cedars-Sinai Medical Center | Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CA2909380A1 (en) | 2013-04-21 | 2014-10-30 | Yeda Research And Development Co. Ltd. | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
JP2016521971A (ja) | 2013-04-23 | 2016-07-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法119条第(e)項に基づき、2014年1月29日出願の米国特許仮出願第61/932,935号、2013年9月17日出願の米国特許仮出願第61/878,769号、および2013年4月23日出願の米国特許仮出願第61/814,920号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、YaqubHANNA、NoaNOVERSHTERN、およびYoachRAISによる米国特許出願(発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法(ISOLATEDNAIVEPLURIPOTENTSTEMCELLSANDMETHODSOFGENERATINGSAME)」)(代理人事件記録簿第58870号)にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。 |
EP2989119B1 (de) | 2013-04-25 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Verwendung von inhibierenden peptiden zur behandlung von entzündlichen erkrankungen |
US20160091485A1 (en) | 2013-04-25 | 2016-03-31 | The Broad Institute, Inc. | Markers for ezh2 inhibitors |
WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
AU2014268603B2 (en) | 2013-05-21 | 2018-03-22 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
KR102280377B1 (ko) | 2013-05-27 | 2021-07-23 | 라쿠토 바이오 테크놀로지스 리미티드 | 효소 시스템-함유 화장료 조성물 |
EP3004334A4 (de) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | Verfahren zur beurteilung eines pml-risikos |
WO2014200767A1 (en) | 2013-06-12 | 2014-12-18 | The General Hospital Corporation | Methods, kits, and systems for multiplexed detection of target molecules and uses thereof |
KR20160054456A (ko) | 2013-06-18 | 2016-05-16 | 디엔에이트릭스, 인코포레이티드 | 종양용해성 아데노바이러스를 사용한 뇌암의 치료 |
WO2014205230A1 (en) | 2013-06-19 | 2014-12-24 | Step Ahead Innovations Inc. | Aquatic environment water parameter testing systems and methods |
EP3013380B1 (de) | 2013-06-24 | 2022-11-23 | Ramot at Tel-Aviv University Ltd. | Bauchnetzgerüst und abgabesystem |
JP6566941B2 (ja) | 2013-06-28 | 2019-08-28 | ベイラー リサーチ インスティテュートBaylor Research Institute | 多発性硬化症のための樹状細胞asgpr標的化免疫治療薬 |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
EP3030663B1 (de) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von leptinotarsa |
WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
SG11201600587VA (en) | 2013-08-01 | 2016-02-26 | Agensys Inc | Antibody drug conjugates (adc) that bind to cd37 proteins |
CN114621346A (zh) | 2013-08-21 | 2022-06-14 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
EP3039030B1 (de) | 2013-08-29 | 2018-09-19 | Yeda Research and Development Co. Ltd. | Selektive inhibitoren der alpha-2-isoform der na,k-atpase und verwendung davon zur verminderung des augeninnendrucks |
SG10201907501QA (en) | 2013-08-30 | 2019-10-30 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants from cellular scaffolding and blood vessel stalk |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
WO2015040609A1 (en) | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
JP6474795B2 (ja) | 2013-10-01 | 2019-02-27 | カディマステム リミテッド | 薬物スクリーニング及び筋萎縮性側索硬化症(als)の処置における使用のための、ヒト多能性幹細胞からのアストロサイトの指向性分化 |
AU2014329535B2 (en) | 2013-10-03 | 2017-09-07 | Oklahoma Medical Research Foundation | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare |
US9476884B2 (en) | 2013-10-04 | 2016-10-25 | University Of Massachusetts | Hybridization- independent labeling of repetitive DNA sequence in human chromosomes |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2015059695A1 (en) | 2013-10-21 | 2015-04-30 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2015059690A1 (en) | 2013-10-24 | 2015-04-30 | Yeda Research And Development Co. Ltd. | Polynucleotides encoding brex system polypeptides and methods of using s ame |
EP3062809B1 (de) | 2013-10-31 | 2020-07-08 | Biokine Therapeutics Ltd. | Ein cxcr4 peptide inhibitor zur behandlung von akuter myeloischer leukämie mit einer flt3-mutation |
NZ719544A (en) | 2013-11-04 | 2022-09-30 | Beeologics Inc | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2015070009A2 (en) | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
WO2015077473A1 (en) | 2013-11-20 | 2015-05-28 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
PT3071593T (pt) | 2013-11-22 | 2019-06-27 | The Board Of Trustees Of The Univ Of Illionis | Recetores das células t de humanos manipulados de alta-afinidade |
WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
US10053712B2 (en) | 2013-12-10 | 2018-08-21 | Yeda Research And Development Co. Ltd. | Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-CoA and bacteria expressing same |
US20150191744A1 (en) | 2013-12-17 | 2015-07-09 | University Of Massachusetts | Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling |
EP3083658B1 (de) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Detektion gram-positiver bakterien mit crp |
EP3083936B1 (de) | 2013-12-19 | 2018-07-04 | Danisco US Inc. | Verwendung von hydrophobinen zur erhöhung des gastransfers in einem aeroben fermentationsprozess |
EP3092491B1 (de) | 2014-01-07 | 2018-10-31 | Bioatla, LLC | Protein-anzielende orthologe |
EP3992210A1 (de) | 2014-01-13 | 2022-05-04 | Baylor Research Institute | Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen |
US10334848B2 (en) | 2014-01-15 | 2019-07-02 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
EP3099719B1 (de) | 2014-01-29 | 2020-04-01 | Dana-Farber Cancer Institute, Inc. | Antikörper gegen die muc1-c/extrazelluläre domäne (/muc1-c/ecd) |
US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
CN111068053A (zh) | 2014-02-03 | 2020-04-28 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 使用酪蛋白激酶i抑制剂以消耗干细胞的用途 |
CN106715695B (zh) | 2014-02-05 | 2020-07-31 | 耶达研究及发展有限公司 | 用于治疗和诊断的微rna和包含所述微rna的组合物 |
CN106573976B (zh) | 2014-02-06 | 2020-05-05 | 耶达研究及发展有限公司 | 抗cd84抗体、包含所述抗体的组合物及其用途 |
US20150247204A1 (en) | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
WO2015118547A1 (en) | 2014-02-10 | 2015-08-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
EP3105587B1 (de) | 2014-02-11 | 2023-09-06 | Brainstorm Cell Therapeutics Ltd. | Verfahren zur qualifizierung von zellen |
WO2015123565A1 (en) | 2014-02-14 | 2015-08-20 | The General Hospital Corporation | Methods for diagnosing igg4-related disease |
WO2015131099A1 (en) | 2014-02-28 | 2015-09-03 | The General Hospital Corporation | Diagnosis of multiple myeloma and lymphoma |
US20170067894A1 (en) | 2014-03-03 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
EP2923709A1 (de) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Mehrstufiger Mehrkomponenten-Malariaimpfstoff |
BR112016022711A2 (pt) | 2014-04-01 | 2017-10-31 | Monsanto Technology Llc | composições e métodos para controle de pragas de inseto |
EP3129075B1 (de) | 2014-04-10 | 2024-09-18 | Bonus Therapeutics Ltd. | Knochenreparaturzusammensetzungen |
PL4026917T3 (pl) | 2014-04-14 | 2024-04-08 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Metoda i zestaw do określania śmierci komórek lub tkanek albo tkankowego lub komórkowego pochodzenia dna za pomocą analizy metylacji dna |
EP3132057B1 (de) | 2014-04-17 | 2019-10-16 | Yeda Research and Development Co. Ltd. | Verfahren und kits zur analyse von an dna angehängten dna-bindungsteilen |
MD20160130A2 (ro) | 2014-04-27 | 2017-04-30 | Ccam Biotherapeutics Ltd. | Anticorpi umanizaţi contra CEACAM1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
ES2870658T3 (es) | 2014-04-28 | 2021-10-27 | Yeda Res & Dev | Respuesta del microbioma a agentes |
US20170191065A1 (en) | 2014-05-04 | 2017-07-06 | Forrest Innovations Ltd. | Compositions and methods of using same for increasing resistance of infected mosquitoes |
EP2942627A1 (de) | 2014-05-05 | 2015-11-11 | MicroBPlex, Inc. | MIT VON NEULICH PROLIFERIERTEN ANTIKöRPER SEKRETIERENDEN ZELLEN NEU SYNTHETISIERTEN ANTIKÖRPERN (MENSA) ELABORIERTE MEDIEN UND VERWENDUNGEN DAVON |
WO2015171938A1 (en) | 2014-05-08 | 2015-11-12 | Novodiax, Inc. | Direct immunohistochemistry assay |
WO2015179435A1 (en) | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
EP3145947A2 (de) | 2014-05-22 | 2017-03-29 | Yeda Research and Development Co., Ltd. | Rekombinante mikroorganismen zur kohlenstofffixierung |
EP3149155B1 (de) | 2014-06-02 | 2020-09-23 | Kadimastem Ltd. | Verfahren zur induzierung der myelinisierung und reifung von oligodendrozyten |
US20170253881A1 (en) | 2014-06-02 | 2017-09-07 | Technion Research & Development Foundation Limited | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
US20170183376A1 (en) | 2014-06-24 | 2017-06-29 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
ES2791199T3 (es) | 2014-06-25 | 2020-11-03 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Identificación de marcadores de células madre cancerosas y uso de los mismos para diagnóstico y tratamiento |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
EP3160448A4 (de) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomale formulierungen zur freisetzung von nukleinsäuren |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
JP6671363B2 (ja) | 2014-07-15 | 2020-03-25 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド | Cd44の単離されたポリペプチドおよびその使用 |
CN106715719B (zh) | 2014-07-21 | 2022-08-02 | 福尔生物治疗有限公司 | 用于确定患者特定突变的药物反应的方法 |
JP6837428B2 (ja) | 2014-07-21 | 2021-03-10 | ノベルラスディクス リミテッド | 患者特有の変異の発癌性指数を決定する方法およびシステム |
RU2021123470A (ru) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с насекомыми-вредителями |
CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
CA2956925C (en) | 2014-08-01 | 2024-02-13 | Dovetail Genomics, Llc | Tagging nucleic acids for sequence assembly |
EP3180621B1 (de) | 2014-08-14 | 2020-04-01 | Memed Diagnostics Ltd. | Rechnerische analyse biologischer daten mit verteiler und hyperebene |
EP3485910A2 (de) | 2014-08-22 | 2019-05-22 | Sorrento Therapeutics, Inc. | Antigenbindende proteine zur bindung von cxcr3 |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
EP2992895A1 (de) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Mehrstufiger Dreikomponenten-Malariaimpfstoff |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
EP3191592A1 (de) | 2014-09-11 | 2017-07-19 | Novartis AG | Hemmung von prmt5 zur behandlung von erkrankungen im zusammenhang mit mtap-mangel |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
CA2944085C (en) | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
US10174320B2 (en) | 2014-09-21 | 2019-01-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Downregulating miR-132 for the treatment of lipid related disorders |
KR20240033093A (ko) | 2014-10-06 | 2024-03-12 | 케모센트릭스, 인크. | C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법 |
EP3207156A1 (de) | 2014-10-13 | 2017-08-23 | Life Technologies Corporation | Verfahren, kits und zusammensetzungen zur bestimmung der genkopienzahl |
WO2016064887A1 (en) | 2014-10-20 | 2016-04-28 | Gen-Probe Incorporated | Red blood cell lysis solution |
EP3209774B1 (de) | 2014-10-24 | 2020-02-26 | DuPont Nutrition Biosciences ApS | Verwendung von prolintoleranten tripeptidylpeptidasen in futterzusatzzusammensetzungen |
US20170306360A1 (en) | 2014-10-24 | 2017-10-26 | Danisco Us Inc. | Method for producing alcohol by use of a tripeptidyl peptidase |
US10570368B2 (en) | 2014-11-13 | 2020-02-25 | Enzootic Holdings Ltd. | Functional sex-reversal of decapod crustacean females |
US20180042994A1 (en) | 2014-11-17 | 2018-02-15 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
EP3221470B1 (de) | 2014-11-17 | 2019-08-14 | Yeda Research and Development Co., Ltd. | Verfahren zur analyse eines mikrobioms |
RU2758608C2 (ru) | 2014-11-19 | 2021-11-01 | Конинклейке Филипс Н.В. | Способ диагностики с использованием hnl |
WO2016079739A2 (en) | 2014-11-20 | 2016-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
WO2016084088A1 (en) | 2014-11-26 | 2016-06-02 | Ramot At Tel-Aviv University Ltd. | Targeted elimination of bacterial genes |
US10883111B2 (en) | 2014-11-27 | 2021-01-05 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
EP3227446A1 (de) | 2014-12-01 | 2017-10-11 | Novartis AG | Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs |
EP3227462B1 (de) | 2014-12-01 | 2020-04-22 | The Broad Institute, Inc. | Verfahren für die in-situ-bestimmung der nukleinsäure-nähe |
AU2015360694B2 (en) | 2014-12-08 | 2021-10-14 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
US10688330B2 (en) | 2014-12-11 | 2020-06-23 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
JP6427278B2 (ja) | 2014-12-23 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | pirinポリペプチド及び免疫モジュレーション |
SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
JP6882981B2 (ja) | 2014-12-30 | 2021-06-02 | セル キュア ニューロサイエンシズ リミテッド | Rpe細胞集団およびそれを作製する方法 |
CN107427534A (zh) | 2014-12-30 | 2017-12-01 | 细胞治疗神经科学有限公司 | 治疗视网膜疾病的方法 |
IL314417A (en) | 2014-12-30 | 2024-09-01 | Cell Cure Neurosciences Ltd | Examination of retinal pigment epithelial cell populations |
CA2970216A1 (en) | 2015-01-04 | 2016-07-07 | Protalix Ltd. | Modified dnase and uses thereof |
WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
EP3256589B1 (de) | 2015-01-22 | 2021-12-22 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von leptinotarsa |
WO2016130516A1 (en) | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
JP6917902B2 (ja) | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Ctla4に結合する抗体医薬 |
CA2976902A1 (en) | 2015-02-17 | 2016-08-25 | Dovetail Genomics Llc | Nucleic acid sequence assembly |
DK3262411T3 (da) | 2015-02-25 | 2022-04-19 | Univ Vanderbilt | Antibody-mediated neutralization of marburg virus |
US20180345047A1 (en) | 2015-02-26 | 2018-12-06 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
SG11201707195SA (en) | 2015-03-09 | 2017-10-30 | Agensys Inc | Antibody drug conjugates (adc) that bind to flt3 proteins |
EP3268462B1 (de) | 2015-03-11 | 2021-08-11 | The Broad Institute, Inc. | Genotyp- und phänotypkupplung |
EP3268475B1 (de) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Köderoligonukleotide zur behandlung von krankheiten |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
GB2554572B (en) | 2015-03-26 | 2021-06-23 | Dovetail Genomics Llc | Physical linkage preservation in DNA storage |
ES2904573T3 (es) | 2015-03-27 | 2022-04-05 | Univ Southern California | Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos |
EP3273971A4 (de) | 2015-03-27 | 2018-12-05 | Yeda Research and Development Co. Ltd. | Verfahren zur behandlung von motoneuronenerkrankungen |
CA2979309A1 (en) | 2015-03-31 | 2016-10-06 | Yeda Research And Development Co. Ltd. | Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof |
US9612534B2 (en) | 2015-03-31 | 2017-04-04 | Tokyo Electron Limited | Exposure dose homogenization through rotation, translation, and variable processing conditions |
WO2016157192A1 (en) | 2015-04-01 | 2016-10-06 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
CN107690429B (zh) | 2015-04-07 | 2022-02-25 | Ela制药有限公司 | 用于治疗和/或预防细胞或组织坏死的组合物,其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶 |
EP3280443B1 (de) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antikörpertherapeutika zur bindung von cd38 |
EP3081575A1 (de) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium-parasiten-antikörper |
EP3288547B1 (de) | 2015-04-27 | 2023-06-07 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Egr1-targeting-moleküle zur behandlung von entzündlichen und hyperproliferativen zuständen |
ES2911341T3 (es) | 2015-04-29 | 2022-05-18 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Composiciones antifitopatogénicas |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
US11845928B2 (en) | 2015-05-04 | 2023-12-19 | Tsinghua University | Methods and kits for fragmenting DNA |
WO2016182984A1 (en) | 2015-05-08 | 2016-11-17 | Centrillion Technology Holdings Corporation | Disulfide-linked reversible terminators |
US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
EP3297680A2 (de) | 2015-05-20 | 2018-03-28 | Yeda Research and Development Co. Ltd | Verfahren zum targeting von seneszenten zellen |
EA201792547A1 (ru) | 2015-05-21 | 2018-04-30 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | Популяции бактерий для стимуляции состояния здоровья |
CN107847546A (zh) | 2015-05-29 | 2018-03-27 | Opko生物科学有限公司 | 聚乙二醇化的胃泌酸调节素变体 |
CN107750125A (zh) | 2015-06-02 | 2018-03-02 | 孟山都技术有限公司 | 用于将多核苷酸递送至植物中的组合物和方法 |
WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
RS59446B1 (sr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti |
CN114984057A (zh) | 2015-06-15 | 2022-09-02 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
SI3360559T1 (sl) | 2015-06-15 | 2020-02-28 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
EP4026563A1 (de) | 2015-06-18 | 2022-07-13 | Yeda Research and Development Co. Ltd | Konditionierungsprotokolle und verwendung davon zur geweberegeneration |
WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
KR102662956B1 (ko) | 2015-06-19 | 2024-05-03 | 옵코 바이오로직스 리미티드 | 장기-작용성 응고 인자 및 그의 제조 방법 |
US11473073B2 (en) | 2015-06-26 | 2022-10-18 | Dupont Nutrition Biosciences Aps | Aminopeptidases for protein hydrolyzates |
US20190017117A1 (en) | 2015-07-10 | 2019-01-17 | West Virginia University | Markers of stroke and stroke severity |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
ES2963038T3 (es) | 2015-07-16 | 2024-03-25 | Yeda Res & Dev | Uso de células T de memoria central antitercero |
WO2017013648A1 (en) | 2015-07-19 | 2017-01-26 | Yeda Research And Development Co. Ltd. | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
CN107846936B (zh) | 2015-07-22 | 2021-06-01 | 芙图法尔马国际有限公司 | 蜜蜂可摄取组成物及使用其生产蜂蜜的方法与由此生产的蜂蜜 |
ES2865024T3 (es) | 2015-07-29 | 2021-10-14 | Hadasit Med Res Service | Producción a gran escala de células de epitelio pigmentario retiniano |
WO2017021963A1 (en) | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
CN108136051A (zh) | 2015-08-04 | 2018-06-08 | Cd诊断股份有限公司 | 检测不良局部组织反应(altr)坏死的方法 |
JP6868608B2 (ja) | 2015-08-05 | 2021-05-12 | セル キュア ニューロサイエンシズ リミテッド | 網膜疾患の処置のための光受容体の調製 |
WO2017021973A1 (en) | 2015-08-05 | 2017-02-09 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
EP3331549B1 (de) | 2015-08-06 | 2020-12-23 | President and Fellows of Harvard College | Verbesserte mikrobenbindende moleküle und verwendungen davon |
WO2017025963A1 (en) | 2015-08-10 | 2017-02-16 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using cd24 |
US20180237790A1 (en) | 2015-08-13 | 2018-08-23 | Forrest Innovation Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
EP3337908A4 (de) | 2015-08-18 | 2019-01-23 | The Broad Institute, Inc. | Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen |
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
WO2017033152A1 (en) | 2015-08-25 | 2017-03-02 | Prothena Biosciences Limited | Methods for detecting phosphorylated alpha-synuclein |
WO2017040380A2 (en) | 2015-08-28 | 2017-03-09 | Research Development Foundation | Engineered antibody fc variants |
WO2017040813A2 (en) | 2015-09-02 | 2017-03-09 | University Of Massachusetts | Detection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids |
US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
CA3036409C (en) | 2015-09-08 | 2023-07-11 | Erik J. Sontheimer | Dnase h activity of neisseria meningitidis cas9 |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
US11001872B2 (en) | 2015-09-22 | 2021-05-11 | Shawn Clark | Designing customized protein-specific buffer system |
ES2765709T3 (es) | 2015-09-29 | 2020-06-10 | Htg Molecular Diagnostics Inc | Procedimientos para subtipificar el linfoma de células B difusas (DLBCL) |
CA3001590A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
US11078528B2 (en) | 2015-10-12 | 2021-08-03 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
KR20180096586A (ko) | 2015-10-19 | 2018-08-29 | 더브테일 제노믹스 엘엘씨 | 게놈 어셈블리, 하플로타입 페이징 및 표적 독립적 핵산 검출을 위한 방법 |
EP3365376A1 (de) | 2015-10-25 | 2018-08-29 | Yeda Research and Development Co., Ltd. | Auf quiescin-sulfhydryl-oxidase (qsox1) abzielende antikörper und verwendungen davon |
AU2016347652A1 (en) | 2015-10-26 | 2018-05-24 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
US11090275B2 (en) | 2015-10-27 | 2021-08-17 | Jay Pharma Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
WO2017077539A1 (en) | 2015-11-03 | 2017-05-11 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
JP6987068B2 (ja) | 2015-11-09 | 2021-12-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 癌マーカーおよび治療標的としてのグリピカン2 |
WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
EP3209310B1 (de) | 2015-11-20 | 2018-01-31 | 4D Pharma Research Limited | Zusammensetzungen mit bakterienstämmen |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
IL293289B2 (en) | 2015-11-30 | 2024-04-01 | Kadimastem Ltd | Methods for differentiation and purification of pancreatic endocrine cells |
EP3176183A1 (de) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki) |
US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CA3007301A1 (en) | 2015-12-04 | 2017-06-08 | Board Of Regents, The University Of Texas System | Slc45a2 peptides for immunotherapy |
ES2924732T3 (es) | 2015-12-16 | 2022-10-10 | Univ Ramot | Partículas que comprenden epiplón descelularizado |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
US10920224B2 (en) | 2015-12-22 | 2021-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Protecting RNAs from degradation using engineered viral RNAs |
EP3397344A4 (de) | 2015-12-28 | 2019-08-28 | B.G. Negev Technologies and Applications Ltd. at Ben-Gurion University | Zusammensetzung und verfahren zur behandlung von amyotropher lateralsklerose |
CA3009127A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
EP3403091B1 (de) | 2016-01-11 | 2021-12-22 | Technion Research & Development Foundation Limited | Verfahren zur bestimmung der prognose von sepsis und behandlung davon |
EP3405024B1 (de) | 2016-01-21 | 2022-12-28 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Parthenokarpe pflanzen und verfahren zur herstellung davon |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
KR20190026642A (ko) | 2016-01-29 | 2019-03-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
EP3408376A1 (de) | 2016-01-31 | 2018-12-05 | Hadasit Medical Research Services and Development Ltd. | Autosomale-identische pluripotente stammzellpopulationen mit nicht identischer geschlechtschromosomenzusammensetzung und verwendungen davon |
CA3012302A1 (en) | 2016-02-04 | 2017-08-10 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
CN109196113B (zh) | 2016-02-11 | 2022-10-04 | 奇根科学有限责任公司 | 合成测序中的多酚添加剂 |
US10036011B2 (en) | 2016-02-11 | 2018-07-31 | Qiagen Waltham, Inc. | Scavenger compounds for improved sequencing-by-synthesis |
US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
EP3708675A1 (de) | 2016-02-14 | 2020-09-16 | Yeda Research and Development Co. Ltd. | Mikrobiombasierte diagnose, vorhersage und behandlung von rezidivierender fettleibigkeit |
WO2017141253A1 (en) | 2016-02-16 | 2017-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth |
WO2017147186A1 (en) | 2016-02-22 | 2017-08-31 | Ursure, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
SG11201807117WA (en) | 2016-02-23 | 2018-09-27 | Dovetail Genomics Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
JP2019511919A (ja) | 2016-02-23 | 2019-05-09 | ブローディ,チャヤ | がん幹細胞の作製およびその使用 |
CA3013383A1 (en) | 2016-02-25 | 2017-08-31 | Dupont Nutrition Biosciences Aps | Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase |
AU2017224122B2 (en) | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
CN114959084A (zh) | 2016-03-03 | 2022-08-30 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
NZ745678A (en) | 2016-03-04 | 2019-03-29 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan |
CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
US10458995B2 (en) | 2016-03-25 | 2019-10-29 | Muralidhar Reddy Moola | Combinatorial synthesis and biomarker development |
KR102418372B1 (ko) | 2016-03-29 | 2022-07-08 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법 |
EP3436480A4 (de) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | Verfahren zur behandlung und diagnose von krebs durch targeting von glycoprotein a repetitions predominant (garp) und zur effektiven immuntherapie allein oder in kombination |
US11162091B2 (en) | 2016-04-27 | 2021-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
WO2017194589A1 (en) | 2016-05-10 | 2017-11-16 | Vib Vzw | Inhibition of tau-mediated early synaptic dysfunction |
EP3954771A1 (de) | 2016-05-13 | 2022-02-16 | Dovetail Genomics, LLC | Rückgewinnung von long-range-bindungsinformationen aus konservierten proben |
EP3458483A1 (de) | 2016-05-16 | 2019-03-27 | President and Fellows of Harvard College | Wässriges biomolekül mit kopplung an co2-plasma-aktivierte oberflächen |
WO2017203520A1 (en) | 2016-05-22 | 2017-11-30 | Yeda Research And Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
US20190100732A1 (en) | 2016-06-02 | 2019-04-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
EP3465200A4 (de) | 2016-06-05 | 2020-07-08 | Berg LLC | Systeme und verfahren zur patientenstratifizierung und identifizierung von potenziellen biomarkern |
US11820833B2 (en) | 2016-06-05 | 2023-11-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Peptides that inhibit binding of EPCR to its ligand to treat inflammation |
US20190160152A1 (en) | 2016-06-09 | 2019-05-30 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
EP3472342A1 (de) | 2016-06-19 | 2019-04-24 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Screening auf chemotherapieresistenz in menschlichen haploidzellen |
JP7334043B2 (ja) | 2016-06-27 | 2023-08-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | メモリーt細胞から作られるベト細胞 |
EP3479119B1 (de) | 2016-06-30 | 2020-08-12 | Koninklijke Philips N.V. | Verfahren zum nachweis eines analyten in einer körperflüssigkeitsprobe mit mehreren zellen |
US11340223B2 (en) | 2016-07-10 | 2022-05-24 | Memed Diagnostics Ltd. | Early diagnosis of infections |
CA3027341A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
EA201990255A1 (ru) | 2016-07-11 | 2019-07-31 | Опко Байолоджикс Лтд | Фактор свертывания крови vii пролонгированного действия и способы его получения |
IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combined treatment to increase endogenous synthesis of nitric oxide |
EP3481967A4 (de) | 2016-07-11 | 2020-04-22 | Bonus Therapeutics Ltd. | Zellzusammensetzungen zur geweberegeneration |
IL302693A (en) | 2016-07-11 | 2023-07-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods and systems for growing cells in culture |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
EP4434516A2 (de) | 2016-07-18 | 2024-09-25 | Ramot at Tel-Aviv University Ltd. | Modulare plattform für gezielte therapeutika |
AU2017300579B2 (en) | 2016-07-20 | 2023-02-09 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Therapeutic agents for neurological and psychiatric disorders |
WO2018017673A1 (en) | 2016-07-20 | 2018-01-25 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
WO2018020489A1 (en) | 2016-07-24 | 2018-02-01 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
ES2965761T3 (es) | 2016-08-08 | 2024-04-16 | Tech Innovation Momentum Fund Israel Limited Partnership | Sistemas bacterianos para el análisis de polipéptidos ubiquitilados |
CN109844532B (zh) | 2016-08-10 | 2022-06-17 | 米密德诊断学有限公司 | 分析生物数据的系统和方法 |
EP3497239A4 (de) | 2016-08-10 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Analyse des methylierungsstatus und kopienzahl |
ES2925527T3 (es) | 2016-08-14 | 2022-10-18 | Univ Ramot | Exosomas derivados de células mesenquimales para tratar trastornos neurológicos |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
JP2020501506A (ja) | 2016-09-07 | 2020-01-23 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | 抗NKp46抗体およびその治療的使用 |
US11485971B2 (en) | 2016-09-14 | 2022-11-01 | Yeda Research And Development Co. Ltd. | CRISP-seq, an integrated method for massively parallel single cell RNA-seq and CRISPR pooled screens |
US11385241B2 (en) | 2016-09-29 | 2022-07-12 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing |
IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of circadian rhythm disorder |
US20180128828A1 (en) | 2016-11-04 | 2018-05-10 | James W. Stave | Direct detection of microorganisms in patient samples by immunoassay |
US11162129B2 (en) | 2016-11-09 | 2021-11-02 | IsoPlexis Corporation | Photoprotective mixtures as imaging reagents in sequencing-by-synthesis |
US20190359956A1 (en) | 2016-11-10 | 2019-11-28 | Yeda Research And Development Co. Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
BR112019010375A2 (pt) | 2016-11-23 | 2019-08-27 | Chemocentryx Inc | método de tratamento de glomeruloesclerose segmental focal |
JP2019535298A (ja) | 2016-11-28 | 2019-12-12 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 単離ポリヌクレオチドおよびポリペプチドおよび関心のある発現産物を発現させるためにそれらを使用する方法 |
CN110199031A (zh) | 2016-11-29 | 2019-09-03 | 基因组影像公司 | 设计用于分析感兴趣的遗传区域中的特定事件的一组多核苷酸序列的方法 |
US20190343782A1 (en) | 2016-11-30 | 2019-11-14 | Yeda Research And Development Co. Ltd. | Methods of treating liver toxicity and disorders |
CA3026989C (en) | 2016-12-01 | 2023-07-11 | Ramot At Tel-Aviv University Ltd. | Combined treatment for nerve injuries |
EP3329905A1 (de) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Topische kosmetische zusammensetzungen enhaltend ein oligopeptid gegen die hautalterung |
EP3329930A1 (de) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmazeutische zusammensetzungen |
EP3548058B1 (de) | 2016-12-05 | 2022-06-22 | Nuritas Limited | Zusammensetzungen enthaltend peptid wkdeagkplvk |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
EP3571295A1 (de) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetisch modifizierte vetozellen und verwendung davon in der immuntherapie |
WO2018140606A1 (en) | 2017-01-26 | 2018-08-02 | Oklahoma Medical Research Foundation | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare |
EP3574009A4 (de) | 2017-01-26 | 2020-11-25 | Zlip Holding Limited | Cd47-antigen-bindende einheit und verwendungen davon |
CA3051466A1 (en) | 2017-01-31 | 2018-08-09 | Vanderbilt University | Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use |
IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
WO2018146162A1 (en) | 2017-02-07 | 2018-08-16 | Academisch Medisch Centrum | Molecular biomarker for prognosis of sepsis patients |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
AU2018234933B2 (en) | 2017-03-16 | 2024-03-21 | Lineage Cell Therapeutics, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
ES2963461T3 (es) | 2017-04-05 | 2024-03-27 | Yeda Res & Dev | Sistema de cultivo ex vivo y métodos de utilización del mismo |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
WO2018207184A2 (en) | 2017-05-10 | 2018-11-15 | Ariel Scientific Innovations Ltd. | Methods of purifying antibodies |
EP3652541B1 (de) | 2017-05-21 | 2022-12-14 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Kombination von markern zur diagnose von krebs |
AU2018272291A1 (en) | 2017-05-22 | 2020-01-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US20200172604A1 (en) | 2017-05-23 | 2020-06-04 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
EP3630834A1 (de) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden |
EP3630973A1 (de) | 2017-05-31 | 2020-04-08 | Tropic Biosciences UK Limited | Verfahren zur auswahl von zellen mit genomeditierungsereignissen |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
HUE052319T2 (hu) | 2017-06-14 | 2021-04-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
ES2917415T3 (es) | 2017-06-14 | 2022-07-08 | 4D Pharma Res Ltd | Composiciones que comprenden una cepa bacteriana |
CN111107859B (zh) | 2017-06-14 | 2022-04-29 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
EP3652344A1 (de) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna-targets als gewebespezifische methylierungsmarker |
EP3652343A1 (de) | 2017-07-13 | 2020-05-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Digitale tröpfchen-pcr-strategie mit zwei sonden zur spezifischen detektion gewebespezifischer zirkulierender dna-moleküle |
US20200165671A1 (en) | 2017-07-13 | 2020-05-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detecting tissue-specific dna |
US10768185B2 (en) | 2017-07-20 | 2020-09-08 | Trustees Of Boston University | Tenofovir detection assay |
US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
JP7145895B2 (ja) | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 組換え二重特異性抗体 |
KR20200050975A (ko) | 2017-09-05 | 2020-05-12 | 글래디에이터 바이오사이언시즈 인코포레이티드 | 엑소좀의 표적화 방법 |
WO2019055825A1 (en) | 2017-09-15 | 2019-03-21 | The Regents Of The University Of California | INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER |
AU2018336126A1 (en) | 2017-09-19 | 2020-04-30 | Tropic Biosciences UK Limited | Modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells |
EP3692152A4 (de) | 2017-10-04 | 2021-12-01 | The Broad Institute, Inc. | Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen |
EP3694545A4 (de) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung |
SG11202002975YA (en) | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
US20200390800A1 (en) | 2017-11-29 | 2020-12-17 | Ramot At Tel-Aviv University Ltd. | Methods of preventing or treating neurogenic shock |
EP3716756A4 (de) | 2017-11-29 | 2021-09-15 | Weedout Ltd. | Zusammensetzungen, kits und verfahren zur bekämpfung von unkraut der gattung amaranthus |
WO2019106680A1 (en) | 2017-12-03 | 2019-06-06 | Yeda Research And Development Co. Ltd. | Treatment of an ischemic heart disease |
CN109870581B (zh) | 2017-12-04 | 2021-05-04 | 厦门万泰凯瑞生物技术有限公司 | 一种定量检测HBsAg的试剂盒及方法 |
WO2019118721A2 (en) | 2017-12-15 | 2019-06-20 | Syngenta Participations Ag | Non-antibody ligands for detecting target proteins |
WO2019116376A1 (en) | 2017-12-17 | 2019-06-20 | Yeda Research And Development Co. Ltd. | Cop9 signalosome (csn) complex modulators and uses thereof |
WO2019130313A1 (en) | 2017-12-28 | 2019-07-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
WO2019156758A2 (en) | 2018-01-05 | 2019-08-15 | Vanderbilt University | Antibody-mediated neutralization of chikungunya virus |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
EP3749368A1 (de) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Verfahren zur identifizierung und verwendung von mitteln zur behandlung von mit darmbarrierefunktionsstörungen einhergehenden krankheiten |
EP3749689A1 (de) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Inhibitoren des 20s-proteasoms |
WO2019155041A1 (en) | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
US20200408771A1 (en) | 2018-02-22 | 2020-12-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Cd153 and/or cd30 in infection |
WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
WO2019167047A1 (en) | 2018-02-28 | 2019-09-06 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
EP3765034A1 (de) | 2018-03-12 | 2021-01-20 | Yeda Research and Development Co. Ltd | Behandlung einer herzkrankheit |
US20210214445A1 (en) | 2018-03-23 | 2021-07-15 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
EP3774047A1 (de) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Verwendung von elektrischen feldgradienten zur kontrolle der genexpression |
IL314908A (en) | 2018-03-29 | 2024-10-01 | Technion Res & Dev Foundation | Bubbles containing PTEN inhibitor and their uses |
CN112292457A (zh) | 2018-04-09 | 2021-01-29 | 领先细胞医疗诊断有限公司 | 用于原位检测核酸的进一步增强信号放大的方法 |
WO2019206095A1 (zh) | 2018-04-24 | 2019-10-31 | 安源医药科技(上海)有限公司 | 针对tim-3的抗体及其用途 |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
WO2019213276A1 (en) | 2018-05-02 | 2019-11-07 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
BR112020023955A2 (pt) | 2018-05-27 | 2021-02-23 | Biolinerx Ltd. | agi-134 combinado com um inibidor de ponto de controle para o tratamento de tumores sólidos |
CN112424365A (zh) | 2018-06-07 | 2021-02-26 | 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 | 核酸构建体及其使用方法 |
CN112384063A (zh) | 2018-06-07 | 2021-02-19 | 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 | 再生及转殖大麻的方法 |
EP3820498A1 (de) | 2018-06-14 | 2021-05-19 | University College Cork-National University of Ireland Cork | Peptid zur krankheitsbehandlung |
WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
US11873322B2 (en) | 2018-06-25 | 2024-01-16 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
US20210292381A1 (en) | 2018-07-04 | 2021-09-23 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
EP3818529A2 (de) | 2018-07-08 | 2021-05-12 | Yeda Research and Development Co. Ltd | Personenspezifische beurteilung des ansprechens auf probiotika |
CA3100961A1 (en) | 2018-07-11 | 2020-01-16 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
WO2020012486A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
KR20210042430A (ko) | 2018-07-31 | 2021-04-19 | 콜플랜트 리미티드 | 담배 형질전환 이벤트 및 이의 검출 방법 및 용도 |
IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
WO2020039440A1 (en) | 2018-08-24 | 2020-02-27 | Yeda Research And Development Co. Ltd. | Methods of modulating m2 macrophage polarization and use of same in therapy |
KR20210061341A (ko) | 2018-09-13 | 2021-05-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 신규한 lilrb4 항체 및 이의 용도 |
CN113038951B (zh) | 2018-09-20 | 2024-04-30 | 耶达研究及发展有限公司 | 治疗肌萎缩侧索硬化的方法 |
US20210338767A1 (en) | 2018-09-25 | 2021-11-04 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
EP3856753A4 (de) | 2018-09-28 | 2022-11-16 | Centrillion Technology Holdings Corporation | Disulfidvernetzte reversible terminatoren |
AU2019362874A1 (en) | 2018-10-15 | 2021-05-27 | University Of Massachusetts | Programmable DNA base editing by Nme2Cas9-deaminase fusion proteins |
CN113196059A (zh) | 2018-10-18 | 2021-07-30 | 俄克拉荷马医学研究基金会 | 表征疾病活动性的系统性红斑狼疮(sle)疾病活动性免疫指数的生物标志物 |
BR112021007690A2 (pt) | 2018-10-22 | 2021-08-10 | Shanghai GenBase Biotechnology Co., Ltd. | anticorpo anti-cldn18.2 e uso do mesmo |
KR20210081397A (ko) | 2018-10-23 | 2021-07-01 | 글리카디얼 디아그노스틱스, 에스.엘. | 당화된 apoj에 특이적인 항체 및 그 용도 |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
CN111196851B (zh) | 2018-11-20 | 2021-11-16 | 厦门万泰凯瑞生物技术有限公司 | 针对人抗缪勒管激素的特异性抗体及其应用 |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
CN113423465A (zh) | 2018-11-28 | 2021-09-21 | 俄勒冈健康与科学大学 | 治疗性的因子xii抗体 |
JP7462632B2 (ja) | 2018-11-30 | 2024-04-05 | カリス エムピーアイ インコーポレイテッド | 次世代分子プロファイリング |
EP3904386A4 (de) | 2018-12-28 | 2022-09-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antikörper und verwendung davon |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
CN113454238A (zh) | 2019-01-25 | 2021-09-28 | 哈佛大学校长及研究员协会 | 用于合成核酸的组合物和方法 |
IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use |
IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
WO2020168162A1 (en) | 2019-02-15 | 2020-08-20 | Bio-Techne Corporation | Methods for multiplex detection of nucleic acids by in situ hybridization |
EP3927807A1 (de) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur herstellung von organoiden für hochdurchsatz-screening von arzneimitteln |
EP3927378A1 (de) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur reduktion von arzneimittelinduzierter nephrotoxizität |
BR112021017265A2 (pt) | 2019-03-05 | 2021-12-21 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Agente de edição de dna, população de células de aves, ave quimérica, método para gerar uma ave quimérica e método para induzir letalidade em um embrião macho de uma ave |
WO2020185763A1 (en) | 2019-03-11 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
US20220175807A1 (en) | 2019-03-31 | 2022-06-09 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
CN113474374A (zh) | 2019-04-16 | 2021-10-01 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
AU2020265250A1 (en) | 2019-04-30 | 2021-11-18 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Compositions comprising the propeptide of lysyl oxidase and uses thereof |
WO2020230133A1 (en) | 2019-05-13 | 2020-11-19 | Yeda Research And Development Co. Ltd. | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
AU2020279080A1 (en) | 2019-05-22 | 2022-01-20 | Hadasit Medical Research Services And Development Ltd. | Methods of culturing human pluripotent cells |
IT201900007222A1 (it) | 2019-05-24 | 2020-11-24 | Univ Degli Studi Di Torino | Composizione di liposomi e metodo di dosaggio basato sull'uso degli stessi |
CN114599675B (zh) | 2019-05-28 | 2024-08-16 | 上海科技大学 | 用于治疗clouston型外胚层发育不良2的组合物和方法 |
AU2020291694A1 (en) | 2019-06-12 | 2022-02-03 | Hadasit Medical Research Services And Development Ltd. | Methods of generating oligodendrocytes |
EP3983540A1 (de) | 2019-06-16 | 2022-04-20 | Yeda Research and Development Co. Ltd | Verfahren zur stabilisierung intrazellulärer rna |
AU2020302791A1 (en) | 2019-06-27 | 2022-02-03 | Dovetail Genomics, Llc | Methods and compositions for proximity ligation |
WO2020261281A1 (en) | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
CN114938647A (zh) | 2019-07-04 | 2022-08-23 | 乌科公司 | 去表位的α-麦醇溶蛋白及其在乳糜泻和麸质敏感性管理中的用途 |
AU2020311636A1 (en) | 2019-07-11 | 2022-03-03 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
WO2021009740A1 (en) | 2019-07-16 | 2021-01-21 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
WO2021016062A1 (en) | 2019-07-19 | 2021-01-28 | The Children's Hospital Of Philadelphia | Chimeric antigen receptors containing glypican 2 binding domains |
CA3145278A1 (en) | 2019-07-26 | 2021-02-04 | Vanderbilt University | Human monoclonal antibodies to enterovirus d68 |
EP4004548A1 (de) | 2019-07-29 | 2022-06-01 | Yeda Research and Development Co. Ltd | Verfahren zur behandlung und diagnose von lungenkrebs |
EP4004212A1 (de) | 2019-07-30 | 2022-06-01 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Verfahren zur steuerung der cannabinoid-synthese in pflanzen oder zellen und nach diesem verfahren hergestellte pflanzen und zellen |
WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
JP2022545265A (ja) | 2019-08-20 | 2022-10-26 | ニューリタス リミテッド | 筋萎縮を治療するためのペプチド |
EP3783012A1 (de) | 2019-08-20 | 2021-02-24 | Nuritas Limited | Antimikrobielles peptid |
WO2021033176A1 (en) | 2019-08-22 | 2021-02-25 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
WO2021038569A1 (en) | 2019-08-27 | 2021-03-04 | Yeda Research And Development Co. Ltd. | Treatment of bacterial vaginosis |
WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
JP2023501871A (ja) | 2019-09-20 | 2023-01-20 | 上海吉倍生物技術有限公司 | Bcma標的化抗体及びキメラ抗原受容体 |
IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembling protein complexes on a chip |
EP4041767A1 (de) | 2019-09-26 | 2022-08-17 | StCube & Co. | Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon |
WO2021063201A1 (zh) | 2019-09-30 | 2021-04-08 | 四川科伦博泰生物医药股份有限公司 | 抗pd-1抗体及其用途 |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
MX2022004872A (es) | 2019-10-22 | 2022-05-13 | Nuritas Ltd | Tratamiento de enfermedad de higado graso no alcoholico. |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
WO2021084526A1 (en) | 2019-10-31 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
AU2020384953A1 (en) | 2019-11-11 | 2022-06-23 | Ibi-Ag Innovative Bio Insecticides Ltd. | Insect control nanobodies and uses thereof |
IL293148A (en) | 2019-11-19 | 2024-07-01 | Protalix Ltd | Removal of constructs from transduced cells |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
MX2022006589A (es) | 2019-12-02 | 2023-01-11 | Caris Mpi Inc | Predictor de respuesta de platino pan-cancer. |
EP4073246A4 (de) | 2019-12-12 | 2023-12-06 | President And Fellows Of Harvard College | Zusammensetzungen und verfahren zur lichtgerichteten biomolekularen barcodierung |
CA3155759A1 (en) | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
AU2020409124A1 (en) | 2019-12-20 | 2022-06-30 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
EP4077731A1 (de) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnose einer frontotemporalen demenz |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
EP3842452A1 (de) | 2019-12-26 | 2021-06-30 | Universitat Autònoma de Barcelona | Gerüstproteine und therapeutische nanokonjugate auf nidogenbasis |
IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
CN113061165A (zh) | 2020-01-02 | 2021-07-02 | 厦门大学 | EB病毒BNLF2b基因编码多肽及其检测用途 |
IL272074B1 (en) | 2020-01-15 | 2024-08-01 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
BR102020002165A2 (pt) | 2020-01-31 | 2021-11-30 | Fundação Oswaldo Cruz | Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas. |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
EP3862014A1 (de) | 2020-02-07 | 2021-08-11 | Nuritas Limited | Behandlung von panx1-assoziierten erkrankungen |
CN115335532A (zh) | 2020-02-09 | 2022-11-11 | Nlc制药有限公司 | Sars-cov-2快速检测测试 |
IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | A method for cell cluster analysis |
US20210277092A1 (en) | 2020-02-11 | 2021-09-09 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) |
EP4107173A1 (de) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Verfahren zur expansion tumorinfiltrierender lymphozyten und deren verwendung |
JP2023514654A (ja) | 2020-02-25 | 2023-04-06 | ブイアイビー ブイゼットダブリュ | ロイシンリッチリピートキナーゼ2のアロステリック調節因子 |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
EP4121441A1 (de) | 2020-03-16 | 2023-01-25 | Yeda Research and Development Co. Ltd | Peptidanaloga und verwendung davon bei der behandlung von erkrankungen, störungen oder leiden im zusammenhang mit einem mutierten p53-protein |
US20230150926A1 (en) | 2020-03-17 | 2023-05-18 | Genevant Sciences Gmbh | Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
MX2022011892A (es) | 2020-03-26 | 2022-10-18 | Univ Vanderbilt | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2). |
WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
BR112022019510A2 (pt) | 2020-03-29 | 2022-11-16 | Yeda Res & Dev | Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher |
IL296698A (en) | 2020-03-31 | 2022-11-01 | Biomuse Ltd | Bacteria for the prevention and treatment of smoking damage to the lungs |
TW202203916A (zh) | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | 使用ccr9抑制劑及抗il—23阻斷抗體治療發炎性腸道疾病的組成物及方法 |
EP4133107A1 (de) | 2020-04-06 | 2023-02-15 | Yeda Research and Development Co. Ltd | Verfahren zur diagnose von krebs und vorhersage des ansprechens auf eine therapie |
EP4132479A1 (de) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiolhaltige zusammensetzungen und verwendungen davon |
EP4135746A1 (de) | 2020-04-13 | 2023-02-22 | Exoprother Medical Ltd. | Vesikel aus zellen mit wildtyp-p53-protein zur antiviralen therapie |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
KR20230002943A9 (ko) | 2020-04-22 | 2024-04-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 검출을 위한 등온 방법, 조성물, 키트, 및 시스템 |
WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
WO2021228141A1 (zh) | 2020-05-15 | 2021-11-18 | 四川科伦博泰生物医药股份有限公司 | 抗体药物缀合物及其制备方法和用途 |
IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Spatial information is developed for the analysis of individual cells |
CN115803062A (zh) | 2020-06-03 | 2023-03-14 | 博泰康医药公司 | 滋养层细胞表面抗原2(trop-2)抗体 |
JP2023530182A (ja) | 2020-06-22 | 2023-07-13 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 多重サブユニットタンパク質モジュール、それを発現する細胞、及びその使用 |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
EP3939999A1 (de) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Antikörper zur neutralisierung der interleukin-11-rezeptor-alpha-unterheinheit (il11ra) und verwendungen davon |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
WO2022038536A1 (en) | 2020-08-18 | 2022-02-24 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
WO2022047359A1 (en) | 2020-08-31 | 2022-03-03 | Berg Llc | Protein biomarkers for pancreatic cancer |
JP2023540526A (ja) | 2020-09-04 | 2023-09-25 | ノヴァロック バイオセラピューティクス, リミテッド | ネクチン-4抗体およびそれの使用 |
IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Weight regulation method |
EP4217370A2 (de) | 2020-09-23 | 2023-08-02 | Yeda Research and Development Co. Ltd | Verfahren und zusammensetzungen zur behandlung von coronavirusinfektionen |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
EP4225902A1 (de) | 2020-10-05 | 2023-08-16 | Protalix Ltd. | Würfelförmige knockout-pflanzenzellen |
WO2022074656A1 (en) | 2020-10-07 | 2022-04-14 | Protalix Ltd. | Long-acting dnase |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for editing RNA and a method for using them |
AU2021374966A1 (en) | 2020-11-09 | 2023-06-15 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
GB202105804D0 (en) | 2020-11-20 | 2021-06-09 | Univ Cape Town | Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan |
AU2021387979A1 (en) | 2020-11-26 | 2023-03-30 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
AU2021393591A1 (en) | 2020-12-04 | 2023-07-06 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling the ubiquitination process of mlkl for disease treatment |
EP4267742A2 (de) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | Auf p21-mrna abzielende dnazyme |
KR20230126725A (ko) | 2020-12-28 | 2023-08-30 | 1이 테라퓨틱스 엘티디. | 침묵화를 위한 P21 mRNA 표적 부위 |
AU2021414160A1 (en) | 2020-12-31 | 2023-07-20 | Nona Biosciences (Suzhou) Co., Ltd. | Human lifr antigen binding protein, preparation method therefor, and application thereof |
WO2022149142A2 (en) | 2021-01-10 | 2022-07-14 | Supermeat The Essence Of Meat Ltd. | Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry |
US20240083843A1 (en) | 2021-01-14 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections |
US20240101717A1 (en) | 2021-01-22 | 2024-03-28 | Bionecure Therapeutics, Inc. | Anti-her-2/trop-2 constructs and uses thereof |
GB2603166A (en) | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
US20240108745A1 (en) | 2021-02-09 | 2024-04-04 | Medilink Therapeutics (Suzhou) Co., Ltd. | Bioactive substance conjugate, preparation method therefor and use thereof |
JP2024506955A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチンを作製する方法 |
IL305314A (en) | 2021-02-18 | 2023-10-01 | Yeda res & development co ltd | A genetically engineered bacterium for vaccine production |
WO2022175532A1 (en) | 2021-02-19 | 2022-08-25 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
WO2022183502A1 (zh) | 2021-03-05 | 2022-09-09 | 上海吉倍生物技术有限公司 | 抗cldn6抗体及其用途 |
JP2024512392A (ja) | 2021-03-08 | 2024-03-19 | イミュノジェン・インコーポレーテッド | がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法 |
KR20230156021A (ko) | 2021-03-09 | 2023-11-13 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Ror1 결합 단백질 및 이의 용도 |
IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for growing mouse embryos outside the uterus |
WO2022208369A1 (en) | 2021-03-30 | 2022-10-06 | Biomx Ltd. | Pseudomonas bacteriophage and uses thereof |
IL307528A (en) | 2021-04-06 | 2023-12-01 | Bpgbio Inc | Protein markers for the prognosis of breast cancer progression |
US20230059578A1 (en) | 2021-04-06 | 2023-02-23 | Berg Llc | Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer |
WO2022216841A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer |
IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
JP2024514195A (ja) | 2021-04-14 | 2024-03-28 | ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド,コーク | 脳血管イベントおよび神経障害の治療 |
CA3214579A1 (en) | 2021-04-14 | 2022-10-20 | Tom Moore | Psg1 for use in the treatment of osteoarthritis |
CA3215979A1 (en) | 2021-04-19 | 2022-10-27 | Ghassan SAED | Methods for detecting or treating endometrial and ovarian hyperproliferative disorders |
EP4337764A1 (de) | 2021-05-12 | 2024-03-20 | Biomx Ltd. | Staphylococcus-bakteriophage und verwendungen davon |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
IL309061A (en) | 2021-06-06 | 2024-02-01 | Yeda res & development co ltd | Combined cancer treatment |
WO2022264132A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
WO2022264076A1 (en) | 2021-06-16 | 2022-12-22 | Seedx Technologies Inc. | Methods of sorting matthiola seeds |
NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
JP2024524924A (ja) | 2021-07-02 | 2024-07-09 | トロピック バイオサイエンシーズ ユーケー リミテッド | バナナ果実における褐変の遅延又は防止 |
EP4370160A1 (de) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Zusammensetzungen und verfahren in zusammenhang mit zellen mit anhaftenden partikeln |
KR20240046506A (ko) | 2021-07-18 | 2024-04-09 | 가미다-셀 리미티드 | 치료용 nk세포 집단 |
WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
JP2024530455A (ja) | 2021-07-30 | 2024-08-21 | ブイアイビー ブイゼットダブリュ | 標的化タンパク質の分解のためのカチオン非依存性マンノース6リン酸受容体結合体 |
WO2023012798A2 (en) | 2021-08-02 | 2023-02-09 | Yeda Research And Development Co. Ltd. | Antibodies for the treatment of cancer |
JP2024536647A (ja) | 2021-08-03 | 2024-10-07 | ジェニシティー リミテッド | 操作されたtcr複合体及びそれを使用する方法 |
EP4130028A1 (de) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Manipulierter tcr-komplex und verfahren zur verwendung davon |
CA3228570A1 (en) | 2021-08-10 | 2023-02-16 | Yona Geffen | Engineered nk cells, methods of their production and uses thereof |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
CA3236778A1 (en) | 2021-11-02 | 2023-05-11 | Erik SONTHEIMER | Nme2cas9 inlaid domain fusion proteins |
AU2022392804A1 (en) | 2021-11-19 | 2024-05-02 | Mirobio Limited | Engineered PD-1 antibodies and uses thereof |
EP4444864A1 (de) | 2021-12-08 | 2024-10-16 | Yeda Research and Development Co. Ltd | Multipotente lungenvorläuferzellen zur lungenregeneration |
IL314470A (en) | 2022-01-25 | 2024-09-01 | Medilink Therapeutics Suzhou Co Ltd | Anti-Her3 antibody, conjugate and use thereof |
GB202201137D0 (en) | 2022-01-28 | 2022-03-16 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
EP4238988A1 (de) | 2022-03-01 | 2023-09-06 | Consejo Superior De Investigaciones Científicas | Antikörper gegen sars-cov-2 und verwendungen davon |
WO2023192976A1 (en) | 2022-04-01 | 2023-10-05 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
AU2023248520A1 (en) | 2022-04-06 | 2024-10-17 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin replacement therapy |
WO2023196866A1 (en) | 2022-04-06 | 2023-10-12 | Mirobio Limited | Engineered cd200r antibodies and uses thereof |
WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
WO2023239710A1 (en) | 2022-06-08 | 2023-12-14 | Onkure, Inc. | Benzopyrimidin-4(3h)-ones as pi3k inhibitors |
WO2023239940A1 (en) | 2022-06-10 | 2023-12-14 | Research Development Foundation | Engineered fcriib selective igg1 fc variants and uses thereof |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
WO2024038160A1 (en) | 2022-08-18 | 2024-02-22 | Vib Vzw | Means and methods to modulate neuron excitability |
WO2024054469A1 (en) | 2022-09-08 | 2024-03-14 | Onkure, Inc. | Isoquinolones as pi3k inhibitors |
WO2024064024A1 (en) | 2022-09-19 | 2024-03-28 | Onkure, Inc. | ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer |
WO2024064002A1 (en) | 2022-09-20 | 2024-03-28 | Onkure, Inc. | Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation |
WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
WO2024081345A1 (en) | 2022-10-14 | 2024-04-18 | Onkure, Inc. | Benzopyrimidin-4(3h)-ones as pi3k inhibitors |
WO2024078729A1 (en) | 2022-10-14 | 2024-04-18 | University College Cork - National University Of Ireland, Cork | Placenta expressed proteins for use in the treatment of tendon injury |
WO2024102466A2 (en) | 2022-11-11 | 2024-05-16 | Igan Biosciences | Iga protease polypeptide agents |
WO2024124041A1 (en) | 2022-12-07 | 2024-06-13 | Advanced Cell Diagnostics, Inc. | Multiplexed detection of nucleic acid targets |
WO2024178172A1 (en) | 2023-02-23 | 2024-08-29 | University Of Rochester | Agents and methods for making closed-end dna thread molecules |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3615222A (en) * | 1968-09-04 | 1971-10-26 | New England Nuclear Corp | Method and apparatus for measuring the amount of a component in a biological fluid |
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
-
1970
- 1970-11-10 NL NL707016396A patent/NL154598B/xx not_active IP Right Cessation
-
1971
- 1971-10-27 ZA ZA717192A patent/ZA717192B/xx unknown
- 1971-10-28 AU AU35082/71A patent/AU468060B2/en not_active Expired
- 1971-10-29 US US00193702A patent/US3850752A/en not_active Expired - Lifetime
- 1971-11-04 FI FI3155/71A patent/FI54033C/fi active
- 1971-11-06 ES ES396741A patent/ES396741A1/es not_active Expired
- 1971-11-08 CH CH1621671A patent/CH617774A5/de not_active IP Right Cessation
- 1971-11-08 DK DK546271AA patent/DK140268B/da not_active IP Right Cessation
- 1971-11-09 BR BR7459/71A patent/BR7107459D0/pt unknown
- 1971-11-09 SE SE7114278A patent/SE451162B/xx unknown
- 1971-11-09 CA CA127,217A patent/CA967464A/en not_active Expired
- 1971-11-09 IT IT53970/71A patent/IT986829B/it active
- 1971-11-09 DE DE2155658A patent/DE2155658C3/de not_active Expired
- 1971-11-09 GB GB5196171A patent/GB1348935A/en not_active Expired
- 1971-11-10 BE BE775187A patent/BE775187A/nl not_active IP Right Cessation
- 1971-11-10 FR FR7140259A patent/FR2113733A5/fr not_active Expired
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2323467A1 (de) * | 1972-05-11 | 1973-11-29 | Akzo Nv | Verfahren zum nachweis und zur bestimmung von haptenen |
DE2743445A1 (de) * | 1976-09-29 | 1978-03-30 | Mochida Pharm Co Ltd | Immunchemisches haptenmessverfahren |
DE2811537A1 (de) * | 1977-03-16 | 1978-09-21 | Miles Yeda Ltd | Empfindlicher quantitativer assay |
EP0174652A2 (de) * | 1984-09-13 | 1986-03-19 | Roche Diagnostics GmbH | Immunchemisches Messverfahren für Haptene und Proteine |
EP0174652A3 (en) * | 1984-09-13 | 1987-07-01 | Boehringer Mannheim Gmbh | Immunochemical test process for hapteus and proteins |
Also Published As
Publication number | Publication date |
---|---|
NL7016396A (de) | 1972-05-15 |
US3850752A (en) | 1974-11-26 |
SE451162B (sv) | 1987-09-07 |
FI54033C (fi) | 1978-09-11 |
AU468060B2 (en) | 1975-12-18 |
IT986829B (it) | 1975-01-30 |
FI54033B (fi) | 1978-05-31 |
ES396741A1 (es) | 1975-05-16 |
DE2155658A1 (de) | 1972-05-18 |
ZA717192B (en) | 1972-08-30 |
DK140268B (da) | 1979-07-16 |
CA967464A (en) | 1975-05-13 |
BE775187A (nl) | 1972-03-01 |
DE2155658C3 (de) | 1978-09-14 |
AU3508271A (en) | 1973-05-03 |
FR2113733A5 (de) | 1972-06-23 |
NL154598B (nl) | 1977-09-15 |
BR7107459D0 (pt) | 1973-06-21 |
DK140268C (de) | 1979-12-10 |
CH617774A5 (de) | 1980-06-13 |
GB1348935A (en) | 1974-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2155658B2 (de) | Verfahren zum nachweis und zur bestimmung von einem hapten oder dessen antikoerper | |
DE3650513T2 (de) | Verzögerter immunologischer Test in fester Phase | |
DE2743444C3 (de) | Immunchemisches Meßverfahren und Reagens zu seiner Durchführung | |
EP0280211B1 (de) | Verfahren zur Bestimmung von Antikörpern | |
Furr | Radioimmunoassay of progesterone in peripheral plasma of the domestic fowl in various physiological states and in follicular venous plasma | |
DE2943648C2 (de) | Spezifische Bindungs-Untersuchungsmethode zur Bestimmung einer Vielzahl von verschiedenen Liganden in einer einzigen Flüssigkeitsprobe | |
DE2902676C2 (de) | Verfahren zur Analyse eines von RF oder C1q verschiedenen Antigens im Serum mittels eines Immunoassays | |
DE2164768B2 (de) | Verfahren zum nachweis und zur bestimmung einer komponente der reaktion zwischen spezifischen bindeproteinen und bindefaehigen substanzen | |
DE3205849C2 (de) | Reagens zur immunologischen Bestimmung | |
DE68910758T2 (de) | Bestimmung mit Affinitätssubstanzen und HPLC-Schritt. | |
DE2206103A1 (de) | Verfahren zum Nachweisen und Bestimmen einer Komponente der Reaktion zwischen spezifisch bindenden Proteinen und den Substanzen, die von diesen Proteinen spezifisch gebunden werden | |
DE3136579C2 (de) | ||
DE2811537A1 (de) | Empfindlicher quantitativer assay | |
CH622099A5 (de) | ||
DE2744836A1 (de) | Immunchemisches messverfahren | |
DE2729268A1 (de) | Festes, mit rezeptor und markiertem liganden ueberzogenes substrat und seine verwendung zur analyse | |
EP0008432A1 (de) | Immunologisches Bestimmungsverfahren | |
DE2548427A1 (de) | Als einheit ausgebildete immunoanalysenausruestung in fester phase und verfahren zu ihrer herstellung | |
DE2608667A1 (de) | Diagnostisches feststoffreagens und verfahren zu dessen herstellung | |
DE3021208C2 (de) | Verfahren zur Bestimmung eines Antigens, Antikörpers oder Antigen-Antikörperkomplexes und Verwendung eines in einer Verpackungseinheit konfektionierten Mittels zur Durchführung des Verfahrens | |
EP0001223A2 (de) | Mit einer Polyhydroxyverbindung beschichteten Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz. | |
DE69232801T2 (de) | Abtrennungsverfahren | |
EP0303284B1 (de) | Immunologisches Bestimmungsverfahren zur Bestimmung von Hapteneigenschaften aufweisenden freien Substanzen | |
DE3781841T2 (de) | Diagnostisches immuntest-verfahren mittels festphasenabscheidung. | |
CH664018A5 (de) | Immunologisches bestimmungsverfahren und reagens fuer immunologische bestimmungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C3 | Grant after two publication steps (3rd publication) |